"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02785120","A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes","TF0023","Recruiting","No Results Available","Ischemic Stroke","Drug: TF0023","The primary efficacy endpoint is the change from baseline in the mRS score for all randomized patients at Week 16 in Part A and Part B.|Death due to any cause after signing the informed consent form through Week 16 and Week 32.|Recurrent stroke after signing the informed consent form through Week 16 and Week 32.|NIHSS score changes after signing the informed consent form through Week 16 and Week 32.|Barthel Index (BI) changes after signing the informed consent form through Week 16 and Week 32.|Extended Glasgow Outcome Scale (GOS-E) changes after signing the informed consent form through Week 16 and Week 32.|Shortening the time for performing the timed Trail-Making Tests|Volume of new fluid attenuation inversion recovery (FLAIR) lesions by DTI-MRI|Blood flow in neck arteries by Ultrasonography after signing the informed consent form through Week 16 and Week 32.|Improvement of atherosclerosis in neck arteries by Ultrasonography after signing the informed consent form through Week 16 and Week 32.|Daily activities changes after signing the informed consent form through Week 16 and Week 32.|Sleeping condition changes after signing the informed consent form through Week 16 and Week 32.|Total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low density lipoprotein cholesterol (VLDL C) changes|Blood pressure changes after signing the informed consent form through Week 16 and Week 32.|To access hemoglobin A1C (HbA1C) changes after signing the informed consent form through Week 16 and Week 32.|To access patient's assessment of disease status|To access investigator's assessment of disease status|To access patient's assessment of response to therapy|To access investigator's assessment of response to therapy","Techfields Inc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TF-TF0023-21","March 1, 2017","October 2020","December 2020","May 27, 2016",,"September 26, 2019","Four Peaks Neurology, Scottsdale, Arizona, United States|General Neuronology, Scottsdale, Arizona, United States|Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States|CarePoint, P.C. dba Blue Sky Neurology, Englewood, Colorado, United States|Tenet South Florida / Delray Medical Center, Delray Beach, Florida, United States|The Neurology Research Group, Miami, Florida, United States|Florida Hospital of Orlando, Orlando, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Henry Ford Health System, Detroit, Michigan, United States|Midwest Physicians Group, Kansas City, Missouri, United States|Washington University School of Medicine - Center for Advanced Medicine (CAM) - Neuroscience Center, Saint Louis, Missouri, United States|Renown Medical Group, Reno, Nevada, United States|Hackensack Neurology Group, Hackensack, New Jersey, United States|Icahn School of Medicine at Mount Sinai (ISMMS) - Institute for Critical Care Medicine, New York, New York, United States|Neurology and Neuroscience Associates, Akron, Ohio, United States|The Ohio State University Wexner Medical Center (OSUWMC) - Neurovascular Stroke Center, Columbus, Ohio, United States|Providence Stroke Center, Portland, Oregon, United States|Neurovascular Associates of Abington, Abington, Pennsylvania, United States|Coastal Nurology, Port Royal, South Carolina, United States|Chattanooga Neurology Associates - Memorial Office, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Neurology Associates of Arlington, PA, Mansfield, Texas, United States|VCU Medical Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02785120"
2,"NCT02180204","Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)","TALISMAN","Withdrawn","No Results Available","Ischemic Stroke","Drug: Tenecteplase|Drug: Alteplase","Neurological outcome|Symptomatic intracranial hemorrhage","Reza Behrouz, DO|Ohio State University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2013H000|TALISMAN","January 2015","June 2020","June 2020","July 2, 2014",,"September 23, 2015","The Ohio State University College of Medicine, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02180204"
3,"NCT01896128","Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke",,"Completed","Has Results","Stroke|Cerebrovascular Accident|Hemiparesis","Drug: Armodafinil|Drug: Placebo","Change in Fugl-Meyer Assessment of Sensorimotor Function From Baseline to Day 100|Change in Functional Independence Measure (FIM) From Baseline to Day 100|Timed 3-Minute Walk Test From Baseline to Day 100|NIH Stroke Scale (NIHSS)|9-Hole Peg Test","Burke Rehabilitation Hospital|Teva Pharmaceutical Industries","All","18 Years and older   (Adult, Older Adult)","Phase 2","19","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BRC-394","January 2008","July 2015","July 2015","July 11, 2013","November 4, 2019","November 4, 2019","The Burke Rehabilitation Hospital, White Plains, New York, United States",,"https://ClinicalTrials.gov/show/NCT01896128"
4,"NCT00868010","Enhancing Rehabilitation After Stroke","Enhance","Unknown status","No Results Available","Ischemic Stroke","Drug: donepezil|Drug: placebo","Functional Independence Measure (FIM)|Cognitive Function (ImPACT battery used to assess attention - working memory continuum, information processing speed, and verbal and visual episodic memory.)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Years and older   (Adult, Older Adult)","Phase 3","200","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R01HD055525|NIH grant: 1 R01 HD055525-01A2","March 2009","August 2013","November 2013","March 24, 2009",,"March 5, 2013","Hillside Rehabilitation Hospital, Warren, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00868010"
5,"NCT02666742","Safety and Efficacy of Periprocedural Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation","STROKE-VT","Terminated","No Results Available","Ventricular Tachycardia","Drug: Apixaban|Drug: Aspirin","Incidence of asymptomatic or symptomatic cerebrovascular embolic and systemic thromboembolic events|Incidence of major periprocedural bleeding|Incidence of minor periprocedural bleeding|All cause mortality","Kansas City Heart Rhythm Institute|Bristol-Myers Squibb","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00003241|CV185-415","February 16, 2017","May 1, 2018","May 1, 2018","January 28, 2016",,"May 2, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02666742"
6,"NCT02054429","Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke",,"Unknown status","No Results Available","Ischemic Stroke","Drug: Insulin","Stroke Scale|MRI","University at Buffalo","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INSULIN","January 2013","December 2016","December 2018","February 4, 2014",,"February 4, 2014","University of Buffalo Neurosurgery, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT02054429"
7,"NCT02142712","Histamine Glutamate Antagonism in Stroke",,"Completed","Has Results","Acute Cerebrovascular Accident|Cerebral Edema","Drug: Diphenhydramine|Drug: Pantoprazole|Drug: Famotidine|Drug: Dextromethorphan","Modified Rankin Score|National Institutes of Health Stroke Severity (NIHSS) Scale|Glasgow Coma Scale (GCS)|Barthel Index","University of Florida","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201400353","December 2014","December 2014","December 2014","May 20, 2014","December 15, 2015","December 15, 2015","Shands Hospital at University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02142712"
8,"NCT02235558","Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke","SAVER-I","Completed","No Results Available","Ischemic Stroke","Drug: Verapamil","The primary endpoint will be the presence or absence of intracranial hemorrhage|Absence of intracranial hemorrhage","Justin Fraser|University of Kentucky","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-0975-F1V","February 1, 2013","March 21, 2016","March 21, 2016","September 10, 2014",,"January 23, 2017","University of Kentucky Deparment of Neurosurgery, UK Chandler Hospital, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02235558"
9,"NCT02838901","Dietary Nitrate Supplements and Ischemic Stroke Recovery",,"Completed","Has Results","Stroke|Ischemic Stroke|Cerebrovascular Accident","Drug: Beet it Beetroot juice|Drug: Beet It Placebo Beetroot juice","Adherence With Intervention|Number of Participants With Adverse Treatment-altering Events|Change in Plasma Nitrate Levels, Micromoles/Liter|Change in Plasma Nitrite Levels, Micromoles/Liter|Gait Speed Change From Baseline|Cerebral Perfusion Imaging|Upper Extremity Grip Strength|Montreal Cognitive Assessment (MoCA) Score|Modified Rankin Score","Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00020739","June 2012","June 2016","June 2016","July 20, 2016","April 10, 2018","April 10, 2018","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02838901"
10,"NCT00836355","Enoxaparin and/or Minocycline in Acute Stroke",,"Terminated","Has Results","Acute Ischemic Stroke","Drug: Enoxaparin|Drug: Minocycline","Indices of Salvaged Ischemic Penumbra and of Final Infarct Volume Based on Quantitative Volumetric Analyses of Pre- and Post-treatment Perfusion-weighted and Diffusion-weighted Brain MR Imaging|NIH Stroke Scale Scores|Modified Rankin Scale Score","NYU Langone Health|James N. Kirby Foundation","All","18 Years to 95 Years   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","08-131","April 2009","December 2009","January 2010","February 4, 2009","April 29, 2016","April 29, 2016","Bellevue Hospital Center, New York, New York, United States|New York University Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00836355"
11,"NCT04123067","Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke",,"Suspended","No Results Available","Stroke, Acute|Hyperglycemia|Diabetes","Drug: Pioglitazone 45 mg|Drug: Placebo oral tablet","Clinical outcomes|Clinical Outcome|Concentration of markers of neutrophil activation and function|Concentration of stress response markers including cortisol, norepinephrine and epinephrine","Milton S. Hershey Medical Center|National Center for Advancing Translational Science (NCATS)","All","21 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00011042","July 1, 2020","December 2020","July 2021","October 10, 2019",,"April 9, 2020","Penn State College of Medicine, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04123067"
12,"NCT01150266","Study for the Use of Alteplase in Patients Who Awaken With Stroke","AWOKE","Withdrawn","No Results Available","Ischemic Stroke","Drug: Alteplase (tPA)","Symptomatic Intracranial Hemorrhage|Modified Rankin Scale|National Institutes of Health Stroke Scale (NIHSS)","University of California, San Diego|National Institute of Neurological Disorders and Stroke (NINDS)|Scripps Health","All","22 Years and older   (Adult, Older Adult)","Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AWOKE|5P50NS044148","August 2011","September 2013",,"June 24, 2010",,"September 13, 2013","University of California, San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01150266"
13,"NCT01975194","Rosuvastatin in African Americans With Cerebrovascular Disease","RIAA","Terminated","No Results Available","Stroke|Transient Ischemic Attack","Drug: Rosuvastatin","LDL value","Wayne State University","All","30 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0481540","January 2012","August 2013","August 2013","November 3, 2013",,"November 5, 2013","Detroit Medical Center, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01975194"
14,"NCT03979781","Personalized Antiplatelet Secondary Stroke PRevenTion","PASSPoRT","Recruiting","No Results Available","Ischemic Stroke|TIA","Drug: tailored antiplatelet selection|Drug: standard of care","Feasibility - Recruitment and Platelet Reactivity|Safety - Bleeding Complications|Patient-centered Outcomes - Satisfaction","State University of New York - Upstate Medical University","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1158092","June 11, 2018","November 6, 2020","November 6, 2020","June 7, 2019",,"June 7, 2019","SUNY Upstate Medical University, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT03979781"
15,"NCT01794182","Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals","GAMES-RP","Unknown status","No Results Available","Ischemic Stroke|Malignant Edema","Drug: RP-1127 (Glyburide for Injection)","The proportion of patients with a modified Rankin Scale (mRS) at Day 90 ≤ 4 without decompressive craniectomy|Safety of RP-1127 in subjects with a severe anterior circulation ischemic stroke who are likely to develop malignant edema.|Proportion of subjects undergoing DC or dead within 14 days|The change between baseline and 72-96 hours in ipsilateral hemispheric swelling measured by MRI|The change between baseline and 72-96 hours in lesional swelling measured by MRI","Remedy Pharmaceuticals, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RPI 203","May 2013","August 2015","April 2016","February 18, 2013",,"June 2, 2015","University of Arizona Medical Center, Tucson, Arizona, United States|Stanford University Medical Center, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Jacksonville, Jacksonville, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Maine Medical Center, Scarborough, Maine, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMASS Memorial Medical Center, Worcester, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Utah Healthcare, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01794182"
16,"NCT02737930","Fluoxetine for Visual Recovery After Ischemic Stroke","FLUORESCE","Recruiting","No Results Available","Acute Stroke|Visual Field Loss","Drug: Fluoxetine|Drug: Placebo","Improvement in size of visual field deficit (degrees)|Improvement in size of visual field deficit (square degrees)|Improvement in parametric mean deviation|Functional field score|Visual Function Questionnaire-25 score|Patient Health Questionnaire-9 score|Modified Rankin Scale score|Post-stroke changes in cortical visual representation as measured by functional magnetic resonance imaging|Post-stroke changes in retinal nerve fiber layer thickness","Bogachan Sahin|University of Rochester","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RSRB00058133","May 2016","June 2020","June 2020","April 14, 2016",,"August 21, 2019","Strong Memorial Hospital, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02737930"
17,"NCT01268683","Glyburide Advantage in Malignant Edema and Stroke Pilot","GAMES-PILOT","Completed","Has Results","Ischemic Stroke","Drug: RP-1127 (Glyburide for injection)","Rate of Recruitment|Safety and Tolerability|Pharmacokinetics/Pharmacodynamics|Clinical and MRI Outcome Data","Remedy Pharmaceuticals, Inc.|University of Maryland, College Park|Massachusetts General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPI 201","May 2011","June 2012","February 2013","December 31, 2010","June 6, 2014","June 6, 2014","Rush University Medical Center, Chicago, Illinois, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01268683"
18,"NCT01183533","Safety of Intravenous Thrombolysis for Wake-up Stroke","Wake-Up Stroke","Completed","Has Results","Ischemic Stroke","Drug: Alteplase (iv t-PA)","Frequency of Symptomatic Hemorrhagic Transformation Safety of iv Rt-PA in Wake up Stroke Patients|90-day Modified Rankin Scale (mRS) Score 0 or 1|Mortality","The University of Texas Health Science Center, Houston|Genentech, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-10-0195","July 2010","October 2013","January 2014","August 17, 2010","November 25, 2014","November 25, 2014","University of Alabama, Birmingham, Alabama, United States|Swedish Medical Center, Englewood, Colorado, United States|UT-Houston Health Science Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01183533"
19,"NCT01849887","Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke",,"Withdrawn","No Results Available","Ischemic Stroke","Biological: bone marrow-derived mesenchymal stem cells|Drug: Placebo","Number of Adverse Events","University of California, Irvine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DR3-07521","January 2016","January 2016","January 2016","May 9, 2013",,"January 22, 2016","University of California Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT01849887"
20,"NCT03347786","Verapamil for Neuroprotection in Stroke",,"Recruiting","No Results Available","Ischemic Stroke","Drug: Verapamil","Serious Adverse Event","Global Neurosciences Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GNI_verap","April 20, 2017","April 2020","April 2020","November 20, 2017",,"August 14, 2019","Our Lady of Lourdes Medical Center, Camden, New Jersey, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Crozer Keystone Health System, Upland, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03347786"
21,"NCT01674868","Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke","FLAN","Withdrawn","No Results Available","Stroke","Drug: fluoxetine|Drug: placebo","Fugl-Meyer Motor Scale (FMMS)|Western Aphasia Battery|Behavioral Inattention Test (BIT)|Functional Independence Measure|Fatigue Severity Scale|Beck Depression Inventory|modified Rankin Scale","Spaulding Rehabilitation Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FLAN SpauldingRH","April 2013","December 2015","December 2015","August 29, 2012",,"June 16, 2015","Spaulding Rehabilitation Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01674868"
22,"NCT03617302","Inorganic Nitrate Supplementation on Cerebrovascular Aging and Arterial Stiffness Study","INCA","Recruiting","No Results Available","Aging|Arterial Stiffness|Endothelial Dysfunction|Hypertension|Cognitive Decline","Drug: Experimental: Nitrate-containing|Drug: Placebo: Nitrate-depleted","Acute change in carotid artery stiffness|Acute change in cerebral blood flow|Internal carotid artery endothelium-dependent dilation","Gary L. Pierce|University of Wisconsin, Madison|University of Iowa","All","50 Years to 79 Years   (Adult, Older Adult)","Early Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201805720","November 1, 2018","June 30, 2022","June 30, 2023","August 6, 2018",,"January 23, 2020","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT03617302"
23,"NCT03417492","Cerebrovascular Reactivity in American Football Players",,"Recruiting","No Results Available","Traumatic Brain Injury|Mild Traumatic Brain Injury|Post-Concussion Syndrome","Drug: Sildenafil Citrate","Effect of single dose sildenafil citrate treatment on global blood oxygen level-dependent (BOLD) response to hypercapnia.|Effect of single dose sildenafil citrate treatment on functional near-infrared spectroscopy (fNIRS) response to hypercapnia.|Maximum tolerable dose of sildenafil therapy without severe adverse events.","University of Pennsylvania|Boston University","Male","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","827103","March 1, 2018","March 1, 2021","September 1, 2021","January 31, 2018",,"August 28, 2019","Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03417492"
24,"NCT02478346","Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions","Fluoescein","Unknown status","No Results Available","Cerebrovascular Disorders|Intracranial Neoplasms","Drug: Fluorescein Sodium","Incidence of Intracerebral lesion","AdventHealth","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","684812","May 2015","December 2018","April 2019","June 23, 2015",,"February 14, 2017","Florida Hospital, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02478346"
25,"NCT01464788","Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke","ARTSS-2","Terminated","Has Results","Ischemic Stroke","Drug: Low Dose Argatroban|Drug: High Dose Argatroban|Drug: rt-PA (alteplase)","Number of Participants With 0 or 1 on Modified Rankin Scale|Number of Participants With Symptomatic Intracranial Hemorrhage Within 48 Hours of tPA Administration","Andrew D. Barreto, MD|The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-11-0464","October 2011","June 11, 2015","June 11, 2015","November 4, 2011","May 11, 2017","May 11, 2017","University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01464788"
26,"NCT02922452","A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects",,"Completed","No Results Available","Ischemic Stroke","Drug: BMS-986141|Drug: Dilitazem","Maximum observed concentration (Cmax)|Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))|Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC (0-T))|Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and death","Bristol-Myers Squibb","All","18 Years to 50 Years   (Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CV006-028","September 2016","November 2016","November 2016","October 4, 2016",,"December 20, 2016","PPD Development, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02922452"
27,"NCT01811693","Field Administration of Stroke Therapy-Blood Pressure Lowering","FAST-BP","Unknown status","No Results Available","Intracerebral Hemorrhage|Ischemic Stroke","Drug: Glycerly Trinitrate","Mean blood pressure change","University of California, Los Angeles","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FBP001","April 2013","December 2015",,"March 14, 2013",,"June 4, 2015","Los Alamitos Medical Center, Los Alamitos, California, United States|FAST-MAG Clinical Trial Coordinating Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01811693"
28,"NCT01762475","Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.",,"Completed","No Results Available","Traumatic Brain Injury|Post-concussive Syndrome","Drug: Sildenafil","Cerebrovascular reactivity|Safety and tolerability","Uniformed Services University of the Health Sciences|Center for Neuroscience and Regenerative Medicine (CNRM)|National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health (NIH)","All","18 Years to 55 Years   (Adult)","Phase 2","59","U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","T-N-2215","January 2013","December 2015","December 2015","January 7, 2013",,"January 1, 2016","National Institute of Health, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01762475"
29,"NCT00893867","Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke","MACSI","Terminated","No Results Available","Acute Ischemic Stroke","Drug: DP-b99|Drug: Placebo","Modified Rankin Scale (mRS) categorical analysis (""shift"")|Recovery, defined as a score of ≤ 1 on modified Rankin Score|Safety and tolerability|recovery as assessed by an NIHSS of not more than 1|'home time'","D-Pharm Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","446","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Ptcl-01373","December 2009","April 2012","April 2012","May 6, 2009",,"October 24, 2012","Research Center of Southern California, Oceanside, California, United States|Associated Neurologists, P.C., Danbury, Connecticut, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|The University of Kentucky The Methodist Hospital, Lexington, Kentucky, United States|University of Louisville, Kentucky Neuroscience Research, Louisville, Kentucky, United States|Tufts Medical Center, Boston, Massachusetts, United States|Capital Health Regional Medical Center Neuroscience Institute, Trenton, New Jersey, United States|Presbitarian Hospital, Charlotte, North Carolina, United States|St. Elizabeth's Medical Center, Youngstown, Ohio, United States|Legacy Meridian Park Medical Center, Tualatin, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|The Methodist Hospital, Houston, Texas, United States|Carilion Clinic, Roanoke, Virginia, United States|Medizinische Universität Innsbruck, Innsbruck, Austria|Landeskrankenhaus Klagenfurt, Klagenfurt, Austria|Abt. Neurologie und Psychiatrie, Linz, Austria|LKH St. Pölten Department of Neurology, St. Pölten, Austria|Santa Casa de Misericordia de Belo Horizonte Departamento de Neurologia, Belo Horizonte, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Hospital Mãe de Deus, Porto Alegre, Brazil|Santa Casa de Misericórdia de Porto Alegre Policlinica Santa Clara Sala de Neurologia, Porto Alegre, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto Unidade de Emergência Centro de Estudos, Ribeirão Preto, Brazil|UNIFESP, San Paulo, Brazil|Hospital São José de Joinville, Santa Catarina, Brazil|Hospital Santa Marcelina, Sao Paulo, Brazil|Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|Grey Nun's Community Hospital, Edmonton, Canada|University of Alberta Hospital, Edmonton, Canada|Hamilton Health Sciences Centre, Hamilton, Canada|Kingston General Hospital, Kingston, Canada|Chinook Regional Hospital, Lethbridge, Canada|CHA- Hôpital de l'Enfant-Jésus, Quebec, Canada|University Hospital Brno, Brno, Czech Republic|University Hospital Hradec Kralove, Clinic of Neurology, Hradec Kralove, Czech Republic|Hospital Jihlava Clinic of Neurology, Jihlava, Czech Republic|Hospital Vítkovice Clinic of Neurology, Ostrava, Czech Republic|County Hospital Pardubice Clinic of Neurology, Pardubice, Czech Republic|Clinic of Neurology, Stroke Center, Charles University, Prague, Czech Republic|University Hospital Kralovske Vinohrady, Prague, Czech Republic|University Hospital Motol Clinic of Neurology, Prague, Czech Republic|CHU Jean Minjoz Besançon, Besancon, France|Hopital Pellegrin-Tripode, Bordeaux, France|CHU Henri Mondor, Créteil, France|Hopital Gui de Chauliac, Montpellier, France|Hôpital Bichat, Paris, France|Hôpital Lariboisière - Service Neurologie, Paris, France|Hôpital Saint Jean, Perpignan, France|Ärztlicher Direktor Neurologische Klinik, Neurologische Klink GmbH der Rhoen-Klinikum AG, Bad Neustadt / Saale, Germany|Marien-Krankenhaus gGmbH, Abteilung für Neurologie, Bergisch Gladbach, Germany|DRK Kliniken Berlin, Klinik fuer Neurologie, Berlin, Germany|Vivantes Klinikum Neukölln, Klinik für Neurologie, Stroke Unit, Berlin, Germany|Klinikum Bremen-Mitte, Bremen, Germany|Klinikum Bremerhaven-Reinkenheide gGmbH, Neurologische Klinik, Bremerhaven, Germany|Klinikum Chemnitz GmbH Chefarzt Klinik für Neurologie, Chemnitz, Germany|Helios Klinikum Erfurt GmbH, Erfurt, Germany|Universitätsklinikum Erlangen, Neurologische klinik, Erlangen, Germany|Universitätsklinikum Essen, Klinik und Poliklinik für Neurologie, Essen, Germany|Neurologische Universitätsklinik Freiburg, Neurozentrum, Freiburg, Germany|Klinikum Fulda, Neurologische Klinik, Fulda, Germany|Evangelische Kliniken Gelsenkirchen GmbH Klinik für Neurologie und Klinische Neurophysiologie, Gelsenkirchen, Germany|Georg-August-Universitat Gottingen Neurologische Klinik, Gottingen, Germany|Ernst Moritz Arndt University, Grifswald, Germany|Askepios Klinik Altona, Hamburg, Germany|Askepios Klinik Heidberg, Hamburg, Germany|Klinikum Köln Merheim, Department of Neurology, Koln, Germany|Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Neurologie, Leipzig, Germany|Klinikum der Otto-von-Guericke-Universität Magdeburg, Neurologische Universitätsklinik, Magdeburg, Germany|Johannes Gutenberg Universitat, Klinik und Poliklinik fur Neurologie, Mainz, Germany|Klinikum 1 Minden, Neurologische Klinik, Minden, Germany|Universität Rostock Chefarzt Abteilung Neurologie, Rostock, Germany|ASKLEPIOS Fachklinikum Teupitz, Teupitz, Germany|Krankenhaus der Bramherzigen Brüder, Trier, Germany|Universitätsklinikum Ulm, Abteilung für Neurologie im RKU, Ulm, Germany|Heinrich Braun Klinikum Zwickau, Zwickau, Germany|Fővárosi Önkormányzat Péterfy Sándor utcai Kórház- Rendelőintézet és Baleseti Központ, Budapest, Hungary|Állami Egészségügyi Központ, Budapest, Hungary|Kenezy Korhaz Rendelointezet Egezsegugyi Szolgaltato Nonprofit Kft., Debrecen, Hungary|University of Debrecen, Medical and Health Science Center, Debrecen, Hungary|Aladár Petz County Teaching Hospital, Gyor, Hungary|PM Flór Ferenc County Hospital, Kistarcsa, Hungary|Borsod-Abaúj-Zemplén County Hospital Miskolc, Miskolc, Hungary|Pécsi Tudományegyetem Klinikai Központ, Pecs, Hungary|Zala Megyei Kórház, Zalaegerszeg, Hungary|Bnai Zion Medical Center, Haifa, Israel|Neurological Dept. Edith Wolfson Medical Center, Holon, Israel|Meir Medical Center, Kfar Saba, Israel|Sourasky Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel Hashomer, Israel|Ospedale Regionale Valle d'Aosta, Aosta, Italy|Dipartimento di Neuroscienze, Ospedale di Brotzu, Cagliari, Italy|Ospedale di Circolo di Varese, Lombardia, Italy|Istituto Scientifico San Raffaele - Stroke Unit, Milano, Italy|Istituto Neurologico C. Mondino, Pavia, Italy|Università di Perugia, Division of Internal and Cardiovascular Medicine - Stroke Unit, Perugia, Italy|Presidio Ospedaliero di Piacenza, Piacenza, Italy|Azienda Ospedaliera Sant'Andrea, Stroke Unit, Rome, Italy|Istituto Patologia Generale U.C.S.C, Rome, Italy|U.O.C. Stroke Unit, Rome, Italy|Università di Roma ""La Sapienza"" - Stroke Unit, Rome, Italy|Azienda Ospedaliera Universitaria ""Santa Maria della Misericordia"" Stroke Unit, Udine, Italy|Dong-A Medical Center, Busan, Korea, Republic of|Inje University BUSAN Paik Hospital, Busan, Korea, Republic of|Inje University ILSAN Paik Hospital, Goyang, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's hospital, Seoul, Korea, Republic of|Catharina Ziekenhuis Neurologie, Eindhoven, Netherlands|Medisch Spectrum Twente Hoofd Afdeling Vasculaire Neurologie, Enschede, Netherlands|Atrium MC Parkstad, Heerlen, Netherlands|Isala Klinieken Ploikliniek Neurologie, Zwolle, Netherlands|Pomerania Traumatology Center, Regional Specialist Hospital im. Nicolaus Copernicus, Gdansk, Poland|Medical University of Lublin, Department of Neurology, Stroke Unit, Lublin, Poland|Samodzielny Publiczny Zespol Zakladow Opieki Zdrowotnej w Sandomierzu, Sandomierz, Poland|Szpital Powiatowy im. Marii Curie - Skłodowskiej w Skarżysku-Kamiennej, Skarżysko-Kamienna, Poland|Wojewodzki Szpital Specjalistyczny Nr 1 im. Prof. Jozefa Gasinskiego, Tychy, Poland|Instytut Psychiatrii i Neurologii Oddział Neurologiczny z Pododdziałem Udarowym, Warsaw, Poland|Medical University of Warsaw, Department of Neurology, Warsaw, Poland|Szpital Wolski im. dr Anny Gostyńskiej Samodzielny Publiczny Zakład Opieki Zdrowotnej, Oddział Neurologii, Warsaw, Poland|Wojskowy Instytut Medyczny, Oddział Neurologii, Warsaw, Poland|Hospital Professor Doutor Fernando Fonseca, EPE, Amadora, Portugal|Centro Hospitalar de Coimbra EPE, Coimbra, Portugal|Hospitais da Universidadde de Coimbra, EPE, Coimbra, Portugal|Centro de Estudos Egas Moniz - Hospital de Santa Maria, Lisboa, Portugal|Hospital de São Sebastião, EPE, Santa Maria da Feira, Portugal|Neurology Clinic, Faculty Hospital in Martin, Martin, Slovakia|University Hospital Nitra, Nitra, Slovakia|Hospital un Poliklinic, Spisska Nova Ves, Slovakia|Faculty Hospital Trnava, Trnava, Slovakia|Neurology dept.,Hospital Zilina, Zilina, Slovakia|Fichmed, Bloemfontein, South Africa|Constantiaberg Medi-clinic, Cape Town, South Africa|Union Hospital, Gauteng, South Africa|Helderberg Research Institute, Western Cape, South Africa|Triervlei Trial Centre, Western Cape, South Africa|Clinical Projects Research, Worcester, South Africa|Hospital Universitario de Albacete, Albacete, Spain|Hospital De La Santa Ta Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Germans Triasy Pujol, Barcelona, Spain|Hospital Vall D'hebron, Barcelona, Spain|Hospital Gregorio Maranon, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain|Consorcio Hospital General Universitario Valencia, Valencia, Spain|Hospital Clinico Universitario De Valladolid, Valladolid, Spain|Universitätsspital Basel, Neurologie, Basel, Switzerland|Universitätsspital Zürich, Klinik für Neurologie, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00893867"
30,"NCT01845441","Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions",,"Unknown status","No Results Available","Stroke|Brain Ischemia|Vasospasm, Intracranial|Hemorrhage, Intracranial","Drug: Dexmedetomidine|Drug: Fentanyl|Drug: Midazolam","Numbers of patient movements (events) that delay or adversely affect the procedure performance and safety.|Preserved neurological examination.|Maintenance of optimal sedation target in both groups.","University Hospitals Cleveland Medical Center|Hospira, now a wholly owned subsidiary of Pfizer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","09-11-10|GIA#PRE-10-1003","April 2012","December 2013","December 2013","May 3, 2013",,"May 3, 2013","University Hospitals of Cleveland, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01845441"
31,"NCT03066115","Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation",,"Withdrawn","No Results Available","Hypoxia|Hypercapnia","Drug: L-NMMA|Drug: Ketorolac|Drug: Ascorbic Acid|Procedure: Intravenous Catheter|Procedure: Transcranial Doppler Ultrasound","Change in cerebral blood flow velocity in the middle cerebral artery|Change in cerebral blood flow velocity in the basilar artery","University of Wisconsin, Madison","All","18 Years to 45 Years   (Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","2016-1014","December 1, 2020","December 1, 2021","December 1, 2021","February 28, 2017",,"January 10, 2019","University of Wisconsin, Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03066115"
32,"NCT00894803","Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke","CLEAR-ER","Completed","Has Results","Ischemic Stroke|Stroke|Brain Infarction","Drug: Eptifibatide|Drug: rt-PA","Symptomatic Intracranial Hemorrhage (sICH) Within 36 Hours of Treatment Onset|Modified Rankin Scale (mRS) Score <1 or Return to mRS Baseline|Barthel Index ≥ 95|Glasgow Outcome Scale (GOS) of 1","University of Cincinnati|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","126","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","P50NS04483-06|00894803","July 2009","October 2012","December 2012","May 7, 2009","March 17, 2014","April 17, 2014","UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|University of California San Diego, San Diego, California, United States|UCLA Medical Center Santa Monica, Santa Monica, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|St. Elizabeth Healthcare Edgewood, Edgewood, Kentucky, United States|St. Elizabeth Healthcare Florence, Florence, Kentucky, United States|St. Elizabeth Healthcare Ft. Thomas, Ft. Thomas, Kentucky, United States|Suburban Hospital, Bethesda, Maryland, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Mission Hospital, Inc., Asheville, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|University Hospital, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|The Jewish Hospital, Cincinnati, Ohio, United States|Mercy Hospital, Western Hills, Cincinnati, Ohio, United States|Mercy Hospital Mt Airy, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|West Virginia University Hospital, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00894803"
33,"NCT02930018","Safety and Efficacy of NA-1 in Subjects Undergoing Endovascular Thrombectomy for Stroke","ESCAPE-NA1","Completed","No Results Available","Stroke, Acute","Drug: NA-1, 2.6 mg/kg|Drug: Placebo","Modified Rankin Score (mRS)|mRS Shift Analysis|NIHSS|Barthel Index|Mortality Rate|Functional Independence based on mRS","NoNO Inc.|University of Calgary","All","18 Years and older   (Adult, Older Adult)","Phase 3","1105","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA-1-007","March 1, 2017","November 20, 2019","November 20, 2019","October 11, 2016",,"January 21, 2020","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|California Pacific Medical Center - Davies Campus, San Francisco, California, United States|Providence Little Company of Mary Medical Center Torrance, Torrance, California, United States|Swedish Medical Center, Englewood, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Baptist Health Medical Center, Jacksonville, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|WellStar Health Systems, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|NYU Lutheran Medical Center, Brooklyn, New York, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Riverside Radiology, Columbus, Ohio, United States|Abington Memorial Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Swedish Medical Center- Cherry Hill Campus, Seattle, Washington, United States|Royal Adelaide Hospital, Adelaide, Australia|Royal Melbourne Hospital, Parkville, Australia|University of Calgary - Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver Stroke Program Research Office/ Vancouver General Hosptial, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre- University Hospital, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Centre, Toronto, Ontario, Canada|St Michael's Hospital, Toronto, Ontario, Canada|University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada|CHUM Hopital Notre-Dame, Montréal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada|CHU de Quebec- Universite Laval- Hopital de l'Enfant-Jesus, Quebec City, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Universitätsklinikum Carl Gustav Carus Dresdner Neurovaskulares Centrum, Dresden, Germany|Klinik für Radiologie und Neuroradiologie, Essen, Germany|University Medical Center Goettingen, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Neurologische Klinik, Universität Heidelberg, Heidelberg, Germany|Beaumont Hospital, Dublin, Ireland|Mater Hospital, Dublin, Ireland|Dongsan Medical Centre, Daegu, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Yonsei Univ, Severence, Seoul, Korea, Republic of|Skåne University Hospital, Lund, Sweden|Karolinksa Institutet, Stockholm, Sweden|Royal Victoria Hospital, Belfast, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02930018"
34,"NCT01310114","Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke",,"Terminated","No Results Available","Stroke, Acute|Middle Cerebral Artery Stroke|Posterior Cerebral Artery Stroke","Biological: Human Placenta-Derived Cells PDA001- (cenplacel-L)|Drug: Placebo","Safety (Type, frequency, severity and potential relationship to study drug of adverse events)|Clinical response defined by a ≥ 1 point decrease from baseline in the Modified Rankin Scale (mRS) at Day 91 post treatment|Clinical response defined by a ≥ 1 point decrease from baseline in the Modified Rankin Scale (mRS) at Day 181 post treatment|Clinical response defined by a ≥ 1 point decrease from baseline in the Modified Rankin Scale (mRS) at 24 months post treatment|Clinical response defined as a ≥ 4 point decrease from baseline in the National Institute of Health Stroke Scale (NIHSS)|Clinical response defined as a clinically significant improvement (at least 20-point increase from baseline) in the Barthel Index (BI)","Celularity Incorporated|Celgene Corporation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCT-PDA001-SK-001","March 2011","March 2013","March 2013","March 8, 2011",,"March 1, 2018","Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01310114"
35,"NCT01977456","Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)","CLEAR-FDR","Completed","Has Results","Stroke|Brain Infarction","Drug: Eptifibatide","The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH).|The Number of Patients Who Experience Any Intracerebral Hemorrhage (ICH).|The Number of Patients Who Develop Parenchymal Hemorrhage Types 1( PH-1) and 2 (PH-2).","Arthur Pancioli|National Institute of Neurological Disorders and Stroke (NINDS)|University of Cincinnati","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","27","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P50NS044283-13","September 2013","January 2015","April 2015","November 6, 2013","November 25, 2015","January 21, 2016","St. Elizabeth Healthcare System Edgewood, Edgewood, Kentucky, United States|St. Elizabeth Healthcare Florence, Florence, Kentucky, United States|St. Elizabeth Healthcare Ft. Thomas, Ft. Thomas, Kentucky, United States|The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|Jewish Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01977456"
36,"NCT02730455","Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke","ACTION2","Completed","Has Results","Acute Ischemic Stroke","Drug: natalizumab|Drug: Placebo","Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90|Percentage of Participants With Excellent Outcome in mRS Score at Day 90|Percentage of Participants With Excellent Outcome in BI Score at Day 90|Stroke Impact Scale-16 (SIS-16) Score Using a Repeated Measures Mixed Effects Model at Day 90|Montreal Cognitive Assessment (MoCA) Score at Day 90|Change From Baseline in National Institute of Health Stroke Scale (NIHSS) Score at Day 90|Number of Participants Experiencing Adverse Events (AE)|Number of Participants Experiencing Serious Adverse Events (SAE)|Percentage of Participants With Dose Response at Day 90","Biogen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","277","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","101SK202|2015-004783-11","July 18, 2016","November 20, 2017","November 20, 2017","April 6, 2016","January 8, 2019","January 8, 2019","Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainesville, Florida, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Altenburg, Germany|Research Site, Bad Neustadt/Saale, Germany|Research Site, Bamberg, Germany|Research Site, Bergisch Gladbach, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Duesseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Leipzig, Germany|Research Site, Ludwigshafen, Germany|Research Site, Mannheim, Germany|Research Site, Minden, Germany|Research Site, Muenster, Germany|Research Site, Trier, Germany|Research Site, Tuebingen, Germany|Research Site, Ulm, Germany|Research Site, Albacete, Spain|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, Lugo, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valladolid, Spain|Research Site, London, Greater London, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, Harrow, Middlesex, United Kingdom|Research Site, Stoke on Trent, Staffordshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02730455/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02730455/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02730455"
37,"NCT01984164","CAndesartan vs LIsinopril Effects on the BRain","CALIBREX","Completed","No Results Available","Hypertension|Mild Cognitive Impairment","Drug: Candesartan|Drug: Lisinopril","Executive function|Memory|Language|Attention|White Matter Hyperintensity (WMH) Volume|rs-fMRI|Cerebral Perfusion and Vasoreactivity (VR)","Emory University|National Institute on Aging (NIA)","All","55 Years and older   (Adult, Older Adult)","Phase 2","176","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00070087|R01AG042127","August 2014","December 3, 2018","December 3, 2018","November 14, 2013",,"January 10, 2020","Emory Univeristy, Atlanta, Georgia, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01984164/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01984164"
38,"NCT01955707","Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke","ACTION","Completed","Has Results","Acute Ischemic Stroke","Drug: natalizumab|Drug: Placebo","Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR])|Change in Infarct Volume From Baseline (DWI) to 24 Hours (FLAIR)|Change in Infarct Volume From Baseline (DWI) to Day 30 (FLAIR)|Change in Infarct Volume From 24 Hours (FLAIR) to Day 5 (FLAIR)|Change in Infarct Volume From 24 Hours (FLAIR) to Day 30 (FLAIR)|Change in Infarct Volume From Day 5 (FLAIR) to Day 30 (FLAIR)|Change in National Institute of Health Stroke Scale (NIHSS) Score From Baseline to 24 Hours, Day 5, Day 30, and Day 90|Modified Rankin Scale (mRS) Distribution at Day 5, Day 30, and Day 90|Barthel Index at Day 5, Day 30, and Day 90|Number of Participants Who Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)","Biogen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","161","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","101SK201|EUDRA CT NO: 2013‐001514‐15","January 2014","February 2015","April 2015","October 7, 2013","July 1, 2016","July 1, 2016","Research Site, San Diego, California, United States|Research Site, Gainesville, Florida, United States|Research Site, Kansas City, Kansas, United States|Research Site, Boston, Massachusetts, United States|Research Site, Golden Valley, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Lake Success, New York, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Tualatin, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Altenburg, Germany|Research Site, Bad Neustadt, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Duesseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Idar-Oberstein, Germany|Research Site, Leipzig, Germany|Research Site, Ludwigshafen, Germany|Research Site, Ludwigshafen, Germany|Research Site, Mannheim, Germany|Research Site, Trier, Germany|Research Site, Tübingen, Germany|Research Site, Ulm, Germany|Research Site, Albacete, Spain|Research Site, Badalona, Spain|Research Site, Barakaldo, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01955707"
39,"NCT03735979","Multi-arm Optimization of Stroke Thrombolysis","MOST","Suspended","No Results Available","Acute Ischemic Stroke","Drug: Argatroban|Drug: Eptifibatide|Drug: Placebo","90-day modified Rankin scores (mRS)|proportion of participants with 90-day mRS 0-1 (or return to their historical mRS)|proportion of participants with 90-day mRS 0-2 (or return to their historical mRS)|90-day ordinal analysis of the mRS","University of Cincinnati|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 3","1200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2018-1464|1U01NS100699-01A1","October 15, 2019","May 2023","April 2024","November 8, 2018",,"March 27, 2020","University of Alabama Hospital, Birmingham, Alabama, United States|Community Regional Medical Center of Fresno, Fresno, California, United States|UCSD Health La Jolla, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCSD Medical Center - Hillcrest Hospital, San Diego, California, United States|San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Swedish Medical Center, Englewood, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Mayo Clinic Hospital, Jacksonville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Hospital, Kansas City, Kansas, United States|St. Elizabeth Medical Center South, Edgewood, Kentucky, United States|St. Elizabeth Hospital, Florence, Kentucky, United States|St. Elizabeth Hospital Fort Thomas, Fort Thomas, Kentucky, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMASS Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Flint, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|University of Minnesota Medical Center Hospital, Minneapolis, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Hospital, Kansas City, Missouri, United States|St. Louis University Hospital, Saint Louis, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|North Shore University Hospital, Manhasset, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|NYP Columbia University Medical Center, New York, New York, United States|NYP Weill Cornell Medical Center, New York, New York, United States|SUNY Upstate University Hospital, Syracuse, New York, United States|Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Akron General Medical Center, Akron, Ohio, United States|Mercy Health West Hospital, Cincinnati, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|The Jewish Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Mercy Hospital Anderson, Cincinnati, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|St. Luke's University Hospital, Bethlehem, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt University Hospital, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|DHR Health, Edinburg, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann-Texas Medical Center, Houston, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|UVA Medical Center, Charlottesville, Virginia, United States|WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States|University of Wisconsin University Hospital, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03735979"
40,"NCT02963376","A Phase 1b in Patients With Acute Ischemic Stroke",,"Completed","No Results Available","Ischemic Stroke","Drug: 0.05 mL/kg DDFPe|Drug: 0.05 mL/kg Placebo|Drug: 0.10 mL/kg DDFPe|Drug: 0.10 mL/kg Placebo|Drug: 0.17 mL/kg DDFPe|Drug: 0.17 mL/kg Placebo","Maximum Tolerated Dose (MTD) of DDFPe","University of Arkansas","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","205529","February 1, 2017","July 9, 2018","July 9, 2018","November 15, 2016",,"August 13, 2018","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02963376"
41,"NCT01605825","A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke",,"Completed","Has Results","Ischemic Stroke","Drug: placebo/dalfampridine-ER|Drug: dalfampridine-ER/placebo","Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs)","Acorda Therapeutics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","DALF-PS-1003","May 2012","February 2013","March 2013","May 25, 2012","March 10, 2014","January 22, 2016","Acorda Site #011, Birmingham, Alabama, United States|Acorda Site #018, La Jolla, California, United States|Acorda Site #016, Newport Beach, California, United States|Acorda Site #006, Fairfield, Connecticut, United States|Acorda Site #002, Atlantis, Florida, United States|Acorda Site #015, Fort Lauderdale, Florida, United States|Acorda Site #003, Decatur, Georgia, United States|Acorda Site #021, Lexington, Kentucky, United States|Acorda Site #009, Boston, Massachusetts, United States|Acorda Site #017, Saginaw, Michigan, United States|Acorda Site #020, Great Falls, Montana, United States|Acorda Site #023, Reno, Nevada, United States|Acorda Site #022, New Brunswick, New Jersey, United States|Acorda Site #019, Buffalo, New York, United States|Acorda Site #007, West Haverstraw, New York, United States|Acorda Site #004, White Plains, New York, United States|Acorda Site #013, Charlotte, North Carolina, United States|Acorda Site #001, Philadelphia, Pennsylvania, United States|Acorda Site #008, Norfolk, Virginia, United States|Acorda Site #010, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01605825"
42,"NCT01808261","Proof of Concept (POC) in Patients With Ischaemic Stroke",,"Terminated","Has Results","Cerebrovascular Accident","Drug: GSK249320 100/mg|Drug: Placebo","Mean Change From Baseline (BL) to Month 3/ Day 90 in Gait Velocity|Mean Change From BL to Month 6/ Day 180 in Gait Velocity|Number of Participants With Indicated Transition From One Gait Velocity Category to Another Category at the Indicated Time Points|Change From BL in Dexterity as Measured by Box and Blocks Test|Number of Participants Experiencing Falls|Number of Falls Over Time|Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs)|Number of Participants With Events Common to Stroke|Change From BL in Vital Signs- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From BL in Vitals Signs-Heart Rate|Change From BL in ECG Parameter-Heart Rate|Change From BL in ECG Parameters|Change From BL in Clinical Chemistry- Albumin and Total Protein|Change From BL in Clinical Chemistry-urea/Blood Urea Nitrogen (BUN), Sodium (Na), Potassium (K), Glucose (Gluc), Chloride (Cl), Calcium (Ca)|Change From BL in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change From BL in Clinical Chemistry- Direct Bilirubin, Total Bilirubin, Creatinine|Change From BL in Eosinophils (EOS), Lymphocytes (LYM), Total Absolute Neutrophil Count (ANC), Platelet (PLT) Count, White Blood Cell (WBC) Count|Change From BL in Hematology- Hemoglobin|Change From Baseline in Hematology- Hematocrit|Change From BL in NIHSS Total Score|Number of Participants With Suicidal Ideation Via Columbia Suicide Severity Rating Scale (CSSRS)|Maximum Observed Plasma Concentration (Cmax) for GSK249320|Time to Reach Maximum Observed Plasma Concentration (Tmax) GSK249320|PK as Measured by Plasma Decay Half-life (t1/2) GSK249320|Area Under the Concentration-time Curve From 0 to 5 Days [AUC(0-5d)] and Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time [AUC(0-inf)] for GSK249320|Clearance (CL) for GSK249320|Volume of Distribution (V1 and V2) and Volume at Steady State (Vss) for GSK249320|Antibodies Against GSK249320, Assessed Using Electrochemi-luminescent Assay (ECL) Assay","GlaxoSmithKline","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","104615","May 18, 2013","July 28, 2014","July 28, 2014","March 11, 2013","October 3, 2017","November 17, 2017","GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Peoria, Illinois, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, St-Jérôme, Quebec, Canada|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Friedrichshafen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Erlangen, Bayern, Germany|GSK Investigational Site, Celle, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Osnabrueck, Niedersachsen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Bremen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Exeter, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Harrow, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Romford, United Kingdom|GSK Investigational Site, Salford, United Kingdom|GSK Investigational Site, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01808261"
43,"NCT02586233","Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke","ASSENT","Completed","No Results Available","Acute Ischemic Stroke|Thrombotic Disease","Drug: DS-1040b|Drug: Placebo","Number of participants with treatment emergent adverse events|Area under the plasma concentration-time curve from time zero to 24 hours (AUC24) for DS-1040b|Maximum concentration (Cmax) of DS-1040b in plasma|Time to Cmax (Tmax) for DS-1040b in plasma|Urinary excretion within 24 hours (Ae0-24) of DS-1040b|Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen in plasma|D-dimer level in plasma|Total activated thrombin-activatable fibrinolysis inhibitor in plasma|Number of participants with recanalization of occlusion at 24 hours|Change from baseline in National Institute of Health Stroke Scale (NIHSS) score from predose to 30 days post-dose|Change from baseline in modified Rankin Scale (mRS) score at Day 90","Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DS1040-A-U103|2015-001824-43","September 2015","May 16, 2019","August 13, 2019","October 26, 2015",,"September 10, 2019","University of South Alabama USA Health System, Mobile, Alabama, United States|UCLA Medical Center Stroke Network, Los Angeles, California, United States|UC Health Memorial Hospital, Colorado Springs, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Henry Ford Health System, Detroit, Michigan, United States|JFK Neuroscience Institute, Edison, New Jersey, United States|Icahn School Medicine at Mount Sinai, New York, New York, United States|Duke University Health System, Durham, North Carolina, United States|OSU - Wexner Medical Center, Columbus, Ohio, United States|Oregon Health Sciences University Hospital, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Palmetto Health, USC School of Medicine, Columbia, South Carolina, United States|Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States|Houston Methodist, Houston, Texas, United States|Royal North Shore Hospital, Sydney, New South Wales, Australia|Royal Adelaide Hospital Neurology Dept., Adelaide, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|St. Annes University Hospital, Brno, Czechia|Vitkovicka nemocnice a.s. Zaluzanskeho, Ostrava Vitkovice, Czechia|CHRU Besançon - Hôpital Jean Minjoz, Besançon, France|Hôpital Pellegrin - CHU Bordeaux, Bordeaux, France|CHRU Lille - Hôpital Roger Salengro, Lille, France|Klinikum Altenburger Land, Altenburg, Germany|Universittsklinikum Essen AR Klinik fr Neurologie, Essen, Germany|Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt am Main, Germany|Ospedale di Citta di Castello, Città di Castello, Italy|Ospedale di Branca Largo Unita d'Italia, Gubbio, Italy|Ospedale Guglielmo da Saliceto Via Taverna, Piacenza, Italy|Ospedaliero di Albenga - Pietra Ligure Dept Neurology, Pietra Ligure, Italy|Azienda Ospedaliero Universitaria, Pisa, Italy|Ospedale Borgo Trento, Verona, Italy|Pusan National University Hospital, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Svet zdravia a.s.,Vseobecna nemocnica Rimavska Sobota, Rimavská Sobota, Slovakia|NsP Spisska Nova Ves, Spišská Nová Ves, Slovakia|Hospital de la santa creu i sant pau C, Barcelona, Spain|Vall d'Hebron Hospital, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Clinico Universitario Lozano Blesa de Zaragoza, Zaragoza, Spain|Chang Gung Memorial Hospital-Linkou Branch, Taoyuan, Hsien, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|University College Hospitals NHS Foundation Trust, London, England, United Kingdom|Queen Elizabeth University Hospital, Glasgow, Scotland, United Kingdom|Salford Royal Hospital, Salford, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02586233"
44,"NCT01994720","[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]","SOCRATES","Completed","Has Results","Acute Ischaemic Stroke|Transient Ischaemic Attack","Drug: ticagrelor|Drug: Acetylsalicylic acid (ASA)","Number of Participants With Composite of Stroke/MI/Death|Number of Participants With Ischaemic Stroke|Net Clinical Outcome|Number of Participants With Composite of Ischaemic Stroke, MI and CV Death|Number of Participants With All-Cause Death|Number of Participants With CV Death|Number of Participants With MI|Number of Participants by Severity of Stroke and Overall Disability|Number of Participants With Stroke|Number of Participants With Fatal Stroke|Number of Participants With Disabling Stroke|Change in NIHSS|EQ-5D at Visit 1 (Enrolment)|EQ-5D at Visit 2 (Day 7+-2d)|EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit|EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit|Number of Participants With PLATO Major Bleeding Event|Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event","AstraZeneca","All","40 Years to 130 Years   (Adult, Older Adult)","Phase 3","13307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","D5134C00001|2012-003895-38","January 7, 2014","March 2, 2016","March 2, 2016","November 26, 2013","June 12, 2017","June 12, 2017","Research Site, Montgomery, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Fort Smith, Arkansas, United States|Research Site, Fullerton, California, United States|Research Site, Glendale, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport, California, United States|Research Site, Oakland, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Torrance, California, United States|Research Site, Englewood, Colorado, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Weston, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Glenview, Illinois, United States|Research Site, Harvey, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Alexandria, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Annapolis, Maryland, United States|Research Site, Frederick, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, West Bloomfield Township, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Helena, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Bayonne, New Jersey, United States|Research Site, Edison, New Jersey, United States|Research Site, Englewood, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, West Orange, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Syracuse, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Clackamas, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Baytown, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Southlake, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, San Martin, Argentina|Research Site, Adelaide, Australia|Research Site, Bedford Park, Australia|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, Darlinghurst, Australia|Research Site, Footscray, Australia|Research Site, Herston, Australia|Research Site, New Lambton Heights, Australia|Research Site, Parkville, Australia|Research Site, Southport, Australia|Research Site, Sydney, Australia|Research Site, Woodville, Australia|Research Site, Aalst, Belgium|Research Site, Assebroek, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Gent, Belgium|Research Site, Godinne, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Tielt, Belgium|Research Site, Wilrijk, Belgium|Research Site, Botucatu, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirao Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Botevgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Lukovit, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Teteven, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Los Angeles, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Temuco, Chile|Research Site, Valdivia, Chile|Research Site, Viña del Mar, Chile|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chongqin, China|Research Site, Guang Zhou, China|Research Site, Guangzhou, China|Research Site, Guilin, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Huai'an, China|Research Site, Jinan, China|Research Site, Lanzhou, China|Research Site, Linhai, China|Research Site, Nanjing, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Wenzhou, China|Research Site, Wu Han, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Research Site, Yangzhou, China|Research Site, Zhanjiang, China|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Liberec, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Trutnov, Czechia|Research Site, Antony, France|Research Site, Bayonne, France|Research Site, Bordeaux Cedex, France|Research Site, Bourg en Bresse, France|Research Site, Brest Cedex 2, France|Research Site, Bron, France|Research Site, Caen, France|Research Site, Corbeil Essonnes Cedex, France|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, La Roche sur Yon, France|Research Site, Le Chesnay Cedex, France|Research Site, Le Coudray Cedex, France|Research Site, Lille, France|Research Site, NICE Cedex 01, France|Research Site, PARIS Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Paris Cedex 18, France|Research Site, Paris, France|Research Site, Pringy Cedex, France|Research Site, Rennes, France|Research Site, Rouen Cedex, France|Research Site, Saint Herblain, France|Research Site, Saint-priest En Jarez, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse, France|Research Site, Tours, France|Research Site, Altenburg, Germany|Research Site, Bad Neustadt, Germany|Research Site, Berlin, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Minden, Germany|Research Site, Münster, Germany|Research Site, Osnabrück, Germany|Research Site, Wiesbaden, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Miskolc, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron-Balf, Hungary|Research Site, Szekszárd, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel Aviv, Israel|Research Site, Carrara, Italy|Research Site, Citta' di Castello, Italy|Research Site, Foligno, Italy|Research Site, Genova, Italy|Research Site, Gubbio, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Piacenza, Italy|Research Site, Pisa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Siena, Italy|Research Site, Varese, Italy|Research Site, Verona, Italy|Research Site, Vibo Valentia, Italy|Research Site, Aki-gun, Japan|Research Site, Asahikawa-shi, Japan|Research Site, Chiba-shi, Japan|Research Site, Chikushi-gun, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chitose-shi, Japan|Research Site, Daito-shi, Japan|Research Site, Date-gun, Japan|Research Site, Eniwa-shi, Japan|Research Site, Fujinomiya-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hakodate-shi, Japan|Research Site, Hamada-shi, Japan|Research Site, Hanamaki-shi, Japan|Research Site, Hatsukaichi-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Higashiibaraki-gun, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Hitachi-shi, Japan|Research Site, Ina-shi, Japan|Research Site, Itami-shi, Japan|Research Site, Izumisano-shi, Japan|Research Site, Izumo-shi, Japan|Research Site, Kaga-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kakegawa-shi, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kashiwazaki-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Komatsu-shi, Japan|Research Site, Komoro-shi, Japan|Research Site, Koshigaya-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maizuru-shi, Japan|Research Site, Marugame-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagano-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nakano-ku, Japan|Research Site, Nakano-shi, Japan|Research Site, Narita-shi, Japan|Research Site, Nihonmatsu-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Okinawa-shi, Japan|Research Site, Onga-gun, Japan|Research Site, Ookawa-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Saijo-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sanuki-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shiroishi-shi, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Suita-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Tachikawa-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takayama-shi, Japan|Research Site, Tokushima-shi, Japan|Research Site, Toyama-shi, Japan|Research Site, Toyohashi-shi, Japan|Research Site, Toyota-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Utsunomiya-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Zentsuji-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Culiacan, Mexico|Research Site, D.F, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Monterrey, Mexico|Research Site, Bellavista, Peru|Research Site, Callao, Peru|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Baguio City, Philippines|Research Site, Cagayan de Oro City, Philippines|Research Site, Cebu, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Chełm, Poland|Research Site, Działdowo, Poland|Research Site, Gdańsk, Poland|Research Site, Gryfice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Końskie, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Ostrołęka, Poland|Research Site, Sandomierz, Poland|Research Site, Warszawa, Poland|Research Site, Włocławek, Poland|Research Site, Łódź, Poland|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Tirgu-Mures, Romania|Research Site, Belgorod, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Levoca, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Spisska Nova Ves, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Albacete, Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain|Research Site, Falun, Sweden|Research Site, Göteborg, Sweden|Research Site, Halmstad, Sweden|Research Site, Karlstad, Sweden|Research Site, Lidköping, Sweden|Research Site, Linköping, Sweden|Research Site, Malmö, Sweden|Research Site, Mora, Sweden|Research Site, Norrköping, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Östersund, Sweden|Research Site, Aarau, Switzerland|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Chur, Switzerland|Research Site, Genève 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Villars-sur-Glâne, Switzerland|Research Site, Zürich, Switzerland|Research Site, Changhua City, Taiwan|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan Hsien, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chonburi, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Thailand|Research Site, Patumthani, Thailand|Research Site, Rajthevi, Thailand|Research Site, Ratchathewi, Thailand|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Eskisehir, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Konya, Turkey|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01994720"
45,"NCT03804476","Phase 1 Study to Assess AER-271",,"Recruiting","No Results Available","Stroke|Stroke, Acute|Stroke, Ischemic","Drug: AER-271|Drug: Placebo","Number of patients that experience adverse events|Number of patients that experience serious adverse events|Number of patients with significant changes in ALT levels|Number of patients with significant changes in AST levels|Number of patients with significant changes in GGT levels|Number of patients with significant changes in WBC|Number of patients with significant changes in RBC|Number of patients with significant changes in Albumin levels|Number of patients with significant changes in Bilirubin levels|Number of patients with significant changes in Platelet counts|Number of patients with significant changes in Hematocrit|Number of patients with significant changes in Creatinine|Number of patients with significant changes in Alkaline Phosphatase levels|Number of patients with significant changes in Cholesterol levels|Number of patients with significant changes in Respiratory Rate|Number of patients with significant changes in Pulse Rate|Number of patients with significant changes in Oral Temperature|Number of patients with significant changes in Blood Pressure|Number of patients exhibiting changes in Physical Examination|Pharmacokinetic parameter: Mean Cmax +/- standard deviation|Pharmacokinetic parameter: Mean AUC +/- standard deviation|Pharmacokinetic parameter: Mean CL +/- standard deviation|Pharmacokinetic parameter: Mean T1/2 +/- standard deviation|Pharmacokinetic parameter: Mean Vss +/- standard deviation|Changes in ECG Parameters: Mean QTcF +/- standard deviation|Changes in ECG Parameters: Mean QRS +/- standard deviation|Changes in ECG Parameters: Mean PR +/- standard deviation","Aeromics, Inc.|Covance","All","18 Years to 45 Years   (Adult)","Phase 1","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","174273","June 26, 2018","April 10, 2019","July 28, 2019","January 15, 2019",,"January 17, 2019","Covance Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03804476"
46,"NCT02222714","Safety Evaluation of 3K3A-APC in Ischemic Stroke","RHAPSODY","Completed","Has Results","Ischemic Stroke","Biological: 3K3A-APC|Drug: Placebo","Number of Participants With Adverse Events That Meet Dose-limiting Toxicity (DLT) Criteria Specified in Protocol|Number of Participants With a Presence of Measurable Bleeds in the Brain (Hemorrhage and Microbleeds) as Determined by 1.5T MRI|PK of 3K3A-APC by Compartmental Analysis (Clearance)|PK of 3K3A-APC by Compartmental Analysis (Volume of Distribution)|PK of 3K3A-APC by Compartmental Analysis (Cmax)|PK of 3K3A-APC by Compartmental Analysis (AUC[0-inf])|PK of 3K3A-APC by Compartmental Analysis (λz)|PK of 3K3A-APC by Compartmental Analysis (Half-life)","ZZ Biotech, LLC|National Institute of Neurological Disorders and Stroke (NINDS)|Cedars-Sinai Medical Center|Massachusetts General Hospital|University of Iowa","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","110","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZZ-3K3A-201 (NN104)|1U01NS088312-01|U01NS077352|U01NS077179-01","October 2014","April 18, 2017","June 29, 2017","August 21, 2014","November 8, 2018","November 8, 2018","Stroke Center, Los Angeles, California, United States|Stroke Center, Chicago, Illinois, United States|Stroke Center, Kansas City, Kansas, United States|Stroke Center, Boston, Massachusetts, United States|Stroke Center, Saint Louis, Missouri, United States|Stroke Center, Buffalo, New York, United States|Stroke Center, New York, New York, United States|Stroke Center, Rochester, New York, United States|Stroke Center, Cincinnati, Ohio, United States|Stroke Center, Columbus, Ohio, United States|Stroke Center, Pittsburgh, Pennsylvania, United States|Stroke Center, Nashville, Tennessee, United States|Stroke Center, Dallas, Texas, United States|Stroke Center, Salt Lake City, Utah, United States|Stroke Center, Charlottesville, Virginia, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02222714/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02222714/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02222714"
47,"NCT02530307","HT-3951 vs. Placebo in Stroke Rehabilitation","RESTORE","Terminated","No Results Available","Ischemic Stroke","Drug: HT-3951|Drug: Placebo","Fugl-Meyer Assessment of Upper Extremity, Part A-D|Index Finger-Tapping Frequency Test|Nine-Hole Peg Test|Hand Grip Strength Dynamometer Test|Arm Motor Ability Test-9|Stroke Impact Scale (hand domain)|Somatosensory evoked potential (if available)|Two-Minute Walk Test|Behavioral, neural activity and motor network connectivity levels, using functional MRI","Dart NeuroScience, LLC","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HT-3951-201","February 2016","December 31, 2017","December 31, 2017","August 21, 2015",,"February 1, 2018","Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Downey, California, United States|Glendale, California, United States|Loma Linda, California, United States|Orlando, Florida, United States|Chicago, Illinois, United States|Grand Rapids, Michigan, United States|Kansas City, Missouri, United States|West Orange, New Jersey, United States|New York, New York, United States|White Plains, New York, United States|Charlotte, North Carolina, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Elkins Park, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02530307"
48,"NCT02422940","Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.","MILESTONE℠","Terminated","Has Results","Post-ischemic Stroke","Drug: dalfampridine-ER 7.5 mg|Drug: dalfampridine-ER 10 mg","The Primary Objective Was to Evaluate Serious and Non-serious Adverse Events for Study Participants as a Measure of Safety and Tolerability of Dalfampridine ER (Extended Release) for at Least 12-months.|Change From Baseline on the Two-Minute Walk Test (2MinWT)|Change From Baseline on the 10 Meter Walk Test (10MWT)|Change From Baseline on the Timed up and Go (TUG) Test|Change From Baseline on the Walking Impact Scale (Walk-12)|Change From Baseline on the Stroke Impact Scale (SIS)|Subject Global Impression (SGI)|Change From Baseline on the 12-item Health Survey (SF-12)","Acorda Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","294","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DALF-PS-1029","April 2015","January 2017","January 2017","April 22, 2015","August 8, 2018","January 22, 2019","Acorda Site #117, Gilbert, Arizona, United States|Acorda Site #109, Berkeley, California, United States|Acorda Site #170, Carlsbad, California, United States|Acorda Site #138, Long Beach, California, United States|Acorda Site #105, Newport Beach, California, United States|Acorda Site #142, Pasadena, California, United States|Acorda Site #153, Sacramento, California, United States|Acorda Site #151, San Diego, California, United States|Acorda Site #163, San Diego, California, United States|Acorda Site #124, Colorado Springs, Colorado, United States|Acorda Site #110, Danbury, Connecticut, United States|Acorda Site #149, Fairfield, Connecticut, United States|Acorda Site #130, Stamford, Connecticut, United States|Acorda Site #115, Atlantis, Florida, United States|Acorda Site #119, Deerfield Beach, Florida, United States|Acorda Site #147, Gainesville, Florida, United States|Acorda Site #128, Hialeah, Florida, United States|Acorda Site #184, Jacksonville, Florida, United States|Acorda Site #103, Miami, Florida, United States|Acorda Site #133, Miami, Florida, United States|Acorda Site #161, Naples, Florida, United States|Acorda Site #106, Tampa, Florida, United States|Acorda Site #181, Honolulu, Hawaii, United States|Acorda Site #171, Chicago, Illinois, United States|Acorda Site #148, Avon, Indiana, United States|Acorda Site #188, Fort Wayne, Indiana, United States|Acorda Site #156, Franklin, Indiana, United States|Acorda Site #146, Lexington, Kentucky, United States|Acorda Site #150, New Orleans, Louisiana, United States|Acorda Site #175, Fulton, Maryland, United States|Acorda Site #136, Boston, Massachusetts, United States|Acorda Site #121, Boston, Massachusetts, United States|Acorda Site #123, East Lansing, Michigan, United States|Acorda Site #164, Farmington Hills, Michigan, United States|Acorda Site #159, Grand Rapids, Michigan, United States|Acorda Site #101, Kansas City, Missouri, United States|Acorda Site #111, Great Falls, Montana, United States|Acorda Site #140, Reno, Nevada, United States|Acorda Site #131, New Brunswick, New Jersey, United States|Acorda Site #177, Stratford, New Jersey, United States|Acorda Site #172, New York, New York, United States|Acorda Site #179, Patchogue, New York, United States|Acorda Site #114, White Plains, New York, United States|Acorda Site #166, Chapel Hill, North Carolina, United States|Acorda Site #167, Durham, North Carolina, United States|Acorda Site #162, Mooresville, North Carolina, United States|Acorda Site #154, Raleigh, North Carolina, United States|Acorda Site #132, Winston-Salem, North Carolina, United States|Acorda Site #137, Columbus, Ohio, United States|Acorda Site #116, Dayton, Ohio, United States|Acorda Site #152, Corvallis, Oregon, United States|Acorda Site #168, Portland, Oregon, United States|Acorda Site #126, Portland, Oregon, United States|Acorda Site #122, Philadelphia, Pennsylvania, United States|Acorda Site #144, Providence, Rhode Island, United States|Acorda Site #157, Memphis, Tennessee, United States|Acorda Site #113, Dallas, Texas, United States|Acorda Site #165, Dallas, Texas, United States|Acorda Site #108, Houston, Texas, United States|Acorda Site #182, Falls Church, Virginia, United States|Acorda Site #176, Richmond, Virginia, United States|Acorda Site #107, Spokane, Washington, United States|Acorda Site #203, Fredericton, New Brunswick, Canada|Acorda Site #202, Halifax, Nova Scotia, Canada|Acorda Site #201, Greenfield Park, Quebec, Canada|Acorda Site #204, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02422940"
49,"NCT00856661","Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)",,"Terminated","Has Results","Stroke","Drug: Desmoteplase|Drug: Placebo","Modified Rankin Scale Score (mRS) (Percentage of Participants With mRS Scores 0-2)|National Institutes of Health Stroke Scale (NIHSS) Score. (Percentage of Participants With NIHSS Scores <=1 or NIHSS Decrease >=8)|Composite of mRS & NIHSS Response (Percentage of Participants With mRS Scores 0-2 and (NIHSS <= 1 or NIHSS Decrease >= 8)|Modified Ranking Scale Score (Using the Ordinal Scale)","H. Lundbeck A/S","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12649A|2008-005539-14","April 2009","October 2014",,"March 6, 2009","December 22, 2015","March 16, 2017","US053, Phoenix, Arizona, United States|US081, Castro Valley, California, United States|US089, La Jolla, California, United States|US043, Loma Linda, California, United States|US008, Los Angeles, California, United States|US020, Palo Alto, California, United States|US050, Pasadena, California, United States|US098, Santa Barbara, California, United States|US051, Thousand Oaks, California, United States|US068, Englewood, Colorado, United States|US063, Fairfield, Connecticut, United States|US104, New Haven, Connecticut, United States|US049, Pensacola, Florida, United States|US109, Atlanta, Georgia, United States|US042, Augusta, Georgia, United States|US052, Columbus, Georgia, United States|US080, Decatur, Georgia, United States|US040, Lawrenceville, Georgia, United States|US067, Macon, Georgia, United States|US085, Savannah, Georgia, United States|US086, Savannah, Georgia, United States|US093, Chicago, Illinois, United States|US101, Chicago, Illinois, United States|US044, Chicago, Illinois, United States|US074, Evanston, Illinois, United States|US073, Glenview, Illinois, United States|US091, Maywood, Illinois, United States|US088, Oak Lawn, Illinois, United States|US016, Indianapolis, Indiana, United States|US072, Des Moines, Iowa, United States|US061, New Orleans, Louisiana, United States|US108, New Orleans, Louisiana, United States|US064, Shreveport, Louisiana, United States|US014, Baltimore, Maryland, United States|US039, Boston, Massachusetts, United States|US003, Boston, Massachusetts, United States|US017, Worcester, Massachusetts, United States|US066, Detroit, Michigan, United States|US096, Detroit, Michigan, United States|US083, Detroit, Michigan, United States|US060, Grand Blanc, Michigan, United States|US078, Grand Rapids, Michigan, United States|US103, Kalamazoo, Michigan, United States|US056, Petoskey, Michigan, United States|US113, Royal Oak, Michigan, United States|US076, Southfield, Michigan, United States|US082, Southfield, Michigan, United States|US079, Troy, Michigan, United States|US059, Gulfport, Mississippi, United States|US048, Springfield, Missouri, United States|US077, Lebanon, New Hampshire, United States|US055, Edison, New Jersey, United States|US115, Neptune, New Jersey, United States|US100, Ridgewood, New Jersey, United States|US075, Albany, New York, United States|US102, Brooklyn, New York, United States|US012, Buffalo, New York, United States|US026, Stony Brook, New York, United States|US037, Greensboro, North Carolina, United States|US069, Winston-Salem, North Carolina, United States|US038, Cleveland, Ohio, United States|US001, Columbus, Ohio, United States|US062, Columbus, Ohio, United States|US046, Toledo, Ohio, United States|US095, Springfield, Oregon, United States|US070, Allentown, Pennsylvania, United States|US023, Philadelphia, Pennsylvania, United States|US099, Pittsburg, Pennsylvania, United States|US084, Pittsburg, Pennsylvania, United States|US092, Providence, Rhode Island, United States|US087, Warwick, Rhode Island, United States|US057, Columbia, South Carolina, United States|US019, Chattanooga, Tennessee, United States|US058, Nashville, Tennessee, United States|US021, Houston, Texas, United States|US031, Houston, Texas, United States|US112, Houston, Texas, United States|US047, Richmond, Virginia, United States|US006, Winchester, Virginia, United States|US011, Madison, Wisconsin, United States|US097, Milwaukee, Wisconsin, United States|BE008, Brugge, Belgium|BE004, Hasselt, Belgium|BE005, Roeselare, Belgium|BE006, Wilrijk, Belgium|BR012, Campinas, Brazil|BR004, Porto Alegre, Brazil|BR008, Porto Alegre, Brazil|BR007, Porto Alegre, Brazil|BR009, Rio de Janeiro, Brazil|BR011, Rio de Janeiro, Brazil|BR006, Salvador, Brazil|CA001, Calgary, Alberta, Canada|CA004, Edmonton, Canada|CA006, Halifax, Canada|CA008, Mississauga, Canada|CA007, Ottawa, Canada|CA012, Toronto, Canada|CA002, Toronto, Canada|CA005, Victoria, Canada|CL002, Santiago, Chile|CL003, Santiago, Chile|CL004, Santiago, Chile|CL006, Santiago, Chile|CL005, Valparaiso, Chile|DK002, Aalborg, Denmark|DK001, Aarhus, Denmark|DK004, Copenhagen NV, Denmark|DK003, Glostrup, Denmark|FI001, Helsinki, Finland|FI002, Tampere, Finland|FI003, Turku, Finland|IE001, Dublin, Ireland|IT010, Ancona, Italy|IT008, Brescia, Italy|IT003, Firenze, Italy|IT004, Imperia, Italy|IT002, Milano, Italy|IT006, Milano, Italy|IT009, Milano, Italy|IT012, Modena, Italy|IT001, Rome, Italy|IT005, Rome, Italy|IT007, Rozzano, Italy|IT011, Verona, Italy|MX002, D.f., Mexico|MX003, Mexico City, Mexico|MX004, Mexico City, Mexico|MX005, Monterrey Nuevo Leon, Mexico|NO003, Bergen, Norway|NO001, Oslo, Norway|NO002, Trondheim, Norway|ZA003, Cape Town, South Africa|ZA002, Cape Town, South Africa|ZA001, Cape Town, South Africa|SE002, Lund, Sweden|SE001, Malmø, Sweden|GB012, Belfast, United Kingdom|GB004, Christchurch, United Kingdom|GB010, Dundee, United Kingdom|GB002, Exeter, United Kingdom|GB009, Glasgow, United Kingdom|GB007, Glasgow, United Kingdom|GB011, Liverpool, United Kingdom|GB006, London, United Kingdom|GB003, London, United Kingdom|GB001, Newcastle upon Tyne, United Kingdom|GB016, Nottingham, United Kingdom|GB014, Sheffield, United Kingdom|GB005, Stoke on Trent, United Kingdom|GB015, Westcliff-on-Sea, United Kingdom|GB013, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00856661"
50,"NCT01429077","Augmenting Language Therapy for Aphasia: Levodopa",,"Completed","Has Results","Nonfluent Aphasia|Stroke","Drug: levodopa/carbidopa|Drug: Placebo comparator","Language Quotient (LQ) on the Western Aphasia Battery|Functional Communication Skills|Participation in Everyday Activities|Western Aphasia Battery - Reading and Writing Scores|Western Aphasia Battery Aphasia Quotient (Maintenance)|Western Aphasia Battery Reading and Writing Scores (Maintenance)|Functional Communication Skills (Maintenance)|Participation in Everyday Activities (Maintenance)","Shirley Ryan AbilityLab|U.S. Department of Education","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","36","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H133G070074","October 2007","March 2012","March 2012","September 5, 2011","November 28, 2013","December 25, 2013","Center for Aphasia Research & Treatment, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01429077"
51,"NCT01221246","Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours","GMAIS","Completed","No Results Available","Stroke","Drug: GM602|Drug: Placebo Comparator","Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 90 days in patients treated with GM602 within 18 hours compared to treated with placebo as primary efficacy endpoint|Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 30 days in patients treated with GM602 compared to treated with placebo|Percent change in Barthel Index (BI) from baseline to 90 days in patients treated with GM602 compared to treated with placebo|Percent change in Barthel Index (BI) from baseline to 30 days in patients treated with GM602 compared to treated with placebo|Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 90 days|Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 30 days|Secondary safety endpoint as measured by all cause mortality data through 3 months for patients treated with GM602 compared with placebo","Genervon Biopharmaceuticals, LLC|University of California, Los Angeles|Huntington Hospital|Hoag Memorial Hospital Presbyterian|Columbia University|California Pacific Medical Center Research Institute|University Hospital Erlangen|Sarasota Memorial Hospital|University of Louisville","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","34","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GEN-002","March 8, 2011","July 7, 2016","July 7, 2016","October 14, 2010",,"August 12, 2019","UCLA Stroke Center (Departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center), Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Huntington Memorial Hospital Stroke Center, Pasadena, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Columbia University Medical Center, New York, New York, United States|University Erlanger Hospital, Chattanooga, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01221246"
52,"NCT01763606","Enoxaparin Versus Aspirin in Patients With Cancer and Stroke",,"Completed","No Results Available","Cancer Patients First-ever Acute Ischemic Stroke","Drug: Enoxaparin|Drug: Aspirin","Safety Outcomes|Feasibility Outcomes|Efficacy Outcomes","Memorial Sloan Kettering Cancer Center|New York Presbyterian Hospital|Weill Medical College of Cornell University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-264","December 18, 2012","April 3, 2019","April 3, 2019","January 9, 2013",,"April 8, 2019","Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Columbia University, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01763606"
53,"NCT00991029","Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial","POINT","Terminated","Has Results","Ischemic Attack, Transient","Drug: Clopidogrel|Drug: placebo","Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes|Major Hemorrhage|Ischemic Stroke|Myocardial Infarction|Death From Ischemic Vascular Causes|Ischemic or Hemorrhagic Stroke|Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage","University of California, San Francisco|Neurological Emergencies Treatment Trials Network (NETT)|Medical University of South Carolina|The Emmes Company, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","4881","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1U01S062835-01A1","May 28, 2010","April 9, 2018","April 9, 2018","October 7, 2009","December 4, 2018","December 4, 2018","Chandler Regional Medical Center, Chandler, Arizona, United States|Banner University Medical Center - Tucson Campus, Tucson, Arizona, United States|Mercy San Juan Medical Center, Carmichael, California, United States|UCSD Health La Jolla, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Desert Regional Medical Center, Palm Springs, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|UC Davis Medical Center, Sacramento, California, United States|Mercy General Hospital, Sacramento, California, United States|Scripps Mercy Hospital San Diego, San Diego, California, United States|UCSD Medical Center - Hillcrest Hospital, San Diego, California, United States|San Francisco General Hospital, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Los Robles Hospital and Medical Center, Thousand Oaks, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|St. Anthony Hospital, Lakewood, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|George Washington University Hospital, Washington, District of Columbia, United States|UF Health Shands Hospital, Gainesville, Florida, United States|University of Florida, Jacksonville, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|the Queen's Medical Center, Honolulu, Hawaii, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|Evanston Hospital, Evanston, Illinois, United States|NorthShore Glenbrook Hospital, Glenview, Illinois, United States|Presence Saint Joseph Medical Center, Joliet, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Southern Illinois University Memorial Medical Center, Springfield, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Hospital, Kansas City, Kansas, United States|St. Elizabeth Medical Center South, Edgewood, Kentucky, United States|St. Elizabeth Hospital, Florence, Kentucky, United States|St. Elizabeth Hospital Fort Thomas, Fort Thomas, Kentucky, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Frederick Memorial Hospital, Frederick, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMASS Memorial Medical Center, Worcester, Massachusetts, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|St. John Hospital and Medical Center, Detroit, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota Medical Center Hospital, Minneapolis, Minnesota, United States|Mayo Clinic Saint Mary's Campus, Rochester, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Mercy Hospital, Saint Louis, Missouri, United States|Mercy Hospital, Springfield, Missouri, United States|Benefis Hospitals Inc, Great Falls, Montana, United States|Great Falls Clinic Hospital, Great Falls, Great Falls, Montana, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Lincoln Medical and Mental Health Center, Bronx, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|New York Presbyterian / Columbia University Medical Center, New York, New York, United States|NYP Weill Cornell Medical Center, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Strong Memorial Hospital, Rochester, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Summa Akron City Hospital, Akron, Ohio, United States|Mercy Health West Hospital, Cincinnati, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|Jewish Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University Hospital, Portland, Oregon, United States|Portland VA Medical Center, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Pennsylvania State Hershey Medical Center, Hershey, Pennsylvania, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina University Hospital, Charleston, South Carolina, United States|Palmetto Health Richland, Columbia, South Carolina, United States|Vanderbilt University Hospital, Nashville, Tennessee, United States|University Medical Center Brackenridge, Austin, Texas, United States|Seton Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital - Dallas, Dallas, Texas, United States|Valley Baptist Medical Center - Harlingen, Harlingen, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University of Texas Health Science Center San Antonio, San Antonio, Texas, United States|UVA Medical Center, Charlottesville, Virginia, United States|Bon Secours St. Francis Medical Center, Richmond, Virginia, United States|Bon Secours St. Mary's Hospital, Richmond, Virginia, United States|Henrico Doctors' Hospital - Forest Campus, Richmond, Virginia, United States|Henrico Doctors' Hospital - Parham Campus, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States|Columbia St. Mary's Hospital, Milwaukee, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States|Gosford Hospital, Gosford, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|The Northern Hospital, Epping, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|University of Calgary - Foothills Campus, Calgary, Alberta, Canada|Grey Nuns Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Center, London, Ontario, Canada|Charles LeMoyne Hospital, Greenfield Park, Quebec, Canada|Montreal General Hospital, Montreal, Quebec, Canada|Notre-Dame Hospital, Montreal, Quebec, Canada|Enfant-Jesus Hospital, Quebec, Canada|Helsinki University Central Hospital, Helsinki, Finland|Turku University Hospital, Turku, Finland|Fleyriat Hospital, Bourg-en-Bresse, France|Pierre Wetheimer Hospital, Bron, France|Adolphe de Rothschild Ophthalmologic Foundation, Paris, France|Bichat-Claude Bernard Hospital, Paris, France|Pitie-Salpetriere Hospital, Paris, France|Foch Hospital, Suresnes, France|University Hospital of Ulm, Ulm, Baden-Württemberg, Germany|Neurological Clinic Bad Neustadt, Bad Neustadt an der Saale, Germany|Vivantes Hospital Neukolln, Berlin, Germany|Central Bremen Hospital, Bremen, Germany|University Hospital Essen, Essen, Germany|University Hospital Frankfurt, Frankfurt, Germany|University Medical Center Hamburg, Hamburg, Germany|Hannover Medical School, Hannover, Germany|University Hospital Heidelberg, Heidelberg, Germany|University Hospital Schleswig-Holstein Kiel Campus, Kiel, Germany|University Medical Center Leipzig, Leipzig, Germany|University Hospital Munster, Munster, Germany|Mexican Association for Clinical Research, Pachuca, Hidalgo, Mexico|Central Hospital Dr. Ignacio Morones Prieto, San Luis Potosí, San Luis Potosi, Mexico|Culiacan General Hospital, Culiacan, Sinaloa, Mexico|Neurosciences Clinical Trials, Culiacan, Sinaloa, Mexico|ABC Medical Center Santa Fe, Mexico City, Mexico|Auckland City Hospital, Auckland, New Zealand|Hospital del Mar, Barcelona, Spain|Santa Creu and Sant Pau Hospital, Barcelona, Spain|Vall d'Hebron Hospital, Barcelona, Spain|Basurto Hospital, Bilbao, Spain|Burgos University Hospital, Burgos, Spain|Hospital Donostia, Donostia, Spain|Girona University HOspital, Girona, Spain|La Fe University Hospital, Valencia, Spain|Miguel Servet Hospital, Zaragoza, Spain|Addenbrooke's Hospital, Cambridge, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Northwick Park Hospital, Harrow, United Kingdom|The Royal London Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|Luton and Dunstable University Hospital, Luton, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Royal United Hospital - Bath, Somerset, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT00991029/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT00991029/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT00991029"
54,"NCT00961350","A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers",,"Completed","Has Results","Gastric Ulcer","Drug: PA32540|Drug: EC Aspirin 325","Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg|The Number of Participants With Gastric and/or Duodenal Ulcers|The Number of Subjects With ""Treatment Success""|The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events|The Number of Participants With Heartburn Resolution at 6 Months, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit","POZEN","All","55 Years and older   (Adult, Older Adult)","Phase 3","530","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PA32540-301","October 2009","February 2012","February 2012","August 18, 2009","January 21, 2016","February 18, 2016","Pozen, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00961350"
55,"NCT00960869","Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers",,"Completed","Has Results","Gastric Ulcer","Drug: PA32540|Drug: EC-Aspirin 325 mg","Number of Participants With Gastric Ulcer Confirmed by Endoscopy|The Number of Participants With Gastric and/or Duodenal Ulcers|The Number of Subjects With ""Treatment Success""|The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events|The Number of Participants With Heartburn Resolution at 6 Months, i.e. no Heartburn Symptoms During the Last 7 Days Prior to the Visit","POZEN","All","55 Years and older   (Adult, Older Adult)","Phase 3","519","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PA32540-302","October 2009","February 2012","February 2012","August 18, 2009","February 17, 2016","February 17, 2016","Pozen, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00960869"
56,"NCT02271217","A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.","MILESTONE℠","Completed","Has Results","Post-Ischemic Stroke","Drug: Placebo|Drug: dalfampridine-ER 7.5mg|Drug: dalfampridine-ER 10mg","Proportion of Subjects Who Show at Least a 20% Improvement on the Two Minute Walk Test (2MinWT) at Week 12|Change From Baseline on the Walking Impact Scale (Walk-12) at Week 12 (Key Secondary)","Acorda Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","377","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DALF-PS-1016","December 2014","September 2016","October 2016","October 22, 2014","December 4, 2017","June 7, 2018","Acorda Site #117, Gilbert, Arizona, United States|Acorda Site #109, Berkeley, California, United States|Acorda Site #138, Long Beach, California, United States|Acorda Site #105, Newport Beach, California, United States|Acorda Site #170, Oceanside, California, United States|Acorda Site #142, Pasadena, California, United States|Acorda Site #153, Sacramento, California, United States|Acorda Site #151, San Diego, California, United States|Acorda Site #163, San Diego, California, United States|Acorda Site #124, Colorado Springs, Colorado, United States|Acorda Site #110, Danbury, Connecticut, United States|Acorda Site #149, Fairfield, Connecticut, United States|Acorda Site #130, Stamford, Connecticut, United States|Acorda Site #115, Atlantis, Florida, United States|Acorda Site #119, Deerfield Beach, Florida, United States|Acorda Site #147, Gainesville, Florida, United States|Acorda Site #128, Hialeah, Florida, United States|Acorda Site #143, Jacksonville, Florida, United States|Acorda Site #103, Miami, Florida, United States|Acorda Site #133, Miami, Florida, United States|Acorda Site #161, Naples, Florida, United States|Acorda Site #145, Sunrise, Florida, United States|Acorda Site #106, Tampa, Florida, United States|Acorda Site #186, Atlanta, Georgia, United States|Acorda Site #181, Kailua, Hawaii, United States|Acorda Site #171, Chicago, Illinois, United States|Acorda Site #148, Avon, Indiana, United States|Acorda Site #188, Fort Wayne, Indiana, United States|Acorda Site #156, Franklin, Indiana, United States|Acorda Site #146, Lexington, Kentucky, United States|Acorda Site #150, New Orleans, Louisiana, United States|Acorda Site #175, Fulton, Maryland, United States|Acorda Site #136, Boston, Massachusetts, United States|Acorda Site #121, Boston, Massachusetts, United States|Acorda Site #120, Worcester, Massachusetts, United States|Acorda Site #164, Bingham Farms, Michigan, United States|Acorda Site #127, Detroit, Michigan, United States|Acorda Site #123, East Lansing, Michigan, United States|Acorda Site #159, Grand Rapids, Michigan, United States|Acorda Site #101, Kansas City, Missouri, United States|Acorda Site #111, Great Falls, Montana, United States|Acorda Site #140, Reno, Nevada, United States|Acorda Site #131, New Brunswick, New Jersey, United States|Acorda Site #177, Stratford, New Jersey, United States|Acorda Site #172, New York, New York, United States|Acorda Site #102, New York, New York, United States|Acorda Site #179, Patchogue, New York, United States|Acorda Site #114, White Plains, New York, United States|Acorda Site #166, Chapel Hill, North Carolina, United States|Acorda Site #167, Durham, North Carolina, United States|Acorda Site #162, Mooresville, North Carolina, United States|Acorda Site #154, Raleigh, North Carolina, United States|Acorda Site #132, Winston-Salem, North Carolina, United States|Acorda Site #187, Bellevue, Ohio, United States|Acorda Site #160, Cleveland, Ohio, United States|Acorda Site #137, Columbus, Ohio, United States|Acorda Site #116, Dayton, Ohio, United States|Acorda Site #152, Corvallis, Oregon, United States|Acorda Site #168, Portland, Oregon, United States|Acorda Site #126, Portland, Oregon, United States|Acorda Site #158, Abington, Pennsylvania, United States|Acorda Site #122, Philadelphia, Pennsylvania, United States|Acorda Site #144, Providence, Rhode Island, United States|Acorda Site #157, Memphis, Tennessee, United States|Acorda Site #113, Dallas, Texas, United States|Acorda Site #165, Dallas, Texas, United States|Acorda Site #108, Houston, Texas, United States|Acorda Site #182, Alexandria, Virginia, United States|Acorda Site #176, Richmond, Virginia, United States|Acorda Site #107, Spokane, Washington, United States|Acorda Site #203, Fredericton, New Brunswick, Canada|Acorda Site #202, Halifax, Nova Scotia, Canada|Acorda Site #201, Greenfield Park, Quebec, Canada|Acorda Site #204, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02271217"
57,"NCT02258880","Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke",,"Withdrawn","No Results Available","Stroke","Drug: SUN13837|Drug: placebo","Mean change from baseline in the Physical Performance Assessment in Stroke (PPAS)|The proportion of responders as measured by the PPAS|Mean change from baseline in PPAS Patient Reported Outcome Subscale|Mean change from baseline in Short Form-36 Physical Functioning Scale (SF-36 PF)|Mean change from baseline in Gait Speed|Proportion of responders as measured by the Modified Rankin Scale (mRS)|Safety/Tolerability - Number of Participants with Adverse Events","Daiichi Sankyo, Inc.|Syneos Health","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASBI 802","September 2014","May 2016","May 2016","October 8, 2014",,"October 20, 2015","Mobile, Alabama, United States|Encinita, California, United States|Oceanside, California, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Savannah, Georgia, United States|Lexington, Kentucky, United States|Marrero, Louisiana, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|Worcester, Massachusetts, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Novi, Michigan, United States|Southfield, Michigan, United States|Kalispell, Montana, United States|Reno, Nevada, United States|Edison, New Jersey, United States|Summit, New Jersey, United States|Brooklyn, New York, United States|Chapel Hill, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Bryn Mawr, Pennsylvania, United States|Hershey, Pennsylvania, United States|Paoli, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Chattanooga, Tennessee, United States|Houston, Texas, United States|Mechanicsville, Virginia, United States|Midlothian, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Edmonton, Alberta, Canada|Victoria, British Columbia, Canada|St-Jerome, Quebec, Canada|Haifa, Israel|Haifa, Israel|Holon, Israel|Kfar-Saba, Israel|Naharyia, Israel|Ramat Gan, Israel|Tel-Aviv, Israel|Bloemfontein, Free State, South Africa|Alberton, Gauteng, South Africa|Krugersdorp, Gauteng, South Africa|Bellville, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT02258880"
58,"NCT01751854","Enhanced Motor Recovery Using Serotonergic Agents in Stroke",,"Completed","No Results Available","Patients With Chronic Stroke","Drug: SSRI|Drug: Placebo","Peak treadmill speed|overground walking speed","Shirley Ryan AbilityLab","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STU00014257|1250--018","December 2004","January 2012","January 2012","December 18, 2012",,"December 28, 2016","Rehabilitation Institute of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01751854"
59,"NCT02905565","NBP in Adult Patients With Acute Ischemic Stroke (AIS)",,"Active, not recruiting","No Results Available","AIS","Drug: NBP Softgel Capsules|Drug: Placebo","Incidence rate of treatment-emergent adverse events (TEAEs)|PK profile of NBP treatment in subjects with AIS|Exploratory efficacy outcome: mRS|Exploratory efficacy outcome: Barthel Index (BI) Assessment|Exploratory efficacy outcome: NIHSS|Exploratory efficacy outcome: Stroke Impact Scale (SIS) Assessment","CSPC-NBP Pharmaceutical Co., Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CSPC-NBP-2001","February 28, 2018","January 2021","January 2021","September 19, 2016",,"April 30, 2020","Investigative Site, Los Angeles, California, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Jacksonville, Florida, United States|Investigative Site, Fort Wayne, Indiana, United States|Investigative Site, Des Moines, Iowa, United States|Investigative Site, Louisville, Kentucky, United States|Investigative Site, Boston, Massachusetts, United States|Investigative Site, Golden Valley, Minnesota, United States|Investigative Site, Saint Louis, Missouri, United States|Investigative Site, Columbia Falls, Montana, United States|Investigative Site, Omaha, Nebraska, United States|Investigative Site, Buffalo, New York, United States|Investigative Site, Asheville, North Carolina, United States|Investigative Site, Columbus, Ohio, United States|Investigative Site, Dayton, Ohio, United States|Investigative Site, Hillsboro, Oregon, United States|Investigative Site, Portland, Oregon, United States|Investigative Site, Portland, Oregon, United States|Investigative Site, Portland, Oregon, United States|Investigative Site, Philadelphia, Pennsylvania, United States|Investigative Site, Charleston, South Carolina, United States|Investigative Site, Columbia, South Carolina, United States|Investigative Site, Chattanooga, Tennessee, United States|Investigative Site, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT02905565"
60,"NCT01369069","Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial","SHINE","Completed","Has Results","Acute Ischemic Stroke|Diabetes|Hyperglycemia","Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL|Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL","Number of Participants With a Favorable Modified Rankin Scale (Yes/No)|Number of Participants With Severe Hypoglycemia (Blood Glucose < 40mg/dL)|Number of Participants With a Favorable NIHSS|Number of Participants With a Favorable Barthel Index|Stroke Specific Quality of Life (SSQOL)","University of Virginia|Neurological Emergencies Treatment Trials Network (NETT)|Medical University of South Carolina|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 3","1151","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","15959|U01NS069498","April 2012","November 19, 2018","November 19, 2018","June 8, 2011","December 16, 2019","December 23, 2019","University of Arizona Medical Center - South Campus, Tucson, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Ronald Regan Medical Center, Los Angeles, California, United States|San Francisco General Hospital, San Francisco, California, United States|California Pacific Medical Center - Davies Campus, San Francisco, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Emory University Hospital - Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Augusta University Medical Center, Augusta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Lincoln Medical and Mental Health Center, Bronx, New York, United States|Kings County Hospital, Brooklyn, New York, United States|SUNY Downstate University Hospital of Brooklyn, Brooklyn, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|The Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Maimonides Medical Center, New York, New York, United States|Summa Akron City Hospital, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Wexner Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|UPMC - Mercy, Pittsburgh, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|St. Thomas Neuroscience Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dell Seton Medical Center at UT, Austin, Texas, United States|Seton Medical Center, Austin, Texas, United States|UT Southwestern-Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern-Zale Lipshy University Hospital, Dallas, Texas, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Memorial Herman Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Froedtert Memorial Hospital, Milwaukee, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01369069/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT01369069/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01369069"
61,"NCT03192215","AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke","ARCADIA","Suspended","No Results Available","Stroke","Drug: Apixaban|Drug: Aspirin","Incidence of recurrent stroke|Incidence of recurrent ischemic stroke or systemic embolism|Incidence of recurrent stroke of any type plus death from any cause|Incidence of symptomatic intracranial hemorrhage (including symptomatic hemorrhagic transformation of an ischemic stroke).|Incidence of major hemorrhage other than intracranial hemorrhage|Incidence of death from any cause","Columbia University|National Institute of Neurological Disorders and Stroke (NINDS)|University of Cincinnati|Medical University of South Carolina|Bristol-Myers Squibb|Pfizer|Roche Pharma AG|Weill Medical College of Cornell University|University of Washington","All","45 Years and older   (Adult, Older Adult)","Phase 3","1100","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAR4607|1U01NS095869-01A1","January 19, 2018","January 18, 2022","April 30, 2022","June 20, 2017",,"April 17, 2020","University of Alabama, Birmingham, Alabama, United States|University of South Alabama University Hospital, Mobile, Alabama, United States|Chandler Regional Medical Center Chandler, AZ, Chandler, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|UAMS Medical Center, Little Rock, Arkansas, United States|Mercy San Juan Medical Center (Dignity Health), Carmichael, California, United States|Eden Medical Center, Castro Valley, California, United States|Rancho Los Amigos National Rehabilitation Center, Downey, California, United States|Community Regional Medical Center, Fresno, California, United States|UCSD Health La Jolla, La Jolla, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Los Alamitos Medical Center, Los Alamitos, California, United States|Kaiser Permanente, Los Angeles, California, United States|Keck Hospital Of USC, Los Angeles, California, United States|Los Angeles County- USC Medical Center, Los Angeles, California, United States|VA Greater Los Angeles - West LA VA Medical Center, Los Angeles, California, United States|Salinas Valley Memorial Hospital, Salinas, California, United States|Scripps Mercy, San Diego, California, United States|UCSD Medical Center - Hillcrest Hospital, San Diego, California, United States|Kaiser Permanent San Diego Medical Center, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|San Francisco General, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Good Samaritan, San Jose, California, United States|Stanford University Medical Center, Stanford, California, United States|Swedish Medical Center, Englewood, Colorado, United States|St. Mary's Medical Center, Grand Junction, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|Med-star Georgetown Univ., Washington, District of Columbia, United States|Medstar Washington, Washington, District of Columbia, United States|UF Health Shands, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Jackson Memorial, Miami, Florida, United States|Univ. Miami Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Intercoastal Medical Group - Hyde Park, Sarasota, Florida, United States|Tampa General, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Grady Memorial, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Southern Illinois University Memorial Medical Center, Springfield, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Mass General Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical, Boston, Massachusetts, United States|Brigham & Womens Hospital, Boston, Massachusetts, United States|U Mass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Flint, Flint, Michigan, United States|Mercy Health St. Mary's, Grand Rapids, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|McLaren Macomb, Mount Clemens, MI, Mount Clemens, Michigan, United States|Abbot Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County, Minneapolis, Minnesota, United States|Univ. of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Regions Hospital, St. Paul, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|St. Louis University Hospital, Saint Louis, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Cox Medical Center South, Springfield, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|Robert Wood Johnson, New Brunswick, New Jersey, United States|Capital Health Medical Center Hopewell, Pennington, New Jersey, United States|Univ. New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Kings County Hospital, Brooklyn, New York, United States|New York Presbyterian - Brooklyn Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Mount Sinai Beth Israel Brooklyn, Brooklyn, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|North Shore University Hospital, Manhasset, New York, United States|NYU Langone, New York, New York, United States|Mount Sinai West, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|Strong Memorial Hospital, Rochester, New York, United States|Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Sanford Medical Center Fargo, Fargo, North Dakota, United States|University of Cincinnati, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, Ohio, United States|UH Cleveland Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|OSU Wexner, Columbus, Ohio, United States|Ohio Health Riverside - Riverside Methodist Hospital, Columbus, Ohio, United States|Miami Valley Hospita, Dayton, Ohio, United States|Mercy Health St Vincent, Toledo, Ohio, United States|OU Medical Center Oklahoma, Oklahoma City, Oklahoma, United States|Legacy Emanuel, Portland, Oregon, United States|Oregon Health and Sciences, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Richland Hospital (formerly Palmetto Health), Columbia, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Valley Bapist, Harlingen, Texas, United States|Baylor College College of Medicine, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|Univ of Texas Health Science Center San Antonio, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Univ of Utah, Salt Lake City, Utah, United States|George E Whalen VA, Salt Lake City, Utah, United States|UVA Medical Center, Charlottesville, Virginia, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Puget Sound VA, Seattle, Washington, United States|Swedish Medical Center - Cherry Hill Campus, Seattle, Washington, United States|WVU Healthcare Ruby Memorial, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03192215"
62,"NCT02148367","Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI","TBI-EPO","Withdrawn","No Results Available","Traumatic Brain Injury","Drug: Erythropoietin","Effect of 4 weeks of EPO administration on numbers of circulating EPCs in patients with persistent symptoms during the subacute period after TBI (within subject comparison).|Comparison of the change of numbers of circulating EPC's between EPO and placebo groups.|Effect of 4 weeks of EPO administration on plasma biomarkers of angiogenesis and inflammation, such as stem cell factor (SCF), vascular endothelial growth factor (VEGF), stromal-derived factor (SDF-1α); and matrix metalloproteinase-9 (MMP-9)|Effect of 4 weeks of placebo administration on numbers of circulating EPCs in patients with persistent symptoms during the subacute period after TBI.","Uniformed Services University of the Health Sciences|National Institutes of Health (NIH)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","0","U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","T-N-2695|306135-7.01-60855","September 2014","June 2016","December 2016","May 28, 2014",,"January 18, 2019","National Institutes of Health, Clinical Center., Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02148367"
63,"NCT02628847","Sildenafil and Stroke Recovery",,"Terminated","No Results Available","Stroke","Drug: sildenafil citrate|Drug: Placebo","Fugl-Meyer Motor Assessment|Fugl-Meyer Assessment|10 meter walk|Wolf Motor Function Test|Motor Activity Log|Stroke Impact Scale","University of Utah","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","53515","March 2012","October 2016","October 2016","December 11, 2015",,"January 5, 2017","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02628847"
64,"NCT02162550","Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus",,"Active, not recruiting","No Results Available","Type 2 Diabetes","Drug: Bydureon|Drug: placebo","Change in carotid plaque volume|Change in reactive hyperemic index|Change in carotid plaque composition","Phoenix VA Health Care System","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 4","148","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1026","June 2014","April 2019","September 2019","June 12, 2014",,"June 14, 2018","Phoenix VA Health Care System, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02162550"
65,"NCT01963832","RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke",,"Withdrawn","No Results Available","Severe Stroke With Affected Arm Motor Function","Drug: Fluoxetine|Drug: Placebo|Procedure: eCMIT|Procedure: Usual Care","Grade 4/5 Motor Activity Log (MAL) Arm Use Scale|Grade 4/5 MAL Arm Use scale|Grade 4/5 Wolf Motor Function Test Performance Rate score","University of Alabama at Birmingham","Male","40 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","F130410007","November 2016","November 2020","November 2021","October 16, 2013",,"January 12, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01963832"
66,"NCT02670824","Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage",,"Completed","No Results Available","Intracerebral Hemorrhage (ICH)","Drug: CN-105|Drug: Placebo","The number and percentage of participants having study procedure-related suspected adverse reactions assessed by change from baseline in vital signs, ECG and clinical labs.","AegisCN LLC","All","18 Years to 50 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CN-105-01","December 2015","May 2016","August 2016","February 2, 2016",,"August 18, 2016","Duke Clinical Research Institute, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02670824"
67,"NCT01730534","Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events","DECLARE-TIMI58","Completed","Has Results","Diabetes Mellitus, Non-Insulin-Dependent|High Risk for Cardiovascular Event","Drug: Dapagliflozin 10 mg|Drug: Placebo tablet","Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke|Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.|Subjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death.|Subjects Included in the Endpoint of All-cause Mortality.","AstraZeneca|Bristol-Myers Squibb|The TIMI Study Group|Hadassah Medical Organization","All","40 Years to 130 Years   (Adult, Older Adult)","Phase 3","17190","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1693C00001","April 25, 2013","September 11, 2018","September 11, 2018","November 21, 2012","December 26, 2019","December 26, 2019","Research Site, Alexander City, Alabama, United States|Research Site, Athens, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Bakersfield, California, United States|Research Site, Greenbrae, California, United States|Research Site, Huntington Park, California, United States|Research Site, La Mesa, California, United States|Research Site, Lomita, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, San Marino, California, United States|Research Site, San Ramon, California, United States|Research Site, Torrance, California, United States|Research Site, Ventura, California, United States|Research Site, Vista, California, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Bristol, Connecticut, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Seaford, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Bradenton, Florida, United States|Research Site, Chiefland, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Spring Hill, Florida, United States|Research Site, Stuart, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Trinity, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Calhoun, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Avon, Indiana, United States|Research Site, Bloomington, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Newburgh, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Topeka, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Beltsville, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Natick, Massachusetts, United States|Research Site, Alpena, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Eagan, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lee's Summit, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Reno, Nevada, United States|Research Site, Edison, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Northport, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Southampton, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Westfield, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Monroe, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canal Fulton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Delaware, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Parma Hts., Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Johnstown, Pennsylvania, United States|Research Site, Kittanning, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Tyrone, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Midland, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Bennington, Vermont, United States|Research Site, Burke, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Burien, Washington, United States|Research Site, Puyallup, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aire, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, La Plata, Argentina|Research Site, La Plata, Argentina|Research Site, Lanus, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Adelaide - Oaklands Park, Australia|Research Site, Ashford, Australia|Research Site, Box Hill, Australia|Research Site, Camperdown, Australia|Research Site, Darlinghurst, Australia|Research Site, Fullarton, Australia|Research Site, Garran, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg West, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Maroubra, Australia|Research Site, Melbourne, Australia|Research Site, Milton, Australia|Research Site, Murdoch, Australia|Research Site, Wollongong, Australia|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Mechelen, Belgium|Research Site, Merksem, Belgium|Research Site, Roeselare, Belgium|Research Site, Tienen, Belgium|Research Site, Turnhout, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Marilia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Jose dos Campos, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Botevgrad, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lukovit, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Calgary, Alberta, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Sydney Mines, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Concord, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Laval, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, ShiJiazhuang, China|Research Site, Tianjin, China|Research Site, Beroun, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Cheb, Czechia|Research Site, Chomutov, Czechia|Research Site, Chrudim III, Czechia|Research Site, Hodonin, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Kromeriz, Czechia|Research Site, Ostrava - Belsky les, Czechia|Research Site, Ostrava - Dubina, Czechia|Research Site, Ostrava - Kuncice, Czechia|Research Site, Ostrava-Moravska, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 6, Czechia|Research Site, Praha, Czechia|Research Site, Prelouc, Czechia|Research Site, Rakovnik, Czechia|Research Site, Slany, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Angers cedex 9, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon Cedex, France|Research Site, Dijon, France|Research Site, La Rochelle, France|Research Site, Le Creusot, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Pessac, France|Research Site, Poitiers Cedex, France|Research Site, TOULOUSE Cedex 9, France|Research Site, Aschaffenburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Causeway Bay, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Tai Po, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Ballasagyarmat, Hungary|Research Site, Berettyóújfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegléd, Hungary|Research Site, Csongrád, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Gyöngyös, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Komárom, Hungary|Research Site, Mórahalom, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Polgár, Hungary|Research Site, Sopron, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Tát, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ács, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Pune, India|Research Site, Vellore, India|Research Site, Afula, Israel|Research Site, Ashkelon, Israel|Research Site, Beer Sheva, Israel|Research Site, Bnei Barak, Israel|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Naharia, Israel|Research Site, Petach Tikva, Israel|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Negrar - VR, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Rozzano, Italy|Research Site, S Maria Capua Vetere, Italy|Research Site, Sessa Aurunca, Italy|Research Site, Verona, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsubara-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Yao-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Jeonju-si, Jeollabuk-do, Korea, Republic of|Research Site, Jung-gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, Acapulco, Mexico|Research Site, Culiacan, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Meridas, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Pachuca de Soto, Mexico|Research Site, Queretaro, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Tijuana, Mexico|Research Site, Veracruz, Mexico|Research Site, Xalapa, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Haarlem, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sliedrecht, Netherlands|Research Site, Sneek, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Bacolod, Philippines|Research Site, Cebu City, Philippines|Research Site, Dasmarinas City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Makati City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Marikina City, Philippines|Research Site, Pasay City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Tanauan City, Philippines|Research Site, Biała Rawska, Poland|Research Site, Bydgoszcz, Poland|Research Site, ChrzanÓw, Poland|Research Site, Gdansk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Katowice, Poland|Research Site, Koluszki, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Mrągowo, Poland|Research Site, Nakło nad Notecią, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Płock, Poland|Research Site, Ruda Śląska, Poland|Research Site, Skierniewice, Poland|Research Site, Sobótka, Poland|Research Site, Sokółka, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Węgrów, Poland|Research Site, Włocławek, Poland|Research Site, Zabrze, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Galati, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Ploiesti, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Tirgu Mures, Romania|Research Site, Târgu Mures, Romania|Research Site, Zalau, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Banská Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolný Kubín, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Košice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lučenec, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Námestovo, Slovakia|Research Site, Piešťany, Slovakia|Research Site, Poprad, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Rimavská Sobota, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Sala, Slovakia|Research Site, Trebišov, Slovakia|Research Site, Trenčín, Slovakia|Research Site, Vrutky, Slovakia|Research Site, Žilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Diepkloof, Soweto, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Goodwood, South Africa|Research Site, Houghton, South Africa|Research Site, Muckleneuk, South Africa|Research Site, Parktown West, South Africa|Research Site, Parktown, South Africa|Research Site, Phoenix, South Africa|Research Site, Somerset West, South Africa|Research Site, Verulam, South Africa|Research Site, Worcester, South Africa|Research Site, Almeria, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Sant Joan Despi, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Borås, Sweden|Research Site, Eksjö, Sweden|Research Site, Finspång, Sweden|Research Site, Gothenburg, Sweden|Research Site, Gothenburg, Sweden|Research Site, Järfälla, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Ostersund, Sweden|Research Site, Rättvik, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden|Research Site, Vällingby, Sweden|Research Site, Changhua, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Muang, Thailand|Research Site, Nakhon Ratchasima, Thailand|Research Site, Pathumthani, Thailand|Research Site, Phisanulok, Thailand|Research Site, Rajthevi, Thailand|Research Site, Ratchaburi, Thailand|Research Site, Ratchathewi, Thailand|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, İzmir, Turkey|Research Site, Dnepropetrovsk, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vynnitsa, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, Addlestone, United Kingdom|Research Site, Aylesbury, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Canterbury, United Kingdom|Research Site, Corsham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Irvine, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Mortimer Reading, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Whitstable, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh City, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01730534/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01730534/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01730534"
68,"NCT00938314","Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients","REGENESIS-LED","Terminated","Has Results","Stroke","Drug: human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|Drug: Saline Placebo","National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90|NIHSS Response >=4 at Day 90|NIHSS Change From Baseline at Day 30|Modified Rankin Scale (mRS) Response <=2 at Day 90|Barthel Index at Day 90|Action Research Arm Test (ARAT) Change From Baseline at Day 90|Gait Velocity Test Change From Baseline at Day 90|Boston Naming Test (BNT) Change From Baseline at Day 90|Line Cancellation Test Change From Baseline at Day 90|Trails A Test Change From Baseline at Day 90|Trails B Test Change From Baseline at Day 90|Geriatric Depression Scale at Day 90","Stem Cell Therapeutics Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NTx®-265-CP-202-IS","August 2009","April 2010","April 2010","July 13, 2009","November 9, 2011","November 29, 2011","University of California, Irvine Medical Center, Orange, California, United States|Foothills Medical Center , University of Calgary, Calgary, Alberta, Canada|Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|Lalitha Super Specialty Hospitals Pvt.Ltd, Guntur, Andhra Pradesh, India|Care Hospital, Hyderabad, Andhra Pradesh, India|Krishna Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India|St.Theresa's General Hospital, Hyderabad, Andhra Pradesh, India|Apollo Hospitals, Hyderabad, Andhra Pradesh, India|Owaisi Hospital and Research Centre, Hyderabad, Andhra Pradesh, India|Mediciti Hospital, Hyderabad, Andhra Pradesh, India|Kamineni Hospital, Hyderabad, Andhra Pradesh, India|DBR & SK Super Speciality Hospital, Tirupati, Andhra Pradesh, India|Latha Superspecialities Hospital, Vijayawada, Andhra Pradesh, India|Suraksha Neuro Centre, Vijayawada, Andhra Pradesh, India|Max Super Speciality Hospital, New Delhi, Delhi, India|M S Ramaiah Memorial Hospital, Bangalore, Karnataka, India|J.S.S Medical College & Hospital, Bangalore, Karnataka, India|Ananthapuri Hospitals and Research Institute, Thiruvananthapuram, Kerala, India|Christian Medical College and Hospital, Ludhiana, Punjab, India|Vijaya Health Center, Chennai, Tamilnadu, India|Christian Medical College Hospital, Vellore, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT00938314"
69,"NCT01422161","Study of Botulinum Toxin and Recovery of Hand Function After Stroke",,"Completed","Has Results","Stroke With Hemiparesis","Drug: Botulinum Toxin commonly known as BOTOX®|Drug: Placebo","Time Taken to Form a Stable Grasp Pre-Treatment|Time Taken to Form a Stable Grasp Post Treatment|Measure of Upper Limb Motor Impairment Measured by Fugl Meyer Scale|Disability Measured by Modified Rankin Scale Score Post-Treatment|Motor Impairment Measured by the Fugl-Meyer Scale Post-Treatment|Disability Measured by Modified Rankin Scale Score Pre-Treatment","NYU Langone Health|Allergan","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","10-01126","April 2010","October 2015","October 2015","August 23, 2011","May 31, 2019","June 20, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01422161"
70,"NCT01732822","A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease","EUCLID","Completed","Has Results","Peripheral Artery Disease","Drug: Ticagrelor|Drug: Clopidogrel","Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke|Composite of CV Death, MI, Ischemic Stroke, and ALI|CV Death|MI|All-cause Mortality|Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)|ALI|Lower Extremity Revascularization|Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])","AstraZeneca","All","50 Years to 130 Years   (Adult, Older Adult)","Phase 3","13885","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D5135C00001|2011-004616-36","December 4, 2012","September 26, 2016","September 26, 2016","November 26, 2012","October 30, 2017","October 30, 2017","Research Site, Alexander City, Alabama, United States|Research Site, Auburn, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Cottonwood, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Fort Smith, Arkansas, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Berkeley, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Chula Vista, California, United States|Research Site, El Cajon, California, United States|Research Site, Fresno, California, United States|Research Site, La Jolla, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Moreno Valley, California, United States|Research Site, Northridge, California, United States|Research Site, Oceanside, California, United States|Research Site, Orange, California, United States|Research Site, Palo Alto, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Stockton, California, United States|Research Site, Torrance, California, United States|Research Site, Torrance, California, United States|Research Site, Loveland, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Guilford, Connecticut, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Newark, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, D.C., District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hudson, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Stuart, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Trinity, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Lithonia, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Martinez, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hinsdale, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Elkhart, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Edgewood, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Bossier City, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Beltsville, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Mount Clemens, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Kalispell, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Belleville, New Jersey, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Camden, New Jersey, United States|Research Site, East Orange, New Jersey, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Elmer, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, Freehold, New Jersey, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Linden, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Ocean City, New Jersey, United States|Research Site, Sewell, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, West Orange, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Hawthorne, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Liverpool, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, The Bronx, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Troy, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Concord, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Minot, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Centerville, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Youngstown, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Dunmore, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Wormleysburg, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Easley, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greenwood, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Hurst, Texas, United States|Research Site, Killeen, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Leesburg, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Midlothian, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Puyallup, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Charleston, West Virginia, United States|Research Site, South Charleston, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Manitowoc, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Buenos aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudadela, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, La Plata, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario Santa Fe, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Canoas, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Salvador, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Tatui, Brazil|Research Site, Uberlândia, Brazil|Research Site, Burgas, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Samokov, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Brossard, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Chicoutimi, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Temuco, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Fuzhou, China|Research Site, Haerbin, China|Research Site, Hubei, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xi'an, China|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jindrichuv Hradec, Czechia|Research Site, Kladno, Czechia|Research Site, Liberec, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 1, Czechia|Research Site, Praha 2, Czechia|Research Site, Slany, Czechia|Research Site, Amiens Cedex 1, France|Research Site, Bayonne, France|Research Site, Bordeaux Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Caen, France|Research Site, Castelnau-Le-Lez, France|Research Site, Dijon, France|Research Site, La Tronche, France|Research Site, Le Chesnay Cedex, France|Research Site, Le Coudray Cedex, France|Research Site, Limoges, France|Research Site, MONTPELLIER Cedex 5, France|Research Site, Nantes Cedex 2, France|Research Site, Paris 14, France|Research Site, Paris Cedex 13, France|Research Site, PARIS Cedex 15, France|Research Site, PESSAC Cedex, France|Research Site, Rambouillet, France|Research Site, Saint-priest En Jarez, France|Research Site, Strasbourg Cedex, France|Research Site, Thionville, France|Research Site, Toulouse Cedex 3, France|Research Site, Toulouse Cedex 9, France|Research Site, Tours, France|Research Site, Vandoeuvre-Les-Nancy, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Erlangen, Germany|Research Site, Ettlingen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kaiserslautern, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Merseburg, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Riesa, Germany|Research Site, Tübingen, Germany|Research Site, Wesel, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Gyöngyös, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Szombathely, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Veszprém, Hungary|Research Site, Ancona, Italy|Research Site, Avellino, Italy|Research Site, Castelfranco Veneto, Italy|Research Site, Catania, Italy|Research Site, Catania, Italy|Research Site, Chieti, Italy|Research Site, Genova, Italy|Research Site, Lecce, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Napoli, Italy|Research Site, Oristano, Italy|Research Site, Padova, Italy|Research Site, Palermo, Italy|Research Site, Perugia, Italy|Research Site, Piacenza, Italy|Research Site, Pisa, Italy|Research Site, Ragusa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Siena, Italy|Research Site, Asahi-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hamada-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Imabari-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsubara-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Mito-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Ogori-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yamagata-shi, Japan|Research Site, Yatsushiro-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokosuka-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monclova, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Queretaro, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Tijuana, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Capelle Aan Den Ijssel, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Cebu City, Philippines|Research Site, Cebu, Philippines|Research Site, Dasmarinas, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Makati, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Taguig City, Philippines|Research Site, Tanauan City, Philippines|Research Site, Vigan, Philippines|Research Site, Białystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Ostrów Mazowiecka, Poland|Research Site, Tarnów, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Zamość, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Buzau, Romania|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Sibiu, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Tg. Mures, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Dunajska Streda, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Poprad, Slovakia|Research Site, Presov, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Albacete, Spain|Research Site, Alcorcón, Spain|Research Site, Alicante, Spain|Research Site, Badalona (Barcelona), Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Boadilla del Monte, Spain|Research Site, Coruña, Spain|Research Site, Getafe, Spain|Research Site, Granada, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Huelva, Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Mallorca, Spain|Research Site, Manises, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Sabadell, Spain|Research Site, Tarragona, Spain|Research Site, Toledo, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Eksjö, Sweden|Research Site, Gävle, Sweden|Research Site, Göteborg, Sweden|Research Site, Karlstad, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Muang, Thailand|Research Site, Songkla, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Bursa, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Cheltenham, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Newcastle upon TYNE, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hcmc, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01732822"
71,"NCT02332655","Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome",,"Active, not recruiting","No Results Available","Sturge-Weber Syndrome","Drug: Cannabidiol","Change in seizure frequency|Change in average seizure duration by seizure type|Change in the number of episodes of status epilepticus, defined as convulsive seizure lasting longer than 10 minutes|Change in the number of uses of rescue medication|Change in the number of ER visits/ hospitalizations","Anne Comi, MD|GW Pharmaceuticals Ltd.|Faneca 66 Foundation|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","All","1 Month to 45 Years   (Child, Adult)","Phase 1|Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00029264","December 2014","April 2019","April 2021","January 7, 2015",,"April 17, 2020","Kennedy Krieger Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02332655"
72,"NCT01710072","Aspirin Attenuates Inflammation in Human Cerebral Aneurysms",,"Completed","No Results Available","The Focus of the Study is to Monitor MRI Signal Changes and Inflammatory Biomarkers With Use of Aspirin in Patients With Unruptured Cerebral Aneurysm","Drug: aspirin","measurement of inflammatory biomarkers|change in the signal intensity of MRI","University of Iowa","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","201108750","August 2011","August 2014","August 2014","October 18, 2012",,"May 29, 2015","University of Iowa hospitals and Clinics, Iowa CIty, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01710072"
73,"NCT02176837","Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage",,"Terminated","Has Results","Subarachnoid Hemorrhage","Drug: Sodium Nitrite","Cerebral Vasospasm","Hope Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SN-03-01","June 2014","January 15, 2017","January 15, 2017","June 27, 2014","February 8, 2018","March 30, 2018","University of Virginia Medical Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02176837"
74,"NCT03000283","Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study",,"Completed","Has Results","Cerebral Hemorrhage|Cerebral Edema|Intracerebral Hemorrhage|Stroke","Drug: Conivaptan","Patient Tolerance of Conivaptan|In-hospital Mortality|Change in Cerebral Edema|Cost|Modified Rankin Scale (mRS) Score","Jesse Corry|Allina Health System","All","19 Years to 79 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSJC-1601","March 22, 2017","February 12, 2019","April 15, 2019","December 22, 2016","April 17, 2020","April 17, 2020","United Hospital, Saint Paul, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03000283/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03000283/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03000283"
75,"NCT04116112","Blood Pressure After Endovascular Stroke Therapy-II","BEST-II","Recruiting","No Results Available","Acute Stroke|Endovascular Thrombectomy","Drug: Nicardipine|Drug: Labetalol|Drug: Hydralazine","Final Infarct Volume|Utility-weighted modified Rankin Score|Number of participants with any hemorrhagic transformation|Number of participants with symptomatic hemorrhagic transformation|Number of participants with neurological worsening associated with antihypertensive treatment","Vanderbilt University Medical Center|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","191520|K23NS113858","January 17, 2020","March 30, 2023","March 30, 2023","October 4, 2019",,"January 22, 2020","Vanderbilt Univeristy Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04116112"
76,"NCT03843008","Melatonin in Acute Stroke",,"Not yet recruiting","No Results Available","Stroke, Acute|Ischemic Stroke","Dietary Supplement: Melatonin","Change in serum Interleukin 6 (IL 6)","University of Florida","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB201801934","April 2020","April 2021","April 2021","February 15, 2019",,"March 13, 2020","University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03843008"
77,"NCT03907046","Anticoagulation in ICH Survivors for Stroke Prevention and Recovery","ASPIRE","Suspended","No Results Available","Intracerebral Hemorrhage|Atrial Fibrillation","Drug: Apixaban|Drug: Aspirin","Stroke or death|Modified Rankin Scale (mRS) score","Yale University|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 3","700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2000026409|1U01NS106513-01A1","January 28, 2020","April 2024","April 2024","April 8, 2019",,"April 7, 2020","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03907046"
78,"NCT03507374","PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis","PINNACLE","Terminated","No Results Available","Stroke|Intracranial Atherosclerosis|Intraplaque Hemorrhage","Drug: Alirocumab|Drug: Placebo","Vessel Wall MRI|Post-Contrast Plaque Enhancement","University of Utah|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00104839","October 30, 2018","April 17, 2020","April 17, 2020","April 25, 2018",,"April 21, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03507374"
79,"NCT01948505","Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit",,"Completed","No Results Available","Post-operative Craniotomy Patients|Carotid Endarterectomy and Carotid Artery Stenosis Patients|Post-op Spine Patients Admitted to the NCCU|Endovascular Patients Undergoing Intracranial Intervention|Traumatic Brain Injuries NPO for at Least 12 Hours","Drug: Intravenous acetaminophen|Drug: Placebo for IV acetaminophen","Level of pain as measured on the 0-10 Numeric Rating Scale (NRS)|Sedation level as measured on the Riker Scale (1-7)","University of Utah","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","00061838","August 2013","November 2016","November 2016","September 23, 2013",,"December 9, 2016","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01948505"
80,"NCT03996148","Time to Post-Anesthesia Neurological Evaluation With Three Different Anesthetic Techniques",,"Completed","No Results Available","Carotid Artery Stenosis","Drug: Remifentanil, Propofol, and Desflurane|Drug: Remifentanil, Dexmedetomidine, and Desflurane|Drug: Remifentanil and Desflurane","Time to first neurological exam","The Cooper Health System","All","18 Years and older   (Adult, Older Adult)","Phase 4","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17-108","September 29, 2017","September 19, 2018","September 19, 2018","June 24, 2019",,"June 24, 2019","Cooper University Hospital, Camden, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03996148"
81,"NCT03845322","Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence","CACTIS","Recruiting","No Results Available","Hematoma, Subdural, Chronic","Drug: Curcumin Pill|Drug: Placebo pills","Measurements by CT of subdural hematoma volume change|Recurrence rate of cSDH with and without CC treatment","University of New Mexico","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-348","December 18, 2018","September 28, 2020","September 28, 2022","February 19, 2019",,"February 19, 2019","University of New Mexico Health Sciences center, Albuquerque, New Mexico, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03845322/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03845322/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03845322"
82,"NCT02872857","Subarachnoid Hemorrhage Recovery And Galantamine","SAHRANG","Completed","No Results Available","Subarachnoid Hemorrhage","Drug: Placebo|Drug: 8mg galantamine twice daily|Drug: 12mg galantamine twice daily","Tolerability as assessed by the number of patients who stay on the study medication|Mortality|Modified Rankin Score|Change in Montreal Cognitive Assessment (MoCA)|EuroQOL score","The University of Texas Health Science Center, Houston","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0228","September 2016","July 20, 2019","July 20, 2019","August 19, 2016",,"December 5, 2019","Houston Methodist Hospital Texas Medical Center, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02872857"
83,"NCT03726749","Tocilizumab Plus a Short Prednisone Taper for GCA",,"Recruiting","No Results Available","Giant Cell Arteritis","Drug: Tocilizumab|Drug: Prednisone","Sustained remission|Number of disease flares|Cumulative prednisone dose|Adverse events|Serious adverse events","Massachusetts General Hospital|Roche-Genentech","All","50 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML40859","November 28, 2018","December 25, 2021","February 2022","October 31, 2018",,"February 25, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03726749"
84,"NCT02955147","Ustekinumab for the Treatment of Giant Cell Arteritis","UGCA","Terminated","No Results Available","Giant Cell Arteritis|Temporal Arteritis|Horton's Disease","Drug: Ustekinumab|Drug: Prednisone","Percentage of patients in glucocorticoid-free remission|Number of disease flares|Cumulative prednisone dose","Massachusetts General Hospital","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016P000932","December 1, 2016","July 25, 2019","September 19, 2019","November 4, 2016",,"February 26, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02955147"
85,"NCT01095731","The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage",,"Completed","No Results Available","Aneurysmal Subarachnoid Hemorrhage","Drug: Tiopronin|Drug: Placebo","Reduction in CSF 3AP Levels|Improve Neurological Outcome following aSAH","E. Sander Connolly|University of Florida|University of Washington|Columbia University","All","21 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAA8597|1R01FD003728-01","April 2010","July 2012","July 2013","March 30, 2010",,"July 11, 2016","University of Florida, Gainesville, Florida, United States|Columbia University Medical Center, New York, New York, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01095731"
86,"NCT02178813","The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization",,"Terminated","No Results Available","Stroke","Drug: Administration of minocycline","Drug Safety/Tolerability (Number of patients that require discontinuation of drug because of side effects)|Progression of procedural stroke on MRI imaging|Neuropsychological test performance|Myocardial Infarction|Markers of neuronal injury","University of Pittsburgh","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO13120002","July 2014","July 2016","July 2016","July 1, 2014",,"June 9, 2017","Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02178813"
87,"NCT00933868","Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke",,"Completed","No Results Available","Stroke","Drug: Magnesium Chloride|Drug: Placebo","Barthel Index|Improvement in muscle strength and function|Change in the Mini-mental status examination|Change in balance, coordination, range of motion|Incidence of adverse events and changes in vital signs","Relox Medical, LLC","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RM-R001","April 2009","May 2010","July 2010","July 7, 2009",,"May 25, 2012","Born Preventive Healthcare Clinic, PC, Grand Rapids, Michigan, United States|Schachter Center for Complementary Medicine, Suffern, New York, United States|Comprehensive Heart Care Inc., Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00933868"
88,"NCT01810302","Safety Study of Nicardipine to Treat Cerebral Vasospasm",,"Terminated","Has Results","Cerebral Vasospasm","Drug: Nicardipine hydrochloride|Drug: Preservative-free normal saline","Number of Participants With Bacterial Meningitis.|Number of Participants With Cerebral Vasospasm.","University of Florida","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","034-2013","August 2013","January 2014","January 2014","March 13, 2013","August 29, 2014","August 29, 2014","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01810302"
89,"NCT01643902","Safety of Intravenous Thrombolytics in Stroke on Awakening","SAIL-ON","Completed","Has Results","Stroke","Drug: tPA","Number of Participants With Symptomatic Intracerebral Hemorrhage Within 36 Hours of Treatment|Functional Outcome by the Modified Rankin Scale at 90 Days","Johns Hopkins University|Genentech, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML28242","January 2013","December 2015","December 2015","July 18, 2012","April 17, 2017","April 17, 2017","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01643902"
90,"NCT00827892","Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage","SHRINC","Completed","No Results Available","Intracerebral Hemorrhage","Drug: Pioglitazone|Drug: Placebo Control","The primary measure of safety will be mortality at discharge.|Secondary measures of safety will include mortality at 3 months and 6 months, symptomatic cerebral edema during hospitalization, clinically significant congestive heart failure, edema, hypoglycemia, anemia, and hepatotoxicity.","The University of Texas Health Science Center, Houston","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-08-0410|P50 NS044227-5","March 2009","April 2013","November 2013","January 23, 2009",,"October 2, 2015","Memorial Hermann Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00827892"
91,"NCT01965756","Effect of Insulin Sensitizer Metformin on AD Biomarkers",,"Completed","Has Results","Alzheimer's Disease|Vascular Dementia|Dementia|Memory Impairment","Drug: Metformin|Drug: Placebos","Word List Memory Total - ADAS-cog|Trails-B","University of Pennsylvania","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UPenn-AHAF_A2012116","January 2013","December 22, 2015","April 2017","October 18, 2013","September 21, 2017","September 21, 2017","University of Pennsylvania, Penn Memory Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01965756"
92,"NCT01137773","Normoglycemia and Neurological Outcome",,"Terminated","Has Results","Acute, Non-traumatic Subarachnoid Hemorrhage|Intraparenchymal Hemorrhage|Brain Injuries","Drug: Insulin|Drug: Conventional insulin treatment","Karnovsky Performance Status Scale of Functional Impairment|Blood Glucose Concentration","University of Louisville","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","UofL IRB #562.06","January 2007","December 2014","December 2015","June 4, 2010","August 10, 2017","August 10, 2017","University of Louisville Hospital, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01137773"
93,"NCT01400256","Blood Pressure Lowering in Acute Stroke Trial","BLAST","Withdrawn","No Results Available","Stroke, Acute","Drug: Valsartan",,"Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CVAL489A US71","August 2007","February 2009","February 2009","July 22, 2011",,"May 9, 2016","Stanford University Medical Center, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01400256"
94,"NCT02148588","Peripheral Sensory Input in Central Post Stroke Pain (CPSP)",,"Completed","Has Results","Central Post Stroke Pain","Drug: Ultrasound-guided peripheral nerve block with 2% lidocaine","Reduction in Spontaneous Pain Intensity After a Peripheral Nerve Block.|Change in the Intensity of Cold Sensation|Change in the Intensity of Warm Sensation|Change in the Intensity of Pinprick Sensation|Change in the Intensity of Brush Sensation|Reported Pain/Dysesthesia Descriptors on NPSI Questionnaire","Washington University School of Medicine|Aarhus University Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","201405121","August 2014","December 15, 2016","January 25, 2017","May 28, 2014","May 2, 2018","May 2, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02148588"
95,"NCT00993057","Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia",,"Completed","No Results Available","Brain Neoplasms|Intracranial Aneurysm","Drug: Insulin","performance of each of glucose sampling and insulin protocols for achieving euglycemia|hypoglycemia|time required to reach euglycemia|relationship of BMI and performance of protocols|relationship of serum biomarkers of insulin resistance and performance of protocols","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU00009023","October 2009","August 2012","August 2012","October 9, 2009",,"December 13, 2019","Dhanesh Gupta, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00993057"
96,"NCT03047980","Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome",,"Active, not recruiting","No Results Available","Sturge-Weber Syndrome","Drug: Sirolimus","Cognitive impairments|Change in quantitative EEG|Sturge-Weber syndrome clinical neuroscore|Sturge-Weber syndrome birthmark score|Impact on sirolimus on seizures","Anne Comi, MD|Children's Hospital Medical Center, Cincinnati|Pfizer|National Institutes of Health (NIH)|Faneca 66 Foundation|National Institute of Neurological Disorders and Stroke (NINDS)|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.","All","3 Years to 31 Years   (Child, Adult)","Phase 2|Phase 3","10","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00079722|2U54NS065705|BVMC6209","January 2017","June 4, 2019","September 1, 2020","February 9, 2017",,"April 16, 2020","Kennedy Krieger Institute, Baltimore, Maryland, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03047980"
97,"NCT01845740","Phase Ib Study of SC Milatuzumab in SLE",,"Unknown status","No Results Available","Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic|Lupus Vasculitis, Central Nervous System|Lupus Nephritis","Drug: milatuzumab|Drug: Placebo","safety|Efficacy","Immunomedics, Inc.|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IMMU-115-04","January 2015","January 2017","May 2017","May 3, 2013",,"October 5, 2015","Cedars Sinai Medical Center-Wallace Rheumatic Study Center, West Hollywood, California, United States",,"https://ClinicalTrials.gov/show/NCT01845740"
98,"NCT01502761","Intra-arterial Magnesium Administration for Acute Stroke",,"Terminated","Has Results","Acute Stroke","Drug: Magnesium Sulfate","Magnesium Concentration in Region of Cerebral Ischemia|Number of Participants With Procedure Related Serious Adverse Event","University of Southern California|University of California, Los Angeles","All","21 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-11-00339","March 2012","May 2016","May 2016","January 2, 2012","August 28, 2017","August 28, 2017","University California Los Angeles: Ronald Reagan and Santa Monica Hospitals, Los Angeles, California, United States|University of Southern California University and LA County Hospitals, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01502761"
99,"NCT01805895","A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients","MACH","Completed","Has Results","Intracerebral Hemorrhage","Drug: Minocycline","Modified Rankin Scale|Safety Assessment","Augusta University|American Heart Association","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00000718","February 2013","December 2016","December 2016","March 6, 2013","April 26, 2018","April 26, 2018","Georgia Health Sciences University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01805895"
100,"NCT00990509","Albumin for Intracerebral Hemorrhage Intervention","ACHIEVE","Terminated","Has Results","Intracerebral Hemorrhage","Drug: Albumin|Drug: Placebo|Procedure: Brain MRI with and without contrast","Mean Hyperintense Acute injuRy Marker (HARM)|Assessment of Safety of Albumin Administration in Primary ICH|Mean Intracerebral Hemorrhage (ICH) Volume","Georgetown University|Baxter Healthcare Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009-173","September 2009","June 2013","June 2013","October 7, 2009","August 29, 2014","August 29, 2014","Georgetown University Hospital, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT00990509"
101,"NCT03826875","Poststroke Depression in Hemorrhagic Stroke",,"Recruiting","No Results Available","Stroke Hemorrhagic|Depression","Drug: Fluoxetine|Drug: Placebo","Depression|Anxiety|Fatigue|Healthcare Utilization|Social Support|Sleep Disturbance|Function","University of Washington","All","18 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","224","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","STUDY00002718","March 1, 2019","February 25, 2024","November 30, 2024","February 1, 2019",,"July 1, 2019","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03826875"
102,"NCT01394926","Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease",,"Terminated","Has Results","Carotid Artery Disease","Drug: Optison","Finding the Optimal Dose of Optison From 3 Different Dose Levels; 0.15mL, 0.5mL, and 1.5mL.|Detecting the Presence of Greater Than or Equal to 50% Stenosis and Greater Than or Equal to 75% Stenosis in the Carotid Arteries When Comparing Pre-contrast to Post-contrast Ultrasound by Dose Group.","GE Healthcare","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE-191-001","June 2011","June 2012","June 2012","July 15, 2011","April 16, 2014","May 2, 2014","GE Healthcare, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01394926"
103,"NCT00964548","Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage",,"Completed","Has Results","Cerebral Vasospasm After Subarachnoid Hemorrhage","Drug: Dantrolene","Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion)|Transcranial Doppler Peak Systolic Velocity (Change From Baseline Peak Systolic Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)|Transcranial Doppler Mean Flow Velocity (Change From Baseline Mean Flow Velocity (Pre-infusion) Over Time Until 135 Minutes Post-infusion)","University of Massachusetts, Worcester|Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-13076","July 2007","October 2009","October 2009","August 25, 2009","May 25, 2012","May 25, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States|UMASS Memorial Medical Center/UMASS Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00964548"
104,"NCT02216513","Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage",,"Terminated","No Results Available","Subarachnoid Hemorrhage","Drug: desferrioxamine (DFO)|Drug: placebo","delayed cerebral ischemia (DCI)|Clinical outcome at discharge","Brigham and Women's Hospital|Dr. Jeffrey Thomas Stroke Shield Foundation","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014P001400","September 2014","June 2015","July 2015","August 15, 2014",,"July 21, 2015","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02216513"
105,"NCT01878136","Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage",,"Withdrawn","No Results Available","Subarachnoid Hemorrhage|Cerebral Vasospasm|Cerebral Aneurysm|Hydrocephalus","Drug: Tissue Plasminogen Activator","Composite Primary Outcome|Rate of new intracranial hemorrhage|Rate of intracranial infection","Rush University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","13011803","March 2015","September 2016","September 2016","June 14, 2013",,"November 11, 2015","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01878136"
106,"NCT01935908","Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study","SPLASH - Pilot","Withdrawn","No Results Available","Subarachnoid Hemorrhage|Seizures","Drug: levetiracetam","Randomization Yield|Protocol Adherence Yield","Vanderbilt University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SPLASH-P1","May 2013","May 2013","May 2013","September 5, 2013",,"November 1, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01935908"
107,"NCT01974700","Seizure Prophylaxis in Aneurysm Repair",,"Terminated","Has Results","Intracranial Aneurysms|Seizures","Drug: Levetiracetam","Incidence of Seizure|Number of Participants Who Returned to Daily Activities.|Number of Participants Who Returned to Work","Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 4","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCBS-0001","July 2013","February 2016","February 2016","November 1, 2013","March 11, 2016","March 11, 2016","IU Health Methodist Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01974700"
108,"NCT02712788","Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage",,"Terminated","Has Results","Cerebral Vasospasm","Drug: Milrinone|Drug: Placebo","Modified Rankin Scale (mRS) at 6 Months|mRS at 12 Months","Indiana University","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1505714749","April 18, 2016","October 24, 2017","May 3, 2018","March 18, 2016","July 2, 2019","July 2, 2019","Indiana University Heath Methodist Hospital, Indianapolis, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02712788/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02712788"
109,"NCT01801072","Seizure Prophylaxis in Aneurysm Repair","SPAR","Active, not recruiting","No Results Available","Intracranial Aneurysms|Seizure","Drug: Levetiracetam","Incidence of seizure","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 4","79","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HUM00064523","February 2013","June 2020","June 2020","February 28, 2013",,"September 20, 2019","University of Michigan Health System, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01801072"
110,"NCT03028298","Sildenafil for DCI",,"Active, not recruiting","No Results Available","Subarachnoid Hemorrhage|Cerebral Vasospasm","Drug: Low dose sildenafil citrate|Drug: High dose sildenafil citrate","Change from baseline in mean arterial blood pressure|Area under the plasma concentration versus time curve (AUC) of sildenafil|Area under the cerebral spinal fluid concentration versus time curve (AUC) of sildenafil|Change from baseline in cerebral autoregulation","University of Mississippi Medical Center","All","21 Years and older   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0134","December 2016","December 2020","July 2021","January 23, 2017",,"March 24, 2020","University of Mississippi Medical Center, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT03028298"
111,"NCT01565590","Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage",,"Terminated","No Results Available","Subarachnoid Hemorrhage, Aneurysmal","Drug: Dexmedetomidine|Drug: propofol","Changes between serum and CSF cytokines over 48 hours|Sedative and analgesic medication requirements|Sedation scores (RASS and CAM-ICU)|ICU length of stay|Hospital length of stay|Glasgow Outcome Scores Extended (GOSE) at discharge|Incidence of delayed cerebral ischemia (DCI)","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 3","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-11-22-01","February 2012","July 2015","July 2015","March 28, 2012",,"February 1, 2018","University Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01565590"
112,"NCT01024972","Safety Study of Dantrolene in Subarachnoid Hemorrhage",,"Completed","Has Results","Subarachnoid Hemorrhage|Cerebral Vasospasm","Drug: Dantrolene|Drug: Placebo","Hyponatremia|Liver Toxicity|In-hospital Mortality","University of Massachusetts, Worcester|American Heart Association","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H-13441","October 2009","July 2013","October 2013","December 3, 2009","March 5, 2015","March 5, 2015","UMASS Medical School / UMass Memorial Medical Center, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01024972"
113,"NCT01588314","Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease",,"Withdrawn","No Results Available","Fabry Disease|Neuropathic Pain","Drug: Gabapentin|Drug: placebo","average reduction in hydrocodone-acetaminophen use|Number and type of adverse events|Pain levels|Define therapeutic level for gabapentin","University of Minnesota|Genzyme, a Sanofi Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1112M07943","April 2012","June 2014","June 2014","April 30, 2012",,"May 29, 2019","University of Minnesota, Fariview, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01588314"
114,"NCT02169219","Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis","SCOUT","Completed","Has Results","Granulomatosis With Polyangiitis|Microscopic Polyangiitis","Drug: Glucocorticoids|Drug: Rituximab","Complete Remission|Disease Response|Partial Remission|Sustained Complete Remission|Limited Flares|Severe Flares|Early Treatment Failures|Vasculitis Damage Index (VDI)","Massachusetts General Hospital|Genentech, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012P001427","June 2014","August 17, 2016","November 1, 2017","June 23, 2014","August 17, 2018","August 17, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02169219/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02169219"
115,"NCT02003638","Assessment Of Vascular Health After Niacin Therapy (AVANT)","AVANT","Completed","Has Results","Coronary Artery Disease|Carotid Artery Disease|Peripheral Artery Disease","Drug: Niacin|Drug: Placebo","Change From Baseline in Arterial Fluorodeoxyglucose (FDG) Uptake Assessed by FDG-PET/CT","University of Pennsylvania","All","45 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","812962","March 2012","January 2013","January 2013","December 6, 2013","June 25, 2014","June 25, 2014","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02003638"
116,"NCT01851720","Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage",,"Terminated","Has Results","Headaches Associated With Subarachnoid Hemorrhage (SAH)","Drug: Low dose fentanyl PCA|Drug: Standard IV fentanyl bolus","Acute Pain Following Sub-Arachnoid Hemorrhage (SAH) is the Primary Outcome Variable and Will be Assessed Using the Numeric Rating Scale (NRS).","Johns Hopkins University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00071159","July 2012","September 15, 2014","September 15, 2014","May 10, 2013","June 22, 2017","June 22, 2017","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01851720"
117,"NCT03084523","Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI",,"Enrolling by invitation","No Results Available","Stroke|Intracranial Aneurysm|Intracranial Atherosclerosis","Drug: Ferumoxytol Injectable Product","Vessel Wall Enhancement with Gadolinium compared to Vessel Wall Enhancement with Ferumoxytol in intracranial atherosclerosis (ICAS) group.|Vessel Wall Enhancement with Gadolinium compared to Vessel Wall Enhancement with Ferumoxytol in intracranial aneurysm (IA) group","University of Utah|AMAG Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB 00093870","April 26, 2017","February 27, 2024","November 2024","March 21, 2017",,"January 27, 2020","University of Utah Health Sciences, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03084523"
118,"NCT00961532","Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept","IMPACT","Completed","Has Results","Intracerebral Hemorrhage","Drug: DDAVP injection (desmopressin acetate)","Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment|Adverse Events : New Fever >=100.4F, Respiratory Distress or Pulmonary Edema on Chest Radiography, Rash, Hypotension (Systolic BP < 100 mm Hg or New Vasopressor Use or Increase in Vasopressor Dose by >25%)","Northwestern University|Northwestern Memorial Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU8168","December 2010","December 2013","December 2013","August 19, 2009","August 28, 2014","August 28, 2014","Northwestern Memorial Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00961532"
119,"NCT00950430","Imaging of Brain Amyloid Plaques in the Aging Population",,"Enrolling by invitation","No Results Available","Alzheimer's Disease|Dementia With Lewy Bodies|Frontotemporal Dementia|Vascular Dementia","Drug: Pittsburgh Compound B (C-11 PiB)|Drug: F-18 FDG|Drug: Tau (18-F-AV-1451)","To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.|Using PiB-PET, to ascertain cross-sectionally the magnitude and the spatial distribution of amyloid deposition in the brain in subjects who are clinically classified as CN, MCI, and demented.|To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.|To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.|To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.","Mayo Clinic|National Institute on Aging (NIA)","All","30 Years to 100 Years   (Adult, Older Adult)","Phase 4","2500","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","08-005553|U01AG006786|R01AG011378","April 2008","April 2023","April 2023","July 31, 2009",,"September 27, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00950430"
120,"NCT01895881","Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial","EPPA","Unknown status","No Results Available","Cerebral Aneurysm|Menopause|Treatment","Drug: Estradiol|Drug: Placebo","Effect of low dose estradiol on a panel of serum markers.|Radiographic change in the cerebral vasculature after treatment.","Rush University Medical Center","Female","40 Years to 52 Years   (Adult)","Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EPPA - 12101906","April 2013","December 2019","December 2019","July 11, 2013",,"January 26, 2018","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01895881"
121,"NCT02011321","Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)","CLEVAS","Unknown status","No Results Available","Subarachnoid Hemorrhage|Cerebral Aneurysm|Vasospasm, Intracranial","Drug: clevidipine","Efficacy: Change of cerebral blood flow velocities during infusion of clevidipine compared to baseline pre-infusion by >10% at 15 min after start of infusion and/or at 1, 2,3 and 4 hours (during the infusion).|Safety and Tolerability: Intracranial pressure (ICP) change during infusion compared to pre-infusion|Safety and tolerability: pressor requirement to counteract a 10% or more drop of mean arterial pressure (MAP) during the infusion period","Henry Ford Health System","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HFHS-CLEVIDIPINE-PV","March 2014","March 2015","September 2015","December 13, 2013",,"December 13, 2013","Henry Ford hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02011321"
122,"NCT01042574","The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy",,"Withdrawn","No Results Available","Hypertension|Intracranial Hemorrhage|Subarachnoid Hemorrhage","Drug: Clevidipine butyrate","The primary endpoint of this trial is the time to achieve the pre-specified SBP target range (110-140) within 30 minutes of the initiation of Cleviprex infusion.|The percentage of patients whose SBP is <90 mmHg within 30 minutes of the initiation of Cleviprex infusion","Methodist Healthcare|The Medicines Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cleviprex Use In ICB Patients","May 2010","December 31, 2010","December 31, 2010","January 5, 2010",,"August 14, 2019","Methodist Healthcare, University Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01042574"
123,"NCT02618382","A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population",,"Unknown status","No Results Available","Subdural Hematoma","Drug: Tranexamic Acid","Medication Related Complications|Postoperative hematoma expansion assessed by preoperative CT comparing width of hematoma to postoperative CTs|Modified Rankin Scale (mRS)|National Institute of Health Stroke Scale (NIHSS)","St. Joseph's Hospital and Medical Center, Phoenix|Barrow Neurological Foundation","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHX15BN048","November 2015","June 2017","January 2018","December 1, 2015",,"December 13, 2016","Barrow Brain and Spine, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02618382"
124,"NCT03204955","A Low ChloridE hyperTonic Solution for Brain Edema","ACETATE","Completed","No Results Available","Subarachnoid Hemorrhage|Acute Kidney Injury","Drug: Sodium chloride /sodium acetate (16.4%)|Drug: Sodium chloride (23.4%)|Drug: PlasmaLyte","Difference between serum chloride level on randomization day and the peak afterwards|Number of patients with acute kidney injury (AKI)|All causes of in-hospital mortality.|All causes of 90 day mortality.|Change in intracerebral pressure (ICP) measured by ICP monitor following hypertonic treatment.|Change in serum sodium level following the administration of the hypertonic solution.","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00090456","June 28, 2017","September 30, 2018","September 30, 2018","July 2, 2017",,"October 15, 2018","Emory University Hospital's Neurointensive Care Unit, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03204955"
125,"NCT00978822","Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage","CLASH","Unknown status","No Results Available","Subarachnoid Hemorrhage|Hypertension","Drug: Clevidipine butyrate injectable emulsion","Ability to control and maintain blood pressure within a certain range by the drug infusion.","Henry Ford Health System|The Medicines Company","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLV-0904-001|PCF Varelas 5605","September 2009","April 2010","June 2010","September 17, 2009",,"September 18, 2009","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00978822"
126,"NCT01196871","Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: Migalastat HCl|Biological: Agalsidase Beta|Biological: Agalsidase Alfa","Change In Area Under The Plasma Concentration Versus Time Curve (AUC) For Active α-Galactosidase A (α-Gal A) Levels After Administration Of Migalastat|Change In Maximum Observed Plasma Concentration (Cmax) For Active α-Gal A Levels After Administration Of Migalastat|Change In Time To Maximum Observed Plasma Concentration (Tmax) And Terminal Elimination Half-life (T1/2) For Active α-Gal A Levels After Administration Of Migalastat|Change In AUC For Total α-Gal A Protein Levels After Administration Of Migalastat|Change In Percentage Of AUCinfinity Extrapolated From The Last Time Point At Which Concentration Is Quantified To Infinity (AUCextrapolated %) For Total α-Gal A Protein Levels After Administration Of Migalastat|Change In Cmax For Total α-Gal A Protein Levels After Administration Of Migalastat|Change In Tmax And T1/2 For Total α-Gal A Protein Levels After Administration Of Migalastat|Change In AUC For Migalastat After Administration Of Agalsidase|Change In Cmax For Migalastat After Administration Of Agalsidase|Change In Tmax And T1/2 For Migalastat After Administration Of Agalsidase|Change From Baseline To Day 7 In Active α-Gal A In Skin Following Treatment With Agalsidase Alone And Co-administration With Migalastat","Amicus Therapeutics","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT1001-013","February 2, 2011","October 9, 2012","October 9, 2012","September 9, 2010","November 1, 2018","December 19, 2018","Birmingham, Alabama, United States|Decatur, Georgia, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Springfield, Virginia, United States|Nedlands, Australia|Parkville, Australia|Edegem, Belgium|Montreal, Canada|Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01196871"
127,"NCT03318783","Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial","SUSHI","Active, not recruiting","No Results Available","Subarachnoid Hemorrhage, Aneurysmal|Delayed Cerebral Ischemia|Vasospasm, Cerebral|Endothelial Dysfunction","Drug: GSK2256294|Drug: Placebo","Number of participants with treatment-related adverse events|Study day 7 and study day 10 serum and CSF EET/ dihyroxyeicosatrienoic (DHET) ratio, by mass spectroscopic analysis (ng/mL)|Study day 7 and study day 10 serum epoxyoctadecenoic acid (EPOME) to dihydroxyoctadec-12-enoic acid (DPOME) ratio, by mass spectroscopic analysis (ng/mL)|Serum biomarkers of endothelial injury from blood samples obtained on study day 7 and study day 10|CSF biomarkers of neuroinflammation, from blood samples obtained on study day 7 and study day 10","Oregon Health and Science University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17614","May 2, 2018","June 2021","December 2021","October 24, 2017",,"April 10, 2019","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03318783"
128,"NCT00930072","Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage",,"Terminated","No Results Available","Vasospasm","Drug: Cervical Sympathetic Block (bupivicaine, clonidine)","To evaluate the feasibility of performing a cervical sympathetic block in patients with severe cerebral vasospasm involving the anterior cerebral circulation following aneurysmal SAH.","University of Washington","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","34225","April 2009","December 2014","December 2014","June 30, 2009",,"September 27, 2017","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00930072"
129,"NCT02432157","Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:","HS3","Unknown status","No Results Available","Subarachnoid Hemorrhage|Cerebral Vasospasm|Hyponatremia","Drug: HTS 3%|Drug: Standard fluid management","Safety (adverse events)|Feasibility (Proportion of patients treated according to the protocol)|Vasospasm (Incidence of cerebral vasospasm defined as clinical deterioration)|Hyponatremia (Incidence of hypovolemic hyponatremia defined as Na <135)","Thomas Jefferson University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","14D.557","January 2015","January 2017",,"May 4, 2015",,"February 11, 2016","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02432157"
130,"NCT01563445","Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage",,"Completed","No Results Available","Acquired Bleeding Disorder|Intracerebral Haemorrhage","Drug: activated recombinant human factor VII|Drug: placebo","Occurrence of a treatment-related serious adverse event (SAE)|Occurrence of adverse events|Change in ICH volume as measured by CT head scans","Novo Nordisk A/S","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","F7ICH-2073","November 2001","March 2003","March 2003","March 27, 2012",,"January 13, 2017","Novo Nordisk Investigational Site, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01563445"
131,"NCT03839355","Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation","ARISTA","Recruiting","No Results Available","Atrial Fibrillation","Drug: Apixaban|Drug: Warfarin","Standardized neurocognitive function score|MRI evidence of silent cerebral infarct|MRI evidence of new cerebral micro-bleeds","Mayo Clinic|Pfizer|Bristol-Myers Squibb","All","60 Years and older   (Adult, Older Adult)","Phase 3","280","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","17-010544","December 19, 2018","December 2022","December 2022","February 15, 2019",,"February 15, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03839355"
132,"NCT00873015","Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm",,"Completed","Has Results","Subarachnoid Hemorrhage","Drug: Sodium nitrite|Drug: Saline","Mean Plasma Nitrite Concentration (Micromol/L)|Safety of a 14 Day Infusion of Sodium Nitrite|Efficacy of 14 Day Infusion of Sodium Nitrite","Hope Pharmaceuticals|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","19","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","14024|1R44NS063485-01","April 2010","November 2010","August 2012","April 1, 2009","July 16, 2013","June 7, 2017","University of Virginia Health System Medical Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00873015"
133,"NCT00871065","Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm",,"Withdrawn","No Results Available","Cerebral Vasospasm|Subarachnoid Hemorrhage","Drug: Sildenafil citrate","Onset of cerebral vasospasm, defined as transcranial Doppler velocity exceeding 120 cm/sec.|Longterm outcome as measured by the Glasgow Outcome Scale and Barthel Index assessments","University of Nebraska","All","19 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","165-08-FB","July 2009","July 2010","January 2011","March 30, 2009",,"May 16, 2017","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00871065"
134,"NCT02864953","Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction","CHARM","Recruiting","No Results Available","Brain Edema|Stroke, Acute","Drug: BIIB093|Drug: Placebo","Proportion of Participants with Improvement in Functional Outcome at Day 90 Assessed via the Modified Rankin Scale (mRS)|Time to All-Cause Death|Proportion of Participants Who Achieved mRS 0-4 at Day 90|Reduction in Midline Shift at 72 Hours|Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)","Biogen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","680","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","252LH301|RPI 301|2017-004854-41","August 29, 2018","March 31, 2021","December 30, 2021","August 12, 2016",,"February 18, 2020","Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Palo Alto, California, United States|Research Site, Sacramento, California, United States|Research SIte, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Gainesville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Kansas City, Kansas, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Edison, New Jersey, United States|Research Site, Neptune, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, Manhasset, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research SIte, Austin, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Seattle, Washington, United States|Research SIte, Madison, Wisconsin, United States|Research Site, Liverpool, New South Wales, Australia|Reseach Site, New Lambton Heights, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Yvoir, Belgium|Research Site, Joinville, Santa Catarina, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirao Preto, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Beijing, China|Reseach Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chongqing, China|Research SIte, Guangzhou, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Pingxiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Suzhou, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xuzhou, China|Research Site, Varazdin, Croatia|Research Site, Zagreb, Croatia|Research Site, Zagreb, Croatia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Prague, Czechia|Research Site, Praha, Czechia|Research Site, Copenhagen, Denmark|Research Site, Glostrup, Denmark|Research Site, Roskilde, Denmark|Research Site, Helsinki, Finland|Research Site, Turku, Finland|Research Site, Caen, Calvados, France|Research Site, Besancon, Doubs, France|Research Site, Brest cedex, Finistere, France|Research Site, Talence, Gironde 5, France|Research Site, Bordeaux, Gironde, France|Research Site, Rennes, Ille-et-Vilaine, France|Research Site, Lille Cedex, La Réunion 16, France|Research Site, Nantes cedex 1, Loire Atlantique, France|Research Site, Le Kremlin Bicêtre cedex, Val De Marne, France|Research Site, Nancy, France|Research Site, Altenburg, Germany|Research Site, Augsburg, Germany|Research Site, Darmstadt, Germany|Research Site, Dresden, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg, Germany|Research Site, Jena, Germany|Research Site, Kassel, Germany|Research Site, Muenster, Germany|Research Site, Budapest, Hungary|Reserch Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Be'er Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Rozzano, Milano, Italy|Research Site, Brescia, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Rome, Italy|Research Site, Rome, Italy|Research Site, Rome, Italy|Research Site, Siena, Italy|Research Site, Toyota-shi, Aichi-Ken, Japan|Research Site, Hachinohe-shi, Aomori-Ken, Japan|Research Site, Kisarazu, Chiba Prefecture, Japan|Research Site, Fukuoka-shi, Fukuoka-Ken, Japan|Research Site, Fukuoka-shi, Fukuoka-Ken, Japan|Research Site, Onga-gun, Fukuoka-Ken, Japan|Research Site, Yukuhashi-shi, Fukuoka-Ken, Japan|Research Site, Koriyama, Fukushima Prefecture, Japan|Research Site, Gifu-shi, Gifu-Ken, Japan|Research Site, Fukuyama-shi, Hiroshima-Ken, Japan|Research Site, Fukuyama-shi, Hiroshima-Ken, Japan|Research Site, Asahikawa-shi, Hokkaido, Japan|Research Site, Kobe, Hyogo Prefecture, Japan|Research Site, Akashi-shi, Hyogo-Ken, Japan|Research Site, Tsuchiura-shi, Ibaraki-Ken, Japan|Research Site, Tsuchiura-shi, Ibaraki-Ken, Japan|Research Site, Morioka-shi, Iwate-Ken, Japan|Research Site, Kawasaki-shi, Kanagawa-Ken, Japan|Reseach Site, Sendai-shi, Miyagi-Ken, Japan|Research Site, Kurashiki, Okayama Prefecture, Japan|Research Site, Okayama-shi, Okayama-Ken, Japan|Research Site, Suita, Osaka Prefecture, Japan|Research Site, Izumisano-shi, Osaka-Fu, Japan|Research Site, Hidaka-shi, Saitama-Ken, Japan|Research Site, Fuchu-shi, Tokyo-To, Japan|Research Site, Mitaka-shi, Tokyo-To, Japan|Research Site, Bunkyo, Tokyo, Japan|Research Site, Tanabe-shi, Wakayama-Ken, Japan|Research Site, Ube-shi, Yamaguchi-Ken, Japan|Research Site, Kofu-shi, Yamanashi-Ken, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Pusan, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Almada, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Matosinhos, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Kazan, Respublka Tatarstan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Cordoba, Córdoba, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain|Research Site, Lugano, Ticino, Switzerland|Research Site, Bern, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Cambridge, Cambridgeshire, United Kingdom|Research Site, London, Greater London, United Kingdom|Research Site, Glasgow, Lanarkshire, United Kingdom|Research Site, Nottingham, Nottinghamshire, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02864953"
135,"NCT01273467","A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)",,"Completed","No Results Available","Stroke|Ischemia|Infarction","Drug: CNTO 0007 or placebo (Stage A)|Drug: CNTO 0007 or placebo (Stage B)","The number and type of adverse events reported|Changes in clinical laboratory test values|Changes in vital signs measurements|Changes in electrocardiograms|Blood concentration of CNTO 0007","Janssen Research & Development, LLC","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR016510|42037788","December 2010",,"July 2013","January 10, 2011",,"March 18, 2014","Portland, Oregon, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01273467"
136,"NCT03495206","Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet",,"Recruiting","No Results Available","Stroke, Acute|Intracranial Hemorrhages","Drug: Y-2(Edaravone And Borneol) Sublingual Tablet","Number of participants who experience treatment-related adverse events (AEs) and serious adverse events (SAEs)|Maximum Plasma Concentration [Cmax]|Time of Observed Cmax[tmax]|Area Under the concentration-time Curve from time zero to the last detectable concentration[AUC0-t]","Yantai YenePharma Co., Ltd.","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Y-2-001","October 25, 2018","December 2020","February 2021","April 11, 2018",,"February 17, 2020","OSF Healthcare System d/b/a Saint Francis Medical, Peoria, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03495206"
137,"NCT01688570","Mechanisms of Neuromuscular Fatigue Post Stroke",,"Completed","No Results Available","Stroke","Drug: duloxetine|Drug: Cyproheptadine|Drug: Placebo","Force generation|Surface electromyography (EMG)of lower leg muscles.","Medical College of Wisconsin","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","27","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","UL1RR031973-02","August 2011","May 2015","May 2015","September 20, 2012",,"November 5, 2015","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01688570"
138,"NCT02448069","Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke","ARTSS-IA","Completed","No Results Available","Stroke|Cerebral Ischemia","Drug: Argatroban","Safety as measured by the incidence (absolute number) of symptomatic intracranial hemorrhage (sICH)|Feasibility of combining Argatroban with usual care as measured by success of starting the study medication bolus before the end of rt-PA infusion. 1. CT to tPA time, 2. CT to groin-puncture compared to institutional stroke-center database|Safety as measured by the incidence (absolute number of cases) of: 1. Groin or retroperitoneal hematoma 2. Major systemic hemorrhage requiring transfusion 3. Arterial perforation or dissection|Rates and completeness of arterial reperfusion as measured by cerebral angiography. Assessed at time of diagnostic (first intracranial injection unilateral to the occlusive lesion) and at the termination of study procedure.|A NIH Stroke Scale (NIHSS) assessment will be performed at baseline and repeated at 24 hours, 48 hours and Day 7/discharge (whichever comes first).","The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-15-0327","May 2015","August 2016","August 2016","May 19, 2015",,"June 21, 2017","University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02448069"
139,"NCT01586975","Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events",,"Completed","Has Results","Stroke|Myocardial Infarctions","Drug: Clopidogrel|Drug: Aspirin 81 mg|Drug: Aspirin >300 mg","PFA1","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","93","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Aspirin Resistance and Stroke|IRB#0996-007 FUND#7810","July 2007","April 2010","December 2011","April 27, 2012","December 3, 2015","December 31, 2015","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01586975"
140,"NCT01968226","TRACER RGD-K5 Carotid Plaque Imaging Study","TRACER","Terminated","Has Results","Carotid Artery Disease|Carotid Stenosis","Drug: [F-18] RDG-K5","Target to Background Ratio (TBR)","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","K5 IND","November 2013","June 2016","June 2016","October 23, 2013","August 10, 2017","September 12, 2017","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01968226"
141,"NCT02133573","Randomized Trial of Maternal Progesterone Therapy",,"Active, not recruiting","No Results Available","Congenital Heart Disease|Periventricular Leucomalacia|Brain Development|Cardiac Surgery|Neurodevelopmental Disability|Fetal Neuroprotection","Drug: Progesterone|Drug: Vaginal lubricant","Motor Scale of the Bayley Scales of Infant and Toddler Development-III|Cognitive and Language Scales of the Bayley Scale of Infant and Toddler Development-III|Fetal brain growth and maturation by MRI|Myelination during fetal brain development by MRI|Brain white matter injury by MRI","Children's Hospital of Philadelphia","All","Child, Adult, Older Adult","Phase 2","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-010710","May 2014","December 2021","December 2021","May 8, 2014",,"March 9, 2020","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02133573"
142,"NCT01747408","Treatment of Subarachnoid Hemorrhage With Human Albumin","ALISAH","Terminated","No Results Available","Subarachnoid Hemorrhage","Drug: Human Albumin","Number of participatns with cardiovascular adverse events as a measure of safety and tolerability|GOS|mRs|NIHSS|SIS","Baylor College of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-21012","June 2006","July 2010","May 2011","December 11, 2012",,"December 11, 2012","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01747408"
143,"NCT01602471","[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis",,"Terminated","Has Results","Carotid Stenosis","Drug: [F-18]RDG-K5","[F-18]RDG-K5 Uptake by Carotid Plaque on PET Scan","Siemens Molecular Imaging","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","K5-C200","May 2012","March 2013","March 2013","May 21, 2012","September 27, 2013","September 27, 2013","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01602471"
144,"NCT02498379","PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)",,"Completed","No Results Available","Atherosclerosis","Drug: Cu[64]-25%CANF-Comb","Biodistribution, dosimetry and safety of Cu[64]-25%CANF-Comb in normal healthy adult volunteers.","Washington University School of Medicine","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201409006V","October 2014","April 2015","April 2015","July 15, 2015",,"April 28, 2016","Washington University in St.Louis, St.Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02498379"
145,"NCT04007263","A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers",,"Completed","No Results Available","Stroke, Ischemic|Pain, Postoperative|Substance Abuse|Subarachnoid Hemorrhage","Drug: Placebo|Drug: NP10679","Incidence of adverse events as a measure of safety and tolerability|Plasma concentration of parent drug","Neurop Inc.|National Institute of Neurological Disorders and Stroke (NINDS)|Pharmaron","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NP10679-002|3R44NS071657-06","April 4, 2019","August 30, 2019","October 10, 2019","July 5, 2019",,"November 4, 2019","Pharmaron CPC, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04007263"
146,"NCT03026504","Baricitinib in Relapsing Giant Cell Arteritis",,"Active, not recruiting","No Results Available","Arteritis, Giant Cell","Drug: Baricitinib","Percentage of subjects experiencing adverse events|Giant Cell Arteritis relapse-free survival","Matthew J Koster|Eli Lilly and Company|Mayo Clinic","All","50 Years and older   (Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-008993","March 9, 2017","June 2020","June 2021","January 20, 2017",,"March 6, 2020","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03026504"
147,"NCT01873716","Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque","BRIGHT-CEA","Completed","No Results Available","Atherosclerosis|Atherosclerotic Plaque|Carotid Stenosis","Drug: Indocyanine green","Tissue uptake of indocyanine green in carotid plaque|Relationship of indocyanine green uptake to carotid plaque histology","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2012P000895","May 2013","January 2016","January 2016","June 10, 2013",,"February 2, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01873716"
148,"NCT01953705","n-3 PUFA for Vascular Cognitive Aging",,"Active, not recruiting","No Results Available","Age Related Cognitive Decline|Alzheimer's Disease|Vascular Dementia|Endothelial Dysfunction|Executive Dysfunction","Drug: Omega 3 PUFA|Drug: Placebo","total cerebral white matter hyperintensity volume|biomarkers of endothelial health|total brain atrophy|medial temporal lobe atrophy|ventricular expansion","Oregon Health and Science University|National Institute on Aging (NIA)","All","75 Years and older   (Older Adult)","Phase 2","102","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01AG043398|R01AG043398-01A1","May 2014","July 2019","August 2019","October 1, 2013",,"June 17, 2019","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01953705"
149,"NCT01396317","Study of Tocilizumab to Treat Polymyalgia Rheumatica",,"Completed","Has Results","Polymyalgia Rheumatica (PMR)","Drug: Tocilizumab","Proportion of Patients in Disease Remission at Six Months From Trial Entry|Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Proportion of Patients Able to Achieve Disease Remission (DR) Off Corticosteroids, Without Disease Relapse or Recurrence|Proportion of Patients Who Develop Disease Relapses|The Cumulative Dose of Prednisone|Total Number of Relapses/Recurrences","Hospital for Special Surgery, New York|Genentech, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11081","April 2011","December 2015","January 2016","July 18, 2011","January 17, 2018","January 17, 2018","Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01396317"
150,"NCT03068442","The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and Cognition",,"Recruiting","No Results Available","Cognitive Impairment|Carotid Artery Plaque|Inflammation","Drug: Imaging with flutemetamol F 18 PET/CT","Carotid intraplaque hemorrhage correlation with carotid plaque inflammation on immunohistochemistry.|Carotid MRI-detected intraplaque hemorrhage and prediction of brain inflammation on PET/CT.|Preoperative MRI-detected carotid intraplaque hemorrhage and prediction of cognitive improvement after endarterectomy.","Scott Mcnally|American Heart Association|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17SDG33460420","February 17, 2017","September 10, 2020","September 10, 2020","March 1, 2017",,"January 30, 2020","University of Utah, Salt Lake City, Utah, United States|George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03068442"
151,"NCT03168581","A Proof of Concept Study to Evaluate CN-105 in ICH Patients","CATCH","Completed","No Results Available","Intracerebral Hemorrhage","Drug: CN-105","CN-105 safety assessment|Mortality|In-hospital neurological deterioration|Improvement in 30-day mortality|Improvement in 30-day functional outcomes","AegisCN LLC|Duke Clinical Research Institute|PharPoint Research, Inc.","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","38","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CATCH|5R01FD005387-02","August 28, 2017","September 30, 2019","January 25, 2020","May 30, 2017",,"March 11, 2020","A.B. Chandler Medical Center-University of Kentucky, Lexington, Kentucky, United States|Duke University Health System, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03168581"
152,"NCT04063215","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy",,"Recruiting","No Results Available","Traumatic Brain Injury","Drug: HB-adMSCs","Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basos|Absolute Neutrophils|Absolute Lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature Granulocytes|Absolute Immature Granulocytes|Platelets|Prothrombin Time|INR|Urine Pregnancy|Whole brain MRI|PET/DT-MRI|Glasgow Outcome Score|Galveston Orientation and Amnesia Test|Rivermead Post-Concussion Symptoms Questionnaire|Automated Neuropsychological Assessment Metrics|Verbal Selective Reminding Test|Verbal Fluency Test|Stroop|Interleukin 1-alpha|Interleukin 4|Tumor necrosis factor alpha|Interleukin 6|Interleukin 10","Hope Biosciences|The University of Texas Health Science Center, Houston","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","24","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Neurologic Injury","January 1, 2020","August 29, 2021","August 29, 2021","August 21, 2019",,"February 13, 2020","Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04063215"
153,"NCT01996436","The Intra-arterial Vasospasm Trial","iVAST","Recruiting","No Results Available","Cerebral Vasospasm","Drug: Nicardipine|Drug: Verapamil|Drug: Nicardipine + Verapamil + Nitroglycerin","Post infusion improvement ratio(PIIR)|To grade clinical outcome using Modified Rankin score","The University of Texas Health Science Center, Houston|Yale University|Thomas Jefferson University|University of Illinois at Chicago|Wake Forest University Health Sciences|Temple University|Geisinger Clinic|Northwell Health|University of Michigan|Lenox Hill Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","IVT_201310 (HSC-MS-13-0586)","August 2016","August 2020","December 2020","November 27, 2013",,"May 8, 2018","Yale School of Medicine, New Haven, Connecticut, United States|University of Illinois College of Medicine at Chicago, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Northwell Health, Manhasset, New York, United States|Lenox Hill, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Geisinger Clinic, Danville, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|University of Texas Medical School at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01996436"
154,"NCT02283294","Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation","AREST","Completed","No Results Available","Transient Ischemic Attack|Stroke|Atrial Fibrillation","Drug: Apixaban|Drug: Warfarin","Composite endpoint of fatal stroke, recurrent ischemic stroke, or TIA|Intracranial hemorrhage assessed by MRI/CT","University of South Florida|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","91","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO00019754","April 2015","June 2019","June 2019","November 5, 2014",,"August 19, 2019","Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Bayfront Health St Petersburg, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02283294"
155,"NCT02541032","PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke","PREMIERS","Recruiting","No Results Available","Periodontal Disease|Stroke|TIA","Procedure: Intensive dental treatment|Procedure: Standard dental treatment|Drug: Arestin","Ischemic Stroke|Transient ischemic attack (TIA)|Myocardial infarction (MI)|Cardiovascular Death|Progression of Atherosclerosis|Vascular Cognitive Impairment|Blood Pressure|hs-CRP|hemoglobin A1c|Fasting Lipids","University of South Carolina|University of North Carolina, Chapel Hill","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","00044329","December 2015","June 2019","June 2020","September 4, 2015",,"April 18, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of South Carolina School of Medicine Department of Neurology, Columbia, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02541032"
156,"NCT01997255","Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)",,"Withdrawn","No Results Available","Sturge Weber Syndrome","Drug: Everolimus","Evaluate the clinical effectiveness of Everolimus as an adjunct treatment to reduce the seizure activity|Clinical progression of facial and/or body port-wine hemangioma|Clinical progression of glaucoma","Baylor College of Medicine|Novartis Pharmaceuticals","All","2 Years to 18 Years   (Child, Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-33251|CRAD001MUS214T","April 2014","April 2016","April 2016","November 28, 2013",,"May 5, 2016","Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01997255"
157,"NCT02429453","FFP Versus PCC in Intracranial Hemorrhage",,"Withdrawn","No Results Available","Intracranial Hemorrhage, Traumatic|Intracranial Hemorrhage, Spontaneous","Drug: Four Factor Prothrombin Complex Concentrate|Biological: Fresh Frozen Plasma","Rapid reversal of warfarin as measured by international normalized ratio (INR) drawn at 30 minutes after transfusion|Radiographic expansion of traumatic intracerebral hemorrhage as measured by CT scan within 24 hours of presentation|Timing of reversal of warfarin as measured by INR drawn at 3 hours, 8 hours and 24 hours after transfusion|Thromboelastography response as measured by results of ROTEM analysis at 30 minutes and 24 hours after transfusion|Absolute INR reversal as measured by INR drawn 24 hours after transfusion|Need for operative intervention as measured by need for neurosurgical procedure during the hospitalization|Estimated blood loss during any neurosurgical procedure|Further transfusion needs as measured by number of units of blood/platelet/plasma products transfused during the hospitalization|In hospital mortality|Total hospital cost|30 day outcome as measured by the Glasgow outcome score|Complications as measured by development of deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, unanticipated intubation, heart failure, or need for aggressive diuresis during the hospitalization","University of Utah","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00078143","April 2015","March 2016","March 2016","April 29, 2015",,"November 16, 2016","University of Utah Medical Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02429453"
158,"NCT02549716","Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH","aSAH","Terminated","Has Results","Subarachnoid Hemorrhage|Stroke","Drug: IV acetaminophen|Drug: Oral acetaminophen|Drug: Oral placebo|Drug: IV placebo","Bioavailability of Acetaminophen in Cerebral Spinal Fluid (CSF) and Blood|Concentrations of Interleukin-1 (IL-1), Interleukin-6 (IL-6), and Thromboxane A-2 (TXA-2) in Cerebral Spinal Fluid (CSF) and Blood|Number of Febrile Periods|Incidence of Vasospasm","Milton S. Hershey Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRBSTUDY00002767","January 5, 2017","June 8, 2018","June 8, 2018","September 15, 2015","April 10, 2019","April 10, 2019","Penn State Hershey Medical Center, Hershey, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02549716/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02549716"
159,"NCT03454893","Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease",,"Recruiting","No Results Available","Fabry Disease","Drug: AVR-RD-01","Incidence of Treatment-Emergent Adverse Events of AVR-RD-01 drug product|Change in the average number of Gb3 inclusions (ie, myelinosomes) per kidney peritubular capillary (PTC) per subject","AvroBio","Male","16 Years to 50 Years   (Child, Adult)","Phase 1|Phase 2","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVRO-RD-01-201","February 21, 2018","July 2021","November 2021","March 6, 2018",,"February 10, 2020","Hackensack University Medical Center, Hackensack, New Jersey, United States|Baylor University Medical Center, Houston, Texas, United States|Royal Melbourne Hospital, Melbourne, Parkville VIC, Australia|Royal Perth Hospital, Perth, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT03454893"
160,"NCT02893826","Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH",,"Terminated","No Results Available","Subarachnoid Hemorrhage, Aneurysmal","Drug: EG-1962 (nimodipine microparticles)|Drug: Enteral Nimodipine","Incidence and severity of adverse events|Proportion of subjects with delayed cerebral infarctions present on CT at Day 30|Pharmacokinetic (PK) profile of EG-1962 as measured by maximum drug concentration in plasma (Cmax)|Pharmacokinetic (PK) profile of EG-1962 as measured by time to reach maximum drug concentration in plasma (Tmax)|Pharmacokinetic (PK) profile of EG-1962 as measured by steady state concentration (Css)|Pharmacokinetic (PK) profile of EG-1962 as measured by AUC area under the plasma concentration-time curve (AUC) from 0 to 24 hours (AUC024h)|Pharmacokinetic (PK) profile of EG-1962 as measured by AUC from 0 to Day 10 (AUC0-10)|Pharmacokinetic (PK) profile of EG-1962 as measured by AUC from 0 to Day 14 (AUC0-14)|Pharmacokinetic (PK) profile of EG-1962 as measured by AUC from 0 to last plasma concentration (AUC0-last)","Edge Therapeutics Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EG-01-1962-04","September 2016","December 2017","March 2018","September 9, 2016",,"July 26, 2018","Dignity Health; St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of California San Francisco, San Francisco, California, United States|University of Maryland Medical Systems, Baltimore, Maryland, United States|University of Alberta Hospital/Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT02893826"
161,"NCT01176565","Antihypertensive Treatment of Acute Cerebral Hemorrhage-II","ATACH-II","Terminated","Has Results","Intracerebral Hemorrhage","Drug: Intravenous nicardipine hydrochloride","Death or Disability According to Modified Rankin Scale Score at 90 Days (3 Months) From Randomization|Quality of Life at 90 Days Using EuroQol (EQ) Measures: EQ-5D (EuroQol Five Dimension), Consisting of Standardized EQ-5D-3L (EuroQol Five Dimension, Three-Level) Questionnaire and EQ VAS (EuroQol Visual Analog Scale) Scores|Hematoma Expansion (Number of Patients With Hematoma Expansion of 33% or Greater Between the Baseline and 24 +/- 6 Hours Head CTs, as Measured by the Central Reader for Patients With Readable Scans for Both Time Points Submitted by Data Lock.)","University of Minnesota|National Institute of Neurological Disorders and Stroke (NINDS)|Medical University of South Carolina|Johns Hopkins University|University of Michigan|Neurocritical Care Research Network|National Cerebral and Cardiovascular Center|Japan Cardiovascular Research Foundation|Beijing Tiantan Hospital|China Medical University Hospital|University Hospital Heidelberg|Seoul National University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1207M17921|U01NS062091|U01NS061861|U01NS059041|U01NS056975|H23-4-3","May 15, 2011","December 21, 2015","March 8, 2016","August 6, 2010","April 25, 2017","April 25, 2017","UAB Comprehensive Stroke Center, Birmingham, Alabama, United States|Maricopa Medical Center, Phoenix, Arizona, United States|Mayo Clinic Pheonix, Scottsdale, Arizona, United States|Banner University Medical Center - South Campus, Tuscon, Arizona, United States|Banner University Medical Center - University Campus, Tuscon, Arizona, United States|Community Regional Medical Center of Fresno, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Ronald Regan UCLA Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Stanford University, Palo Alto, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Good Samaritan Hospital, San Jose, California, United States|Santa Clara Valley Medical Center, Santa Clara, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Yale - New Haven Hospital, New Haven, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|University of Florida Gainesville, Gainesville, Florida, United States|Baptist Medical Center Jacksonville, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa General Hospital, Tampa, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Eastern Idaho Medical Consultants, Idaho Falls, Idaho, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Southern Illinois University Memorial Medical Center, Springfield, Illinois, United States|Lutheran Hospital Indiana, Fort Wayne, Indiana, United States|Parkview Hospital, Fort Wayne, Indiana, United States|Kansas University Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|Interim LSU Hospital, New Orleans, Louisiana, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center, Shreveport, Shreveport, Louisiana, United States|Maine Medical Center, South Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Wayne State University - Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Essentia Health St. Mary's Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|St. Cloud Hospital, St. Cloud, Minnesota, United States|Regions Hospital, St.Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Neuroscience Institute, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|St. Joseph's Regional Medical Center, Clifton, New Jersey, United States|New Jersey Neuroscience Institute, JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|New York City Health and Hospitals Corp. / Kings County Hospital, Brooklyn, New York, United States|Mamoides Medical Center, Brooklyn, New York, United States|Sister of Charity/Buffalo Mercy Hospital, Catholic Health System, Buffalo, New York, United States|UHS Wilson Medical Center, Johnson City, New York, United States|North Shore University Hospital, Manhasset, New York, United States|SUNY Downstate, New York, New York, United States|Columbia University, New York, New York, United States|Lincoln Medical and Mental Health Center, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Strong Stroke Center, Rochester, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Guilford Neurologic Associates, Greenboro, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Novant Clinical Research Institute/Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest Baptist Medical Center (Wake Forest School of Medicine), Winston-Salem, North Carolina, United States|Akron General Hospital, Akron, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University - Wexner Medical Center, Columbus, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Oklahoma University Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Univ/ Hershey Med Center, Hershey, Pennsylvania, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Mercy Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Wellspan York Hospital, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Palmetto Health, Columbia, South Carolina, United States|Vanderbilt Stroke Center, Nashville, Tennessee, United States|Seton Medical Center Austin, Austin, Texas, United States|St. David's Medical Center, Austin, Texas, United States|University Medical Center Brackenridge, Austin, Texas, United States|UT Southwestern - Parkland Hospital, Dallas, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Memorial Herman - Texas Medical Center, Houston, Texas, United States|Baylor College of Medicine - Ben Taub Community Hospital, Houston, Texas, United States|Baylor College of Medicine - St. Luke's Episcopal Hospital, Houston, Texas, United States|Methodist Hospital - The Neurological Institute, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|West Virginia University - Ruby Memorial Hospital, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwakee, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|University of Alberta, Edmonton, Alberta, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei, China|The Second Hospital of Shanxi Medical University, Taiyuan City, Shanxi, China|Baotou Central Hospital, Baotou, China|Beijing Tiantan Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Datong Third People's Hospital, Datong, China|The First Hospital of Shanxi Medical University, Taiyuan City, China|The First People's Hospital of Taizhou, Taizhou City, China|Tianjin Fourth Central Hospital, Tianjin, China|Wuhan Brain Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|People's Hopital of Zhengzhou, Zhengzhou, China|Charité Universtity Medicine Berlin, Berlin, Germany|University of Bonn, Bonn, Germany|University Hospital Dresden, Dresden, Germany|Clinic Frankfurt Hoechst, Frankfurt, Germany|University Hospital Halle, Halle (Saale), Germany|University Hospital Heidelberg, Heidelberg, Germany|University Hospital Leipzig, Leipzig, Germany|University Hospital Mannheim, Mannheim, Germany|University Hospital Meunster, Munster, Germany|University of Tubingen, Tubingen, Germany|Nagoya Medical Center, Nagoya City, Aichi, Japan|Nakamura Memorial Hospital, Sapporo, Hokkaido, Japan|Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Kanagowa, Japan|Saiseikai Kumamoto Hospital, Kumamoto City, Kumamoto, Japan|Kyushu Medical Center, Fukuoka, Japan|Gifu University Hospital, Gifu, Japan|St. Marianna - Toyoko, Kawasaki, Japan|St. Marianna University Hospital, Kawasaki, Japan|Kobe City Medical Center General Hospital, Kobe City, Japan|Kawasaki Medical School, Okayama, Japan|National Cerebral and Cardiovascular Center, Osaka, Japan|Kohnan Hospital, Sendai, Japan|Toranomon Hospital, Tokyo, Japan|Saiseikai Central Hospital - Tokyo, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|Kyorin University, Tokyo, Japan|Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|Seoul National University Boramae Hospital, Seoul, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hopital, Taichung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Taipei Veteran's Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01176565"
162,"NCT00908856","Autologous Cell Therapy After Stroke",,"Withdrawn","No Results Available","Stroke","Biological: autologous bone marrow mononuclear cell transfusion|Biological: marrow stromal cells|Drug: placebo","death|myocardial infarction|pulmonary embolism|ischemic stroke|deep venous thrombosis|other arterial or venous thrombosis|Infection requiring IV antibiotics","University of California, Irvine|University of California, San Diego","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2003-3040","January 2016","December 2017","December 2017","May 27, 2009",,"February 4, 2016","UC Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00908856"
163,"NCT04141020","Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms",,"Not yet recruiting","No Results Available","Cerebral Aneurysm","Procedure: Microsurgical clipping|Procedure: Endovascular treatment|Drug: Sirolimus","Change in gene expression from control arteries.|Change in gene expression between blood samples.|Change in gene expression.","University of Miami|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","20190857|1R01NS111119-01A1","June 1, 2020","June 1, 2025","June 1, 2025","October 28, 2019",,"April 6, 2020","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04141020"
164,"NCT01489995","Migalastat Food Effect Study",,"Completed","No Results Available","Fabry Disease","Drug: A (migalastat)|Drug: B (migalastat)|Drug: C (migalastat)|Drug: D (migalastat)|Drug: E (migalastat)","Maximum observed plasma concentration of migalastat HCl after a single dose|Time of occurence of maximum observed plasma concentration of migalastat HCl after a single dose|Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to infinity|Terminal phase half life of migalastat HCl after a single dose|Apparent clearance following oral dosing of migalastat HCl after a single dose|Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to the time of the last quantifiable concentration|Adverse Events|Clinical Laboratory Tests|Vital Signs|ECGs|Physical Examination","Amicus Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116050","October 2011","December 2011","December 2011","December 12, 2011",,"December 18, 2013","GSK Investigational Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01489995"
165,"NCT01730469","Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function",,"Completed","No Results Available","Fabry Disease","Drug: AT1001 150 mg","Number of subjects with adverse events to assess safety and tolerability|Clinical laboratory test values to assess safety and tolerability|Vital signs to assess safety and tolerability|Physician examination to assess safety and tolerability|Measure of ECG to assess safety and tolerability|Maximum observed concentration (Cmax) of AT1001|Time to achieve maximum concentration (Tmax) of AT1001|Apparent terminal elimination half life (t1/2 ) of AT1001|Area under the concentration-time curve from time zero to the last measurable concentration (AUC 0-t ) of AT1001|Area under the concentration-time curve extrapolated to infinity (AUC 0-inf) of AT1001|Apparent terminal elimination rate constant for AT1001|Oral clearance of AT1001|Oral volume of distribution of AT1001","Amicus Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116431","August 2011","April 2012","April 2012","November 21, 2012",,"August 3, 2017","GSK Investigational Site, Costa Mesa, California, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01730469"
166,"NCT01662895","High-Dose Deferoxamine in Intracerebral Hemorrhage","HI-DEF","Terminated","Has Results","Intracerebral Hemorrhage","Drug: Deferoxamine|Drug: Normal saline","Number of Subjects With Modified Rankin Scale (mRS) Score 0-2|Number of Subjects With mRS Score 0-3","Beth Israel Deaconess Medical Center|Medical University of South Carolina|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital|Tufts Medical Center|University of Massachusetts, Worcester|University of Pennsylvania|Johns Hopkins University|University of Maryland, College Park|University of Virginia|Duke University|University of North Carolina|University of Florida|The Cleveland Clinic|Henry Ford Hospital|Ohio State University|St. Joseph's Hospital and Medical Center, Phoenix|University of California, San Francisco|Oregon Health and Science University|Yale New Haven Hospital|University of Iowa|Hartford Hospital|The University of Texas Health Science Center, Houston|Rhode Island Hospital|Stanford University|University of Washington|University of Calgary|Hopital de l'Enfant-Jesus|University of Alberta|Dalhousie University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012P-000005|U01NS074425","March 18, 2013","January 15, 2014","May 10, 2018","August 13, 2012","May 30, 2019","June 12, 2019","St. Joseph's Hospital, Phoenix, Arizona, United States|Stanford University Hospital, Palo Alto, California, United States|San Francisco General Hospital, San Francisco, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|The University of Florida College of Medicine, Jacksonville, Florida, United States|University of Iowa Hospital, Iowa City, Iowa, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|The University of Texas Health Science Center, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Foothills Medical Center, Calgary, Alberta, Canada|Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada|Halifax Infirmary, Halifax, Nova Scotia, Canada|Hôpital de l'Enfant-Jésus - CHU de Québec, Québec, Canada",,"https://ClinicalTrials.gov/show/NCT01662895"
167,"NCT02915198","Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes","VA-IMPACT","Recruiting","No Results Available","Prediabetic State|Atherosclerosis|Metformin","Drug: Metformin XR|Drug: Placebo","Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization|Time in days to Cardiovascular Outcomes|Time in days to Oncologic Outcome|Time in days to Diabetes Outcome","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 4","7868","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2002","February 21, 2019","August 21, 2024","August 21, 2024","September 26, 2016",,"April 16, 2020","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02915198"
168,"NCT02489344","Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: GZ/SAR402671","Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Urinalysis|Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities|Change From Baseline in Plasma Globotriaosylceramide (GL-3) Concentration at Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso GL-3) Concentration at Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in Plasma Monosialodihexosylganglioside (GM3) Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in Urine GL-3 Concentration At Weeks 26, 52, 104, and 156|Change From Baseline in High Sensitivity Cardiac Troponin T At Weeks 26, 52, 104, and 156|Change From Baseline in Podocyturia Counts (Per Milligram of Creatinine) At Weeks 12, 26, and 156|Summary of Shifts From Baseline in Skin GL-3 Score in Superficial Capillary Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Endothelial Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Summary of Shifts From Baseline in Skin GL-3 Score in Perineurium Cells Over Time: Number of Participants in Categories of Shift in GL-3 Score|Change From Baseline in Mental Component Summary and Physical Component Summary of the Short Form-36 (SF-36) Health Survey at Weeks 26, 52, 104 and 156|Gastrointestinal (GI) Symptoms: Number of Participants With Abdominal Pain at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Abdominal Pain Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Days With Abdominal Pain Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Participants With Abdominal Distension at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Abdominal Distension Severity Score at Baseline and Weeks 2, 4, 8, 12, 18, 26, and 156|Gastrointestinal Symptoms: Number of Participants in Categories of Response Regarding Eating Less Due to Abdominal Pain/Bloating at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Satisfaction Over Bowel Habits at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Frequency of Bowel Movements - Most Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Frequency of Bowel Movements - Least Number of Times Bowel Movement Per Day at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Influence of GI Symptoms of Fabry Disease on Life at Baseline and Weeks 2, 4, 8, 12, 18, 26, 52, 104, and 156|Gastrointestinal Symptoms: Number of Participants With Stool Consistency Assessment by Bristol Stool Scale Scoring at Baseline and Weeks 26, 52, 104, and 156|Change From Baseline in Beck Depression Inventory (BDI) Total Score at Weeks 26, 104, and 156|Change From Baseline in Albumin/Creatinine Ratio (ACR) and Protein/Creatinine Ratio (PCR) at Weeks 26, 52, 104, and 156|Number of Participants in Categories of Echocardiogram (ECHO) Results at Baseline and at Weeks 26, 52, 104, and 156|Number of Participants in Categories of Brain Magnetic Resonance Imaging (MRI) Results at Baseline and Weeks 26, and 156|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Weeks 26, 52, 104, and 156","Genzyme, a Sanofi Company|Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS14116|2014-004995-49|U1111-1165-9049","July 7, 2015","November 20, 2018","November 20, 2018","July 3, 2015","December 9, 2019","December 9, 2019","Investigational Site Number 840002, Atlanta, Georgia, United States|Investigational Site Number 840003, Cincinnati, Ohio, United States|Investigational Site Number 840001, Fairfax, Virginia, United States|Investigational Site Number 250001, Garches, France|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 826002, Cambridge, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02489344/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT02489344/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02489344"
169,"NCT01282242","A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients","MR WITNESS","Completed","Has Results","Acute Stroke","Drug: IV rt-PA","Number of Subjects With Symptomatic Intracerebral Hemorrhage|Number of Subjects With Symptomatic Cerebral Edema","Lee Schwamm|National Institute of Neurological Disorders and Stroke (NINDS)|Genentech, Inc.|Massachusetts General Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","88","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010P001880","January 2011","January 2016","May 2016","January 24, 2011","April 11, 2017","June 15, 2017","University of Arizona, Tucson, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|NIH/ NINDS, Washington Hospital, Suburban Hospital, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|Washington University School of Medicine/Barnes Jewish Hospital, Saint Louis, Missouri, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States|Seton/UT Southwestern Medical Center, Austin, Texas, United States|Intermountain Healthcare, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01282242"
170,"NCT02228460","Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: GZ/SAR402671","Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Mean Change From Baseline at Week 26 in Skin GL-3 Score in Superficial Skin Capillary Endothelium|Change From Baseline in Plasma GL-3 Concentration at Week 26|Change From Baseline in Plasma Lyso Globotriaosylceramide (Lyso-GL-3) Concentration at Week 26|Change From Baseline in Plasma Glucosylceramide (GL-1) Concentration at Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Endothelial Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Deep Vessels Smooth Muscle Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline at Week 26 in Skin GL-3 Score in Perineurium Cells: Number of Participants in Categories of Shift in GL-3 Score From Baseline to Week 26|Change From Baseline in Urine Globotriaosylceramide (GL-3) Concentration at Week 26|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Pharmacokinetics (PK): Maximum Plasma Drug Concentration (Cmax) of GZ/SAR402671|PK: Plasma Trough Concentration (Ctrough) of GZ/SAR402671|PK: Time to Reach Maximum Plasma Drug Concentration (Tmax) of GZ/SAR402671|PK: Area Under Plasma Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24) of GZ/SAR402671|PK: Terminal Half-life (t1/2z) of GZ/SAR402671|PK: Apparent Total Body Clearance of GZ/SAR402671 at Steady State (CLss/F)|PK: Apparent Volume of Distribution of GZ/SAR402671 (Vss/F) at Steady State|PK: Cumulated Amount of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (Ae0-24)|PK: Percentage of Dose of GZ/SAR402671 Excreted in Urine From 0 to 24 Hours (fe0-24)|PK: Renal Clearance (CLR) of GZ/SAR402671 From 0 to 24 Hours","Genzyme, a Sanofi Company|Sanofi","Male","18 Years to 49 Years   (Adult)","Phase 2","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACT13739|2013-005324-41|U1111-1152-1456","November 2014","September 2016","September 2016","August 29, 2014","December 17, 2019","December 17, 2019","Investigational Site Number 840002, Atlanta, Georgia, United States|Investigational Site Number 840003, Cincinnati, Ohio, United States|Investigational Site Number 840001, Fairfax, Virginia, United States|Investigational Site Number 250001, Garches, France|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 826003, Birmingham, United Kingdom|Investigational Site Number 826002, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02228460"
171,"NCT02702778","Delayed Release Prednisone in PMR",,"Terminated","No Results Available","Polymyalgia Rheumatica","Drug: Delayed-Release (DR) Prednisone|Drug: Immediate Release (IR) Prednisone","Change of the severity of morning stiffness from baseline to end of study (28days)|Relative reduction in the duration of morning stiffness (minutes)|Relative IL-6 treatment response.|Changes in plasma IL-6 compared with changes in the severity of morning stiffness|Patient reported outcomes in accordance with the OMERACT PMR objectives|Performance characteristics of additional clinical measures of disease outcome.","Dinora, Inc.|Analgesic Solutions|PharPoint Research, Inc.","All","50 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HZNP-PRE-IIS02","February 2016","December 31, 2016","March 31, 2017","March 9, 2016",,"May 3, 2017","Clinical Research Site, Miami, Florida, United States|Clinical Research Site, Mineola, New York, United States|Clinical Research Site, Duncansville, Pennsylvania, United States|Clinical Research Site 2, Wyomissing, Pennsylvania, United States|Clinical Research Site, Wyomissing, Pennsylvania, United States|Clinical Research Site, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02702778"
172,"NCT03600805","Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA",,"Suspended","No Results Available","Giant Cell Arteritis","Drug: Sarilumab SAR153191|Drug: Sarilumab matching placebo|Drug: Prednisone|Drug: Prednisone matching placebo","Proportion of patients with sustained remission|Components of sustained remission (composite measure)|Cumulative corticosteroid dose|Time to first GCA flare|Change in glucocorticoid toxicity index|Adverse events|Pharmacokinetic","Sanofi|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15068|2017-002988-18|U1111-1200-2184","November 20, 2018","November 2022","April 2023","July 26, 2018",,"April 15, 2020","Investigational Site Number 8400023, Tuscaloosa, Alabama, United States|Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400029, Washington, District of Columbia, United States|Investigational Site Number 8400002, Boca Raton, Florida, United States|Investigational Site Number 8400017, Gainesville, Florida, United States|Investigational Site Number 8400028, Plantation, Florida, United States|Investigational Site Number 8400007, Boise, Idaho, United States|Investigational Site Number 8400014, Iowa City, Iowa, United States|Investigational Site Number 8400027, Baton Rouge, Louisiana, United States|Investigational Site Number 8400012, Boston, Massachusetts, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 8400024, Saint Louis, Missouri, United States|Investigational Site Number 8400022, New York, New York, United States|Investigational Site Number 8400018, Portland, Oregon, United States|Investigational Site Number 8400016, Duncansville, Pennsylvania, United States|Investigational Site Number 8400019, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400020, Nashville, Tennessee, United States|Investigational Site Number 8400011, Dallas, Texas, United States|Investigational Site Number 8400025, Lufkin, Texas, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0360003, Camberwell, Australia|Investigational Site Number 0360006, Clayton, Australia|Investigational Site Number 0360001, Kogarah, Australia|Investigational Site Number 0360002, Maroochydore, Australia|Investigational Site Number 0360005, Murdoch, Australia|Investigational Site Number 0360007, Woodville, Australia|Investigational Site Number 0400002, Innsbruck, Austria|Investigational Site Number 0400001, Wien, Austria|Investigational Site Number 0560005, Bruxelles, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 1240007, Hamilton, Canada|Investigational Site Number 1240010, Montreal, Canada|Investigational Site Number 1240008, Ottawa, Canada|Investigational Site Number 1240001, Rimouski, Canada|Investigational Site Number 1240005, Sherbrooke, Canada|Investigational Site Number 1240003, Trois-Rivières, Canada|Investigational Site Number 1910001, Zagreb, Croatia|Investigational Site Number 2080002, Aarhus C, Denmark|Investigational Site Number 2080003, Svendborg, Denmark|Investigational Site Number 2080004, Ålborg, Denmark|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2460001, Helsinki, Finland|Investigational Site Number 2460002, Turku, Finland|Investigational Site Number 2500005, Brest Cedex, France|Investigational Site Number 2500008, Lille, France|Investigational Site Number 2500009, Marseille, France|Investigational Site Number 2500002, Montivilliers, France|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500007, Mulhouse, France|Investigational Site Number 2500004, Paris, France|Investigational Site Number 2500001, Paris, France|Investigational Site Number 2500006, Pessac, France|Investigational Site Number 2760009, Berlin, Germany|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Dresden, Germany|Investigational Site Number 2760003, Kirchheim Unter Teck, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 2760007, Tübingen, Germany|Investigational Site Number 3480001, Debrecen, Hungary|Investigational Site Number 3760006, Ashkelon, Israel|Investigational Site Number 3760001, Haifa, Israel|Investigational Site Number 3760004, Haifa, Israel|Investigational Site Number 3760007, Jerusalem, Israel|Investigational Site Number 3760003, Kfar Saba, Israel|Investigational Site Number 3760002, Petah-Tikva, Israel|Investigational Site Number 3760005, Tel Hashomer, Israel|Investigational Site Number 3800006, Ferrara, Italy|Investigational Site Number 3800003, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800004, Pisa, Italy|Investigational Site Number 3800005, Rozzano, Italy|Investigational Site Number 3800009, Siena, Italy|Investigational Site Number 5280007, Den Haag, Netherlands|Investigational Site Number 5280005, Leeuwarden, Netherlands|Investigational Site Number 5280008, Rotterdam, Netherlands|Investigational Site Number 5280009, Sittard-Geleen, Netherlands|Investigational Site Number 5280001, Venlo, Netherlands|Investigational Site Number 6200001, Almada, Portugal|Investigational Site Number 6200005, Aveiro, Portugal|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 6200003, Lisboa, Portugal|Investigational Site Number 6200004, Ponte De Lima, Portugal|Investigational Site Number 6430005, Kemerovo, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430006, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 7050001, Ljubljana, Slovenia|Investigational Site Number 7240010, Bilbao, Spain|Investigational Site Number 7240009, Córdoba, Spain|Investigational Site Number 7240011, La Coruña, Spain|Investigational Site Number 7240013, Madrid, Spain|Investigational Site Number 7240014, Madrid, Spain|Investigational Site Number 7240016, Sabadell, Spain|Investigational Site Number 7240015, Santa Cruz De Tenerife, Spain|Investigational Site Number 7520001, Uppsala, Sweden|Investigational Site Number 7520003, Örebro, Sweden|Investigational Site Number 7560002, St. Gallen, Switzerland|Investigational Site Number 8260006, Aberdeen, United Kingdom|Investigational Site Number 8260008, Dudley, United Kingdom|Investigational Site Number 8260004, Gateshead, United Kingdom|Investigational Site Number 8260003, Leeds, United Kingdom|Investigational Site Number 8260005, Manchester, United Kingdom|Investigational Site Number 8260002, Plymouth, United Kingdom|Investigational Site Number 8260011, Portsmouth, United Kingdom|Investigational Site Number 8260001, Southend, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03600805"
173,"NCT03992404","Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury","PATTERN","Active, not recruiting","No Results Available","Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury","Drug: NT 201|Drug: Placebo","Change from baseline in derived Modified Ashworth Scale-Bohannon (MAS) ankle score (knee extended) at weeks 4 to 6|Co-Primary: Global Impression of Change Scale (GICS) assessed by physician at Week 4 to 6|Occurrence of treatment emergent adverse events [TEAEs] in the Main Period|Change from Study Baseline in Goal Attainment Scale [GAS] at Week 6|Global Impression of Change Scale (GICS) assessed by the study subject at Week 4 to 6|Global Impression of Change Scale (GICS) assessed by the caregiver at Week 4 to 6","Merz Pharmaceuticals GmbH","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M602011014|2018-001639-35","September 16, 2019","June 2023","December 2024","June 20, 2019",,"April 6, 2020","New England institute for clinical research; Merz Investigational Site #0010441, Stamford, Connecticut, United States|Howard A. Rusk Rehabilitation Center; Merz investigational site #0010283, Columbia, Missouri, United States|Icahn School of Medicine at Mount Sinai, neurology department, Merz Investigational Site #0010191, New York, New York, United States|Weill Cornell Medical Center, Department of Rehabilitation Medicine; Merz Investigational Site #0010440, New York, New York, United States|University of Pittsburgh Medical Center, Physical Medicine & Rehabiliation, Merz Investigational Site #0010211, Pittsburgh, Pennsylvania, United States|Medical College of Wisconsin,Department of PM&R, Merz Investigational Site #0010237, Milwaukee, Wisconsin, United States|St George Hospital, Department of Rehabilitation Medicine, Merz Investigational Site #0610004, Kogarah, Australia|Royal Melbourne Hospital, Department of Rehabilitation Medicine; Merz Investigational Site #0610002, Parkville, Australia|UCL Bruxelles, Physical Medicine & Rehabilitation Department, Merz Investigational Site #0320013, Bruxelles, Belgium|UCL Mont Godinne, Physical Medicine & Rehabilitation Department; Merz Investigational Site #0320008, Yvoir, Belgium|Neurology and Physiotherapy Skopalikova, Merz Investigational Site #4200049, Brno, Czechia|Fakultni nemocnice Kralovske Vinohrady, Neurology Department, Merz Investigational Site #4200050, Prague, Czechia|Raymond Poincaré University Hospital, Service de MPR Pôle Handicap-Rééducation; Merz Investigational Site #0330018, Garches, France|Institut Universitaire de Readaptation Clemenceau, Physical Medicine / Rehabilitation Medecine, Merz Investigational site # 0330063, Strasbourg, France|Uniklinik RWTH Aachen, Neurologie, Merz Investigational Site #0490191, Aachen, Germany|Heinrich Heine University Duesseldorf, Department of Neurology; Merz Investigational Site #0490071, Düsseldorf, Germany|CBBM, Institut für Neurogenetik, Haus 66; Merz Investigational Site #0490332, Lübeck, Germany|DKD HELIOS Medical Center, Fachbereich Neurologie, Merz Investigational Site #0490081, Wiesbaden, Germany|Neurologische Klinik und Poliklinik des Universitätsklinikums Würzburg, Merz Investigational Site #0490302, Würzburg, Germany|Azienda Ospedaliera Universitaria Ospedali Riuniti Di Foggia; Merz Investigational Site #0390018, Foggia, Italy|Ospedale Maggiore della Carita, Dipartimento di Medicina fisica e Riabilitativa, Merz Investigational Site #0390017, Novara, Italy|AOUI -Ospedale Borgo Roma, U.O.C Neuroriabilitazione, Merz Investigational Site #0390014, Verona, Italy|Specjalistyczna Praktyka Lekarska Dr. n. med Stanisław Ochudło, Merz Investigational Site #0480077, Katowice, Poland|Specjalistyczne Gabinety Sp z o.o., Merz Investigational Site #0480059, Krakow, Poland|NeuroKlinika Gabinet Lekarski Prof Andrzej Bogucki, Merz Investigational Site #0480101, Lodz, Poland|Centrum Medyczne MEDICOS S.A., Merz Investigational Site #0480096, Lublin, Poland|""AMED"" Centrum Medyczne, Merz Investigational Site #0480100, Warsaw, Poland|Projekt Samodzielni Sp z o.o., Merz Investigational Site #0480099, Warsaw, Poland|Instytut Psychiatrii i Neurologii, II Klinika Neurologiczna, Merz Investigational Site #0480023, Warsaw, Poland|Mazowiecki Szpital Brodnowski, Merz investigational site #0480064, Warsaw, Poland|Federal State Budgetary Educational Institution of Higher Education ""Krasnoyarsk State Medical University n.a. Professor V.F. Voino-Yasenetskiy of Ministry Healthcare of Russian Federation"", Merz Investigational Site #0070306, Krasnoyarsk, Russian Federation|State Autonomous Institution of Healthcare of Moscow City ""Moscow Scientific and Practical Centre of Medical Rehabilitation, Regenerative and Sports Medicine of Moscow City Healthcare Department"", Merz Investigational Site #0070011, Moscow, Russian Federation|Federal State Autonomous Institution ""National Medical Research Centre ""Treatment and Rehabilitation"" of the Ministry of Health of the Russian Federation, Neurology department, Merz Investigational Site # 0070305, Moscow, Russian Federation|Federal State Budgetary Institution ""National Medical Research Centre of Psychiatry and Neurology n.a. V.M. Bekhterev"" of the Ministry of Healthcare of the Russian Federation, Merz Investigational Site #0070009, Saint Petersburg, Russian Federation|Hospital Universitario La Paz, Merz Investigational Site #0340007, Madrid, Spain|Hospital Universitari Mútua de Terrassa, Merz Investigational Site #0340003, Terrassa, Spain|Centre Hospitalier Universitaire Vaudois - Neurorehabilitation and Physical Medicine, Merz Investigational Site #0410013, Lausanne, Switzerland|Cambridge University Hospitals NHS Foundation Trust; Merz Investigational Site 0440023, Cambridge, United Kingdom|Royal Devon and Exeter Foundation Trust Hospital, Department of Neurology, Merz Investigational Site #0440047, Exeter, United Kingdom|The Walton Centre NHS Foundation Trust; Neuroscience Research Centre; Merz Investigational site #0440004, Liverpool, United Kingdom|National Hospital for Neurology and Neurosurgery - UCLH; Merz Investigational Site #0440033, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03992404"
174,"NCT01827046","Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III","MISTIE-III","Completed","Has Results","Intracerebral Hemorrhage","Drug: rt-PA","Dichotomized, Adjudicated Modified Rankin Scale Score 0-3 vs. 4-6 at 365 Days Post Ictus (Adjusted)|Dichotomized Extended Glasgow Outcome Scale (eGOS) Score UGR-US vs. LS-Death at 365 Days Post Ictus (Adjusted)|All Cause Mortality Longitudinally From Ictus to 365 Days (Adjusted)|Clot Removal (Amount of Residual Blood)|Patient Disposition: Home Days Over 365 Days Time From Ictus.|Patient Disposition: Patient Location at 365 Days Post Ictus (i.e., Good vs. Bad Location) (Adjusted)|Dichotomized, Adjudicated, Cross-sectional Modified Rankin Scale (mRS) Score 0-3 vs. 4-6 180 Days Post Ictus (Adjusted)|Dichotomized Extended Glasgow Outcome Scale (eGOS) Score UGR-US vs. LS-Death at 180 Days Post Ictus (Adjusted)|Type and Intensity of ICU Management: ICU Days|Type and Intensity of ICU Management: Hospital Days|EQ-VAS|EuroQol 5 Dimensional Scale (EQ-5D)","Johns Hopkins University|National Institute of Neurological Disorders and Stroke (NINDS)|Genentech, Inc.|Emissary International LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","499","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NA_00080619|U01NS080824|ICH02","December 30, 2013","September 2018","September 2018","April 9, 2013","September 27, 2019","September 27, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Good Samaritan Hospital, Phoenix, Arizona, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Mercy San Juan Medical Center, Carmichael, California, United States|Scripps Health, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|Stanford University, Stanford, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Northshore University Health System, Evanston, Evanston, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Heath System, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|St. Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Rutgers - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, New York, United States|University of Buffalo, Buffalo, New York, United States|North Shore Long Island Jewish Health System, Manhasset, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|State University of New York, Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Providence Brain and Spine Institute, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern at Dallas, Dallas, Texas, United States|University of Texas, Houston, Houston, Texas, United States|University of Texas at San Antonio, San Antonio, Texas, United States|Intermountain Neurosciences Institute, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Fairfax INOVA Hospital, Falls Church, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal Adelaide Hospital, North Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|University of Alberta, Edmonton, Alberta, Canada|McMaster University, Hamilton, Ontario, Canada|Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Bayi Brain Hospital, Beijing Military General Hospital, Beijing, China|Southwest Hospital, Third Military Medical University, Chongqing, China|University of Bonn, Bonn, Germany|University of Heidelberg, Heidelberg, Germany|University of Mainz, Mainz, Germany|University of Munich, Munich, Germany|University of Pecs, Pecs, Baranya County, Hungary|University of Debrecen, Debrecen, Hungary|University of Szeged, Szeged, Hungary|The Chaim Sheba Medical Center at Tel Hashomer, Tel Hashomer, Ramat-Gan, Israel|Rabin Medical Center, Petach Tikva, Israel|Hospital Universitario Cruces, Barakaldo, Biscay, Spain|Vall d'Hebron University Hospital, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Bellvitge, Barcelona, Spain|Hospital Universitario Mutua de Terrassa, Barcelona, Spain|Hospital Universitario Rio Hortega, Valladolid, Spain|Salford Royal NHS Foundation Trust, Salford, Manchester, United Kingdom|South Glasgow University Hospital, Glasgow, United Kingdom|Newcastle Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|University of Southampton Hospital, Southampton, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01827046/SAP_002.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01827046/Prot_003.pdf","https://ClinicalTrials.gov/show/NCT01827046"
175,"NCT02175225","Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial",,"Completed","Has Results","Intracerebral Hemorrhage","Drug: Deferoxamine Mesylate|Drug: Placebo (for Deferoxamine Mesylate)","Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days|Number of Subjects Experiencing Serious Adverse Events|Number of Subjects With Serious Adverse Events Within 7 Days|Proportion of Patients With mRS Score 0-3 at 90 Days|Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 180 Days|Proportion of Patients With Modified Rankin Scale (mRS) Score 0-3 at 180 Days|Proportion of Subjects With Good Outcome (mRS 0-2) in the Early vs. Delayed Treatment Time Windows","Beth Israel Deaconess Medical Center|Medical University of South Carolina|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital|University of Massachusetts, Worcester|University of Pennsylvania|Johns Hopkins University|Duke University|University of North Carolina|University of Florida|Henry Ford Hospital|Ohio State University|St. Joseph's Hospital and Medical Center, Phoenix|University of California, San Francisco|Oregon Health and Science University|Yale New Haven Health System Center for Healthcare Solutions|University of Iowa|Hartford Hospital|The University of Texas Health Science Center, Houston|Rhode Island Hospital|Stanford University|University of Washington|University of Calgary|Hopital de l'Enfant-Jesus|University of Alberta|Rush University Medical Center|University Hospitals Cleveland Medical Center|Columbia University|Weill Medical College of Cornell University|NYU Langone Health|Mount Sinai Hospital, New York|Loyola University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","294","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012P000005|U01NS074425","October 2014","February 10, 2018","May 30, 2018","June 26, 2014","May 30, 2019","May 30, 2019","St. Joseph's Hospital / Barrow Neurological Institute, Phoenix, Arizona, United States|Stanford University Medical Center, Palo Alto, California, United States|San Francisco General Hospital, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|University of Florida, Jacksonville, Florida, United States|Loyola University Medical Center, Chicago, Illinois, United States|RUSH University Medical Center, Chicago, Illinois, United States|University of Iowa Medical Center, Iowa City, Iowa, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Columbia University, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospital Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University Medical Center, Portland, Oregon, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Health Sciences Center, Houston, Texas, United States|Foothills Hospital - University of Calgary, Calgary, Alberta, Canada|University of Alberta - Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada|CHU de Québec - Hôpital de l'Enfant-Jésus, Québec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02175225/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT02175225/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02175225"
176,"NCT01464307","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke","PLUS","Completed","Has Results","Post-stroke Spasticity of the Lower Limb","Drug: IncobotulinumtoxinA (400 Units)|Drug: Placebo Comparator","Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4|Co-primary Variable: Investigator's Global Assessment of Efficacy at Week 12|Response Rate for Plantar Flexors at All Post-Baseline Visits for Subjects With an Improvement (Reduction) of at Least 1 Point From Baseline in the Ashworth Scale (AS)|Ashworth Scale (AS) for Plantar Flexors at All Post-Baseline Visits","Merz Pharmaceuticals GmbH","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","290","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MRZ 60201/SP/3002|2010-024579-23","December 2011","August 2014","May 2015","November 3, 2011","November 7, 2016","November 7, 2016","Merz Investigational Site #001184, Downey, California, United States|Merz Investigational Site #001208, Long Beach, California, United States|Merz Investigational Site #001244, Fairfield, Connecticut, United States|Investigational site #001188, Doral, Florida, United States|Merz Investigational Site # 001110, Overland Park, Kansas, United States|Merz Investigational Site #001209, Columbia, Missouri, United States|Merz Investigational Site #001210, St. Louis, Missouri, United States|Merz Investigational Site #001198, Stratford, New Jersey, United States|Merz Investigational Site #001207, Plainview, New York, United States|Merz Investigational Site #001009, Winston-Salem, North Carolina, United States|Merz Investigational Site #001206, Nashville, Tennessee, United States|Merz Investigational Site #001183, Houston, Texas, United States|Merz Investigational Site #001204, Halifax, Nova Scotia, Canada|Merz Investigational Site #001202, Winnipeg, Canada|Merz Investigational Site #420024, Ostrava-Poruba, Czech Republic|Merz Investigational Site #420031, Ostrava-Vitkovice, Czech Republic|Merz Investigational Site #420030, Praha, Czech Republic|Merz Investigational Site #420047, Rychnov nad Kneznou, Czech Republic|Merz Investigational Site #033018, Garches, France|Merz Investigational Site #033024, Rennes, France|Merz Investigational Site #049022, Beelitz-Heilstätten, Germany|Merz Investigational Site #049071, Düsseldorf, Germany|Merz Investigational Site #049079, Hamburg, Germany|Merz Investigational Site #049304, Kiel, Germany|Merz Investigational Site #049072, München, Germany|Merz Investigational Site #049148, München, Germany|Merz Investigational Site #049303, Regensburg, Germany|Merz Investigational Site #049302, Würzburg, Germany|Merz Investigational Site #039006, Messina, Italy|Merz Investigational Site #039011, Roma, Italy|Merz Investigational Site #039012, Roma, Italy|Merz Investigational Site #048057, Gdansk, Poland|Merz Investigational Site #048044, Kielce, Poland|Merz Investigational Site #048080, Krakow, Poland|Merz Investigational Site #048054, Krakow, Poland|Merz Investigational Site #048031, Krakow, Poland|Merz Investigational Site #048022, Lodz, Poland|Merz Investigational Site #048051, Lublin, Poland|Merz Investigational Site #048053, Poznan, Poland|Merz Investigational Site #048081, Poznan, Poland|Merz Investigational Site #048055, Warszawa, Poland|Merz Investigational Site #048023, Warszawa, Poland|Merz Investigational Site #048056, Warszawa, Poland|Merz Investigational Site #048033, Warszawa, Poland|Merz Investigational Site #007010, Krasnoyarsk, Russian Federation|Merz Investigational Site #007011, Moscow, Russian Federation|Merz Investigational Site #007009, St. Petersburg, Russian Federation|Merz Investigational Site #007012, Stavropol, Russian Federation|Merz Investigational Site #034027, Madrid, Spain|Merz Investigational Site #034028, Majadahonda, Spain|Merz Investigational Site #034026, Sevilla, Spain|Merz Investigational Site #034030, Sevilla, Spain|Merz Investigational Site #034029, Terrassa, Spain",,"https://ClinicalTrials.gov/show/NCT01464307"
177,"NCT01392300","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke","PURE","Completed","Has Results","Post-stroke Spasticity of the Upper Limb","Drug: IncobotulinumtoxinA (400 Units)|Drug: Placebo Comparator","Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern|Investigator's Global Impression of Change|Response Rates on the Ashworth Scale at Week 4 Calculated for the Primary Target Clinical Pattern|Response Rates on the Ashworth Scale at Week 8 Calculated for the Primary Target Clinical Pattern|Response Rates on the Ashworth Scale at Week 12 Calculated for the Primary Target Clinical Pattern|Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Flexed Wrist|Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Wrist|Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Flexed Wrist|Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Flexed Elbow|Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Elbow|Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Flexed Elbow|Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Clenched Fist|Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Clenched Fist|Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Clenched Fist|Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Thumb-in-palm|Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Thumb-in-palm|Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Thumb-in-palm|Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Pronated Forearm|Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Pronated Forearm|Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Pronated Forearm|Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.|Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.|Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.|Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.|Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.|Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.|Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.|Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.|Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.|Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.|Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.|Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.|Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.|Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.|Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.|Changes From Baseline to Week 4 in Disability Assessment Scale - Principal Therapeutic Target Domain|Changes From Baseline to Week 8 in Disability Assessment Scale - Principal Therapeutic Target Domain|Changes From Baseline to Week 12 in Disability Assessment Scale - Principal Therapeutic Target Domain|Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Hygiene|Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Hygiene|Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Hygiene|Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Dressing|Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Dressing|Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Dressing|Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Limb Position|Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Limb Position|Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Limb Position|Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Pain|Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Pain|Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Pain","Merz Pharmaceuticals GmbH","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","317","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MRZ 60201/SP/3001|2010-023043-15","September 2011","March 2013","February 2014","July 12, 2011","February 11, 2016","January 16, 2017","Merz Investigational Site #001184, Downey, California, United States|Merz Investigational Site #001017, Fountain Valley, California, United States|Merz Investigational Site #001188, Miami, Florida, United States|Merz Investigational Site #001037, Augusta, Georgia, United States|Merz Investigational Site #001186, Chicago, Illinois, United States|Merz Investigational Site # 001110, Overland Park, Kansas, United States|Merz Investigational Site #001198, Stratford, New Jersey, United States|Merz Investigational Site #001240, Chapel Hill, North Carolina, United States|Merz Investigational Site #001009, Winston-Salem, North Carolina, United States|Merz Investigational Site #001241, Philadelphia, Pennsylvania, United States|Merz Investigational Site #001211, Pittsburgh, Pennsylvania, United States|Merz Investigational Site #001245, Chattanooga, Tennessee, United States|Merz Investigational Site #001226, Houston, Texas, United States|Merz Investigational Site #420046, Brno, Czech Republic|Merz Investigational Site #420029, Brno, Czech Republic|Merz Investigational Site #420028, Olomouc, Czech Republic|Merz Investigational Site #420024, Ostrava-Poruba, Czech Republic|Merz Investigational Site #420025, Pardubice, Czech Republic|Merz Investigational Site #420030, Praha, Czech Republic|Merz Investigational Site #420045, Praha, Czech Republic|Merz Investigational Site #420047, Rychnov nad Kneznou, Czech Republic|Merz Investigational Site #049134, Rostock, Germany|Merz Investigational Site #036004, Budapest, Hungary|Merz Investigational Site # 036009, Budapest, Hungary|Merz Investigational Site #036005, Nyiregyhaza, Hungary|Merz Investigational Site #036008, Szeged, Hungary|Merz Investigational Site #091003, Porur, Chennai, India|Merz Investigational Site #091006, Bangalore, Karnataka, India|Merz Investigational Site #091002, Trivandrum, Kerala, India|Merz Investigational Site #091007, Chennai, Tamil Nadu, India|Merz Investigational Site #091008, Coimbatore, Tamil Nadu, India|Merz Investigational Site #091001, Lucknow, Uttar Pradesh, India|Merz Investigational Site #091004, New Delhi, India|Merz Investigational Site # 048029, Gdansk, Poland|Merz Investigational Site #048044, Kielce, Poland|Merz Investigational Site #048031, Krakow, Poland|Merz Investigational Site #048050, Lodz, Poland|Merz Investigational Site #048051, Lublin, Poland|Merz Investigational Site #048032, Olsztyn, Poland|Merz Investigational Site #048053, Poznan, Poland|Merz Investigational Site #048023, Warszawa, Poland|Merz Investigational Site #048052, Warszawa, Poland|Merz Investigational Site #048033, Warszawa, Poland|Merz Investigational Site #007010, Krasnoyarsk, Russian Federation|Merz Investigational Site #007011, Moscow, Russian Federation|Merz Investigational Site #007009, St. Petersburg, Russian Federation|Merz Investigational Site #007005, Stavropol, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01392300"
178,"NCT02790632","Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage","NEWTON2","Terminated","No Results Available","Subarachnoid Hemorrhage, Aneurysmal","Drug: EG-1962 (nimodipine microparticles)|Drug: Enteral Nimodipine","Proportion of subjects with a favorable outcome measured on the Extended Glasgow Outcome Scale [Primary Efficacy Endpoint]|Proportion of subjects with favorable neurocognitive outcome measured by the Montreal Cognitive Assessment [Secondary Efficacy Endpoint]","Edge Therapeutics Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","374","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EG-01-1962-03","July 2016","June 2018","June 2018","June 6, 2016",,"July 26, 2018","University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Dignity Health; St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of California, San Francisco-Fresno, Fresno, California, United States|Keck Hospital of USC, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|UCSF, San Francisco, California, United States|Yale New Haven Hospital (YNHH), New Haven, Connecticut, United States|UF Health Shands Florida, Gainesville, Florida, United States|Baptist Medical Center/Lyerly Neurosurgery, Jacksonville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Tallahassee Neurological Clinic, Tallahassee, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|University of Maryland Medical Systems, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|UNC Hospitals Neuroscience Intensive Care Unit, Chapel Hill, North Carolina, United States|Duke University Medical Pavilion, Durham, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston Air Force Base, South Carolina, United States|Semmes Murphey Neurological Clinic, Memphis, Tennessee, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|University of Washington, Harborview Medical Center, Seattle, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, Australia|Medizinische Universitat Innsbruck/Tirol Universitatsklinik fur Neurologie, Innsbruck, Austria|University of Alberta Hospital/Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM), Hopital Notre Dame, Montréal, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Faculty Hospital Hradec Kralove, Hradec Králové, Hradec Kralov, Czechia|Faculty Hospital Brno, Brno, South Moravian Region, Czechia|Faculty Hospital Ostrava, Ostrava, Czechia|Military University Hospital Prague, Prague, Czechia|Tampere University Hospital, Tampere, Pirkanmaa, Finland|Helsinki University Hospital, Helsinki, Finland|Neuro Intensive Care Unit 102i; Campus Charite Mitte (CCM), Berlin, Germany|Universitatsklinikum Erlangen, Neurologische Klinik, Koptkliniken, Erlangen, Germany|Klinik für Neurochirurgie des Universitätsklinikum Essen, Essen, Germany|Klinik für Neurochirurgie, Zentrum der Neurologie und Neurochirurgie, Goethe-Universitätsklinikum Frankfurt am Main, Frankfurt am Main, Germany|Universitätsklinikum Hamburg Eppendorf, Klinik und Poliklinik für Neurochirurgie, Neues Klinikum, Hamburg, Germany|Neurochirurgische Klinik der Universität Heidelberg, Heidelberg, Germany|Zentrum fur Neurochirurgie der Uniklinik Koln, Köln, Germany|Klinik und Poliklinik für Neurochirurgie des Universitatsklinikum Leipzig, Leipzig, Germany|Neurochirurgische Klinik, Universitatsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany|Neurochirurgische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universitat Munchen, Munchen, Germany|Neutochirurgische Klinik und Poliklinik des Universitatsklinikum Wurzburg, Würzburg, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, New Kowloon, Hong Kong|Rabin Medical Center, Petaẖ Tiqwa, Petah-Tikva, Israel|Rambam Health Care Center, Haifa, Israel|Hadassah Hebrew University Medical Center, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|Auckland City Hospital, Auckland, New Zealand|National Neuroscience Institute, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02790632"
179,"NCT03712345","Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)",,"Recruiting","No Results Available","Granulomatosis With Polyangiitis (GPA)|Microscopic Polyangiitis (MPA)","Drug: IFX-1|Drug: Placebo","Number and percentage of subjects who experience at least one treatment-emergent adverse event (TEAE) per treatment group.|Proportion of subjects achieving clinical response (reduction in BVAS of ≥50% and no worsening in any body system)|Proportion of subjects with clinical remission (BVAS = 0)|IFX 1 concentration pre- and postdose at each IMP administration visit|IFX 1 concentration at predose (0 hours), after the end of the infusion (+10minutes), and at 2, 6, 24, and 48 hours after the start of the infusion for subjects in the PK substudy","InflaRx GmbH|Iqvia Pty Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IFX-1-P2.6","October 15, 2018","December 31, 2021","March 31, 2022","October 19, 2018",,"March 3, 2020","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Loma Linda University Clinical Trial Center, Loma Linda, California, United States|Science Connections, LLC, Doral, Florida, United States|University of Miami, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|LSU Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University Of MI Medcl Ctr-RHU, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|Northwell Health, LLC PRIME, New Hyde Park, New York, United States|Hospital for Special Surgery, New York, New York, United States|University of Rochester Medical Center - Strong Memorial Hospital, Rochester, New York, United States|UNC Kidney Center, UNC-CH Division of Nephrology and Hypertension, Chapel Hill, North Carolina, United States|Trinity Medical Group, Minot, North Dakota, United States|Ohio State University Clinical Trials Management Office, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|BRCR Medical Center, Inc., Camp Hill, Pennsylvania, United States|Altoona Center for Clinical Research, P.C., Duncansville, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Low Country Rheumatology, PA, North Charleston, South Carolina, United States|Adriana Pop Moody Clinic PA, Corpus Christi, Texas, United States|Texas Health Resources, Dallas, Texas, United States|Texas Research Institute, Fort Worth, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|UVA University Physicians Charlottesville, Charlottesville, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|St. Josephs Healthcare, Hamilton, Ontaria, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|CHUM Centre de Recherche, Québec, Quebec, Canada|Centre de Recherche Musculo-Squelettique, Trois-Rivières, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03712345"
180,"NCT01893190","Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage","NEWTON","Completed","No Results Available","Ruptured Cerebral Aneurysm|Ruptured Berry Aneurysm","Drug: Nimodipine|Drug: Nimodipine Microparticles","Dose Escalation Period|PK measurements","Edge Therapeutics Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EG-01-1962-02|2013-000954-23","September 2013","January 2016","January 2016","July 8, 2013",,"February 5, 2018","Barrow Neurological Institute, Phoenix, Arizona, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Maryland Medical Cnter, Baltimore, Maryland, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Mayfield Clinic Inc, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network - Toronto General Division, Toronto Western Hospital, Toronto, Ontario, Canada|University of Saskatchewan, Royal University Hospital, Saskatoon, Saskatchewan, Canada|Charles University, Department of Neurosurgery, Prague, Czechia|Helsinki University Central Hospital, Helsinki, Finland",,"https://ClinicalTrials.gov/show/NCT01893190"
181,"NCT02501434","Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin","ASTROH","Recruiting","No Results Available","Aneurysmal Subarachnoid Hemorrhage|Neurobehavioral Manifestations|Vasospasm, Intracranial|Intracranial Aneurysm|Heparin-induced Thrombocytopenia Type II","Drug: Continuous Low-Dose IV Unfractionated Heparin Infusion","Montreal Cognitive Assessment (MoCA)|Rate of ""Major Bleeding"" or ""Clinically Relevant Non-Major Bleeding""|Rate of ""Major Bleeding""|Rate of Type II Heparin Induced Thrombocytopenia (HIT)|Rate of Deep Venous Thrombosis (DVT) or Pulmonary Embolism (PE)|All Cause - Mortality Rate|Incidence of Any Fever (> 38.3 degrees C; > or = 101.0 degrees F)|Incidence of multiple fevers (> 2 episodes)|Mean daily fever burden|Glasgow Coma Score|National Institutes of Health Stroke Scale (NIHSS)|Center for Epidemiologic Studies Depression Scale (CES-D)|Trail Making Test Parts A&B|Cerebral Vasospasm|Incidence of clinical cerebral vasospasm requiring rescue therapy|Incidence of CT or MRI imaging demonstrating cerebral vasospasm related cerebral infarction|Ordinal Regression Analysis of the modified Rankin Scale score (mRS)|Relative frequency of ""good outcome"" as defined by dichotomized mRS score 0-2|Barthel Index|Return to work status|Lawton instrumental activities of daily living (IADL)|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS)|Plasma biomarker levels (hsCRP, procalcitonin, IL-6, TNF-alpha, P-Selectin, sICAM-1, HMGB-1, MRP-8/14)|Cerebrospinal Fluid (CSF) biomarker levels (hsCRP, procalcitonin, IL-6, TNF-alpha, P-Selectin, sICAM-1, HMGB-1, MRP8/14)|Rate of Serious Adverse Events (SAEs)","Robert F James, MD, FACS, FAANS|University of Louisville","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","15.0662","April 2016","March 2019","December 2020","July 17, 2015",,"October 25, 2017","Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Rush University, Chicago, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|Mount Sinai Ichan School of Medicine, New York, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02501434"
182,"NCT03338998","Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).",,"Recruiting","No Results Available","Hemorrhagic Stroke|Intracerebral Hemorrhage (ICH)","Drug: BAF312|Drug: Placebo","Absolute perihematoma edema (aPHE)|Plasma BAF312 concentrations","Novartis Pharmaceuticals|Novartis","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CBAF312X2207","December 24, 2017","November 1, 2021","November 1, 2021","November 9, 2017",,"March 24, 2020","Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, New Haven, Connecticut, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03338998"
183,"NCT03585270","Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain","REACT","Active, not recruiting","No Results Available","Aneurysmal Subarachnoid Hemorrhage","Drug: Clazosentan|Drug: Placebo","Occurrence of clinical deterioration due to delayed cerebral ischemia (DCI) from study drug initiation up to 14 days post-study drug initiation|Occurrence of all-cause new or worsened cerebral infarction* ≥ 5 cm3 (total volume) at Day 16 post-study drug initiation|Long-term clinical outcome assessed by the Glasgow Outcome Scale Extended (GOSE) at Week 12 post-aSAH, dichotomized as follows: poor outcome (score ≤ 4) and good outcome (score > 4)","Idorsia Pharmaceuticals Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ID-054-304|2018-000241-39","February 5, 2019","May 2021","October 2021","July 12, 2018",,"April 24, 2020","Stanford Hospital & Clinics - Stanford School of Medicine Dept. of Neurosurgery, Stanford, California, United States|Baptist Health Jacksonville, Jacksonville, Florida, United States|Mayo clinic, Dept of Neurosurgery, Jacksonville, Florida, United States|University of Illinois - Department of Neurosurgery, Chicago, Illinois, United States|University of Maryland Medical Systems - Neurosurgery, Baltimore, Maryland, United States|Boston University School of Medicine / Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center Dept of Neurosurgery, Boston, Massachusetts, United States|Washington University - Dept. of Neurosurgery, Saint Louis, Missouri, United States|Northwell Health, Department of Neurosurgery, Manhasset, New York, United States|Mt Sinai Hospital, New York, New York, United States|Columbia University Medical Center Dept. of Neurology - Neurological Intensive Care Unit, New York, New York, United States|University of Cincinnati, Neurosurgery, Cincinnati, Ohio, United States|University Hospitals Case Medical Center - Department of Neurosurgery, Cleveland, Ohio, United States|The Ohio State University -Wexner Medical Center, Columbus, Ohio, United States|Oklahoma University Health Sciences Center - Department of Neurology, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Neurosurgery, Hershey, Pennsylvania, United States|Temple University Hospital - Lung Center, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Department of Neurosurgery, Nashville, Tennessee, United States|Virginia Commonwealth University, Department of Neurosurgery, Richmond, Virginia, United States|Medizinische Universität Innsbruck; Universitätsklinik für Neurologie und Psychiatrie, Innsbruck, Austria|Kepler Universitätsklinikum, Universitätsklinik für Neurochirurgie, Linz, Austria|Hospital Erasme, Service de Soins Intensifs, Brussels, Belgium|Hospital - Cliniques Universitaires Saint-Luc, Service de Neurochirurgie, Brussels, Belgium|Neurology Department, University Hospital, Gent, Belgium|Hospital UZ Leuven, Neurosurgery Department, Leuven, Belgium|University Hospital Sart Tilman Liege, Liège, Belgium|University of Calgary & Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital Department of Neurological Surgery, Edmonton, Alberta, Canada|Winnipeg Regional Health Authority Health Sciences Centre, Winnipeg, Manitoba, Canada|Halifax Infirmary, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|Royal University Hospital Department of Neurology, Saskatoon, Saskatchewan, Canada|Fakultní nemocnice Brno Neurochirurgická klinika, Brno, Czechia|""Fakultní nemocnice Hradec Králové Neurochirurgická klinika"", Hradec Králové, Czechia|Fakultní nemocnice Ostrava Neurochirurgická klinika, Ostrava-Poruba, Czechia|University Hospital in Pilsen, Department of Neurosurgery, Plzen, Czechia|Ústřední vojenská nemocnice Praha Neurochirurgická klinika, Praha, Czechia|Masarykova nemocnice v Ústí nad Labem Neurochirurgie, Ústí Nad Labem, Czechia|Aalborg Neurosurgery, Aalborg, Denmark|Odense Universitets Hospital Neurokirurgisk afdelning, Odense, Denmark|Helsingin yliopistollinen keskussairaala Neurokirurgian klinikka, Helsinki, Finland|Kuopio University Hospital, Kuopio, Finland|Tampereen yliopistollinen sairaala Neurokirurgian klinika, Tampere, Finland|Turku University Hospital Neurosurgery, T-hospital, Turku, Finland|Hôpital neurologique Pierre Wertheimer Service de Reanimation, Bron, France|Hôpital Gabriel Montpied, ICU DEPT, Neuro reanimation departement, Clermont-Ferrand, France|Hôpital de la Timone 2, Intensive Care Unit SAR 1, Marseille, France|Hôpital Gui de CHAULIAC, Montpellier, France|Hospital Lariboisiere Paris, Paris, France|Hôpital Pitié-Salpêtrière, Service de neuroréanimation chirurgicale Babinski, Paris, France|CHRU Reims Hopital Maison Blanche, Reims, France|CHU Rennes, Pontchaillou, Rennes, France|Univ Hosp Toulouse, University Hospital Purpan Pierre Paul Riquet Hospital, Toulouse, France|Klinik für Diagnostische Radiologie und Neuroradiologie, Augsburg, Augsburg, Germany|Charite Universitätsmedizin Berlin - Klinik und Poliklinik für Neurochirurgie, Berlin, Germany|Heinrich-Heine Universität Düsseldorf -Klinik für Neurochirugie, Düsseldorf, Germany|University of Erlangen-Nürnberg, Dpt. of Neurosurgery, Erlangen, Germany|University Hospital of Essen, Department of Neurosurgery, Essen, Germany|Universitätsklinik Frankfurt, Klinik und Poliklinik für Neurochirurgie, Dept of neurosurgery, Frankfurt, Germany|Bezirkskrankenhaus Günzburg - Klinik für Neurochirugie, Günzburg, Germany|Asklepios Klinik St. Georg - Neurochirugie, Hamburg, Germany|University Hospital of Hamburg-Eppendorf, Dpt. of Neurosurgery, Hamburg, Germany|Neurochirurgische Universitätklinik des Heidelberg, Dept of Neurosurgery, Heidelberg, Germany|Universitätsklinikum Schleswig Hollstein Lübeck (UKSH) Klinik für Neurochirugie, Lübeck, Germany|Technical University-Klinikum rechts der Isar, Abt. Neurochirurgie, München, Germany|University Regensburg, Dpt. of Neurosurgery, Regensburg, Germany|Debreceni Egyetem, Idegsebészet, Debrecen, Hungary|BAZ Megyei Kórház és Egyetemi Oktató Kórház Neuroradiológiai és angiográphiás osztály, Miskolc, Hungary|Pécsi Tudományegyetem Klinikai Központ, Idegsebészeti Klinika, Pécs, Hungary|Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, Idegsebészeti Klinika, Szeged, Hungary|Rambam Healthcare Campus, Neurology Department, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Beilinson Hospital, Rabin Medical Center, Department of Neurosurgery, Petah tikva, Israel|The Chaim Sheba Medical Centre - Neurosurgery, Ramat Gan, Israel|Istituto delle Scienze Neurologiche di Bologna, Dipartimento di Neurochirurgia e Neuroradiologia Interventistica, Bologna, Italy|ASST Monza, Hospital San Gerardo, TERAPIA INTENSIVA Neurochirurgica, Monza, Italy|Azienda Ospedaliera Padova-Università degli Studi di Padova - Istituto di Anestesia e Rianimazione, Padova, Italy|Azienda Ospedaliero Universitaria di Parma, struttura complessa Neurochirurgia, Parma, Italy|Fondazione Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore, UOS Terapia Intensiva Neurochirurgic, Rome, Italy|Szpital Uniwersytecki nr 1 im. dr. Antoniego Jurasza, Bydgoszcz, Poland|Klinika Neurochirurgii, Gdańsk, Poland|Oddział Neurochirurgii i Neurotraumatologii z Pododdziałem Leczenia Chorób Naczyniowych Centralnego Układu Nerwowego, Poznań, Poland|Katedra i Klinika Neurochirurgii Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego, Łódź, Poland|Hospital Universitario Germans Trias i Pujol - Neurology Department, Badalona, Spain|Hospital Vall d'Hebron Departamento Neuroradiología, Barcelona, Spain|Hospital Clinic Barcelona, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|University Hospital of Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|Hospital Universitario 12 de Octubre, Departamento Neurosurgery Division Neuroradiology, Madrid, Spain|Hospital Universitari son Espasses, Palma De Mallorca, Spain|Sahlgrenska Universitetssjukhuset, Verksamheten för neurokirurgi, Neurosjukvården, Göteborg, Sweden|Linköping Universitetssjukhuset, Neurokirurgiska kliniken, Linköping, Sweden|Lunds Universitetssjukhus, Neurokirurgiska avd. NIVA, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT03585270"
184,"NCT00833989","Safety Escalating Repeat IV, in Stroke Patients","MAG111539","Completed","Has Results","Ischaemic Attack, Transient","Drug: GSK249320|Drug: PLACEBO","Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)|Number of Participants With Vital Signs Changes of Potential Clinical Importance|Number of Participants With Electrocardiogram (ECG) Values Outside Range of Potential Clinical Importance|Number of Participants With Nerve Conduction Testing (NCT) Values|Number of Participants With White Matter Changes and Demyelination Assessed by Magnetic Resonance Imaging (MRI)|Number of Participants With Abnormal Clinical Chemistry Parameters|Number of Participants With Abnormal Hematological Parameters|Number of Participants With Positive Antibodies to GSK249320|Mean Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC 0-inf) and Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC0-t)|Mean Maximum Observed Concentration (Cmax) and Last Observed Quantifiable Concentration (Ct)|Mean Time of Occurrence of Cmax (Tmax) and Time of Last Observed Quantifiable Concentration (Tlast)|Mean Terminal Phase Half-life (t1/2)|Mean Terminal Phase Rate Constant ( Lambda-Z)|Mean Clearance of GSK249320|Mean Change in Mean Gait Velocity|Mean Change in Berg Balance Scale (BBS) Total Score|Mean Change in Total Fugl-Meyer Motor (FM) Assessment|Mean Change in Total Box and Blocks Transferred on Affected Side|Mean Change in Grip Strength on Affected Side|Number of Participants With Modified Rankin Scale (mRS)|Change From Baseline of National Institutes of Health Stroke Scale (NIHSS)|Mean Barthel Total Score|Mean Total Montreal Cognitive Assessment (MoCA) Score|Mean Geriatric Depression Scale (GDS)|Mean Change in Transcranial Magnetic Stimulations (TMS) Evaluated by Peak to Peak MEP by % Stimulation Level|Serum Levels of the S100β Protein","GlaxoSmithKline","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","111539","July 8, 2009","January 31, 2011","January 31, 2011","February 2, 2009","October 16, 2017","November 17, 2017","GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Fort Collins, Colorado, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wiesbaden, Hessen, Germany|GSK Investigational Site, Celle, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany",,"https://ClinicalTrials.gov/show/NCT00833989"
185,"NCT03425539","Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease","MODIFY","Recruiting","No Results Available","Fabry Disease","Drug: Lucerastat|Drug: Placebo","Response to study treatment on neuropathic pain defined as a reduction from baseline to Month 6 of at least 30% in the ""modified"" Brief Pain Inventory-Short Form 3 (BPI-SF3) score of ""neuropathic pain at its worst in the last 24 hours""|Change from baseline to Month 6 in the average daily 11-point Numerical Rating Scale (NRS-11) score of ""abdominal pain at its worst in the last 24 hours"" in subjects with GI symptoms at baseline.|Change from baseline to Month 6 in the number of days with at least one stool of a Bristol Stool Scale (BSS) consistency Type 6 or 7 in subjects with GI symptoms at baseline.|Change from baseline to Month 6 in plasma globotriaosylceramide (Gb3).","Idorsia Pharmaceuticals Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ID-069A301","June 21, 2018","May 15, 2021","June 15, 2021","February 7, 2018",,"April 29, 2020","University of Alabama at Birmingham - Nephrology Research Clinic, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|University of Arizona Center for Applied Genetics & Genomics Medicine, Tucson, Arizona, United States|University of California Irvine, Irvine, California, United States|University of California - Los Angeles, Los Angeles, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation, Gainesville, Florida, United States|Emory University School of Medicine; Department of Human Genetics, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Stead Family Children's Hospital - Division of Medical Genetics, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Infusion Associates, Grand Rapids, Michigan, United States|University of Minnesota - Pediatric Gene Therapy, Minneapolis, Minnesota, United States|St. Peter's University Hospital Genetics & Genomic Medicine, New Brunswick, New Jersey, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center - Human Genetics Dept., Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh (UPMC), Pittsburgh, Pennsylvania, United States|Greenwood Genetic Center, Greenville, South Carolina, United States|Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States|University of Utah - Division of Medical Genetics, Salt Lake City, Utah, United States|Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States|Royal Melbourne Hospital - Department of Nephrology, Parkville, Australia|Royal Perth Hospital, Department of Nephrology, Perth, Australia|Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse, Vienna, Austria|University Hospital Ghent, Ghent, Belgium|University Hospital Leuven, Leuven, Belgium|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|M.A.G.I.C Clinic Ltd, Calgary, Canada|Queen Elizabeth II Health Sciences Center - Halifax Infirmary - Division of Nephrology, Halifax, Canada|Research Center, Hôpital Du Sacré-Coeur de Montréal, Montréal, Canada|Vancouver Hospital & Health Sciences - Vancouver General Hospital, Vancouver, Canada|Health Sciences Center Winnipeg, Winnipeg, Canada|Charite Campus Virchow-Klinikum - Nephrologie und Internistische Intensivmedizin, Berlin, Germany|SphinCS GmbH, Hochheim, Germany|Fachinternistische Gemeinschaftspraxis Markgräferland, Mühlheim, Germany|Medizinische Klinik und Poliklinik I der Universität - Schwerpunkt Nephrologie, Würzburg, Germany|Hosp Alma Mater Studiorum, Dublin, Ireland|AOU CAREGGI - NEPHROLOGY and CARDIOMIOPATIE, Florence, Italy|ASST Monza, Hospital San Gerardo, Nephrology, Monza, Italy|University of Naples Federico II (Nephrology), Naples, Italy|Hospital Academisch Medisch Centrum - Department of Internal Medicine Div. Endrocrinology and Metabolism, Amsterdam, Netherlands|Haukeland University Hospital Helse Bergen HF, Bergen, Norway|University Hospital in Cracow - Dep. of of Allergies and Immunology, Krakow, Poland|Cardinal Wyszynski Institute of Cardiology, Warsaw, Poland|Department of Pediatric Nutrition and Metabolic Diseases; The Children's Memorial Health Institute, Warsaw, Poland|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Universitari de Bellvitge; Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Ramon y Cajal. Servicio de Medicina Interna, Madrid, Spain|Hospital Quironsalud Zaragoza, Zaragoza, Spain|Universität Zürich Psychiatrische Universitätsklinik, Zurich, Switzerland|University Hospital Birmingham NHS Foundation Trust - Center for Rare Diseases, Birmingham, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Lysosomal Storage Disorders Unit, Department of Hematology - Royal Free London NHS Foundation Trust, London, United Kingdom|The Royal Free Hospital, Department of Haematology Royal Free London NHS Foundation Trust, London, United Kingdom|National Hospital for Neurology and Neurosurgery, London, United Kingdom|Salford Royal (Hope) Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03425539"
186,"NCT02886494","A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia",,"Completed","No Results Available","Alzheimer's Disease or Vascular Dementia","Drug: BAC|Drug: Matched placebo","Change in Alzheimer Disease Assessment Scale-cognitive (ADAS-cog) score at Week 12 visit compared to baseline|Change in ADAS-cog score at all post treatment visits (except Week 12 visit) compared to baseline|Clinician's Interview Based Impression of Change-Plus Caregiver Input (CIBIC-plus) score at all post treatment visits|Change in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) score at all post treatment visits compared to baseline|Change in Mini-Mental State Examination (MMSE) score at all post treatment visits compared to baseline|Change in Neuropsychiatric Inventory (NPI) score at all post treatment visits compared to baseline|Adverse event incidence","Charsire Biotechnology Corp.","All","40 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BAC-02","December 2016","November 1, 2018","November 1, 2018","September 1, 2016",,"July 30, 2019","Clinical Research Consortium, Tempe, Arizona, United States|Woodland International Research Group, Little Rock, Arkansas, United States|Woodland Research Northwest, LLC, Rogers, Arkansas, United States|Pacific Research Network, LLC, San Diego, California, United States|NeuroTrials Research, Inc., Atlanta, Georgia, United States|The Cognitive and Research Center of NJ, Springfield, New Jersey, United States|Advanced Memory Research Institute of NJ, PC, Toms River, New Jersey, United States|SPRI, Brooklyn, New York, United States|Wake Research Associates, Raleigh, North Carolina, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02886494"
187,"NCT02056574","Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms","ENACT-2","Withdrawn","No Results Available","Subarachnoid Hemorrhage|Ruptured Intracranial Aneurysm","Drug: NA-1|Drug: Placebo","Modified Rankin Scale (mRS)|National Institutes of Health Stroke Scale (NIHSS)|Mortality|In-hospital length of stay","NoNO Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA-1-006","November 2015","November 2019","April 2020","February 6, 2014",,"August 4, 2015","Barrow Neurological Institute, Phoenix, Arizona, United States|Colorado Neurological Institute, Englewood, Colorado, United States|University of Michigan - Neurosurgery, Ann Arbor, Michigan, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Wisconsin, Madison, Wisconsin, United States|Foothills Medical Centre, Calgary, Alberta, Canada|QEII Health Sciences Centre - Halifax Infirmary, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Hopital de l'Enfant Jesus, Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02056574"
188,"NCT03661528","Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor",,"Recruiting","No Results Available","Acute Intracranial Hemorrhage","Drug: andexanet alfa","Proportion of patients with good or excellent hemostatic efficacy as rated by an independent adjudication committee|Change from baseline in anti-fXa activity","Portola Pharmaceuticals|Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","440","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-513","January 18, 2019","March 1, 2023","November 1, 2023","September 7, 2018",,"December 24, 2019","Holy Cross Hospital, Fort Lauderdale, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Beaumont Health, Troy, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Harrington Heart & Vascular Institute, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Seton Medical Center - Austin, Austin, Texas, United States|Dell Seton Medical Center, Austin, Texas, United States|Marshall Health, Huntington, West Virginia, United States|Medizinische Universität Innsbruck, Innsbruck, Austria|Klinikum Klagenfurt, Abteilung für Neurologie, Klagenfurt, Austria|Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria|Kepler Universitätsklinikum, Med. Campus II., Linz, Austria|Christian-Doppler Klinik, Landeskliniken Salzburg, Universitätsklinik für Neurologie, Salzburg, Austria|Krankenhaus der Barmherzige Brüder KH Wien, Neurologie, Wien, Austria|Medizinische Universität Wien, Neurologie, Wien, Austria|UZ Leuven campus Gasthuisberg, Leuven, Belgium|University of Calgary, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|CHU Bordeaux, Groupe Hospitalier Pellegrin, Bordeaux, France|Centre Hospitalier Fleyriat Service de Neurologie, Bourg-en-Bresse, France|CHU Gabriel Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU Edouard Herriot, Anaesthesia-resuscitation, Lyon, France|Hôpital Central, Neurologie, Nancy, France|Hopital Sainte Anne, GHU Paris Psychiatrie et Neurosciences, Paris, France|Fondation Ophtalmologique Rothschild - Hôpital, Neurovascular unit, Paris, France|Hopital Bichat, Paris, France|Hôpital Lariboisière, Neurologie, Paris, France|CHU Purpan-Pierre Paul de Riquet, Toulouse, Intensive care-resuscitation, Toulouse, France|Klinikum Altenburger Land, Neurologie, Altenburg, Germany|RHÖN-KLINIKUM Campus Bad Neustadt, Bad Neustadt An Der Saale, Germany|Klinikum Bremen-Nord, Stroke Unit, Bremen, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Klinikum Dortmund, Neurologische Klinik, Dortmund, Germany|Krankenhaus Dresden Friedrichstadt, II. Medizinische Klinik, Innere Medizin, Angiologie und Hämostaseologie, Dresden, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinik Erlangen, Neurologische Klinik, Erlangen, Germany|Alfried-Krupp Krankenhaus Essen, Neuologie, Essen, Germany|Klinikum Frankfurt - Klinik für Neurologie, Frankfurt, Germany|Universitätsmedizin Greifswald, Abteilung Transfusionsmedizin am Institut für Immunologie, Greifswald, Germany|UMG-Universitätsmedizin Göttingen, Göttingen, Germany|Asklepios Klinik Barmbek, Abteilung Neurologie, Hamburg, Germany|Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Neurologie Kopf- und Neurozentrum, Hamburg, Germany|Medizinische Hochschule Hannover Klinik für Neurologie OE 7210, Hanover, Germany|Universitätsklinik Heidelberg , Neurologische Klinik, Heidelberg, Germany|Klinikum Konstanz, Konstanz, Germany|""UKSH - Klinik für Neurologie des Universitätsklinikums Schleswig-Holstein Campus Lübeck, Lubeck, Germany|Universitätsklinikum Mannheim, Neuroligische Klinik, Mannheim, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Nordwest-Krankenhaus Sanderbusch gGmbH, Neurologie, Sanderbusch, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Assuta Ashdod Medical Center, Ashdod, Israel|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah tikva, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Sourasky Medical Center, Tel Aviv-Yafo, Israel|Azienda Unità Sanitaria Locale (AUSL) Bologna Ospedale Maggiore, Bologna, Italy|Azienda Socio-Sanitaria Territoriale (ASST) Grande Ospedale Metropolitano ""Niguarda"" Dipartimento di Neuroscienze Struttura Complessa di Neurologia e Stroke Unit, Milano, Italy|Fondazione Policlinico ""Tor Vergata"" Dipartimento di Neurologia, Roma, Italy|Azienda Ospedaliera ""San Camillo-Forlanini"" Padiglione ""Lancisi"", Roma, Italy|Policlinico ""Umberto I"" Università degli Studi di Roma ""La Sapienza"" Dipartimento di Neurologia e Psichiatria, Roma, Italy|Policlinico ""Gemelli"" Area Neuroscienze Neurologia, Roma, Italy|Academic Medical Center, Amsterdam, Netherlands|Hospital Universitario de Albacete, Albacete, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Fairfield General Hospital, Bury, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Northwick Park Hospital, Harrow, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|St.George's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03661528"
189,"NCT01225562","Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin","PEGASUS","Completed","Has Results","Myocardial Infarction|Cardiovascular Death|Atherothrombosis|Stroke","Drug: Ticagrelor 90 mg|Drug: Ticagrelor 60 mg|Drug: Ticagrelor Placebo","Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization|Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients|Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization|Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization","AstraZeneca","All","50 Years to 130 Years   (Adult, Older Adult)","Phase 3","21379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D5132C00001|2009-017242-30","October 2010","December 2014","December 2014","October 21, 2010","December 9, 2015","January 25, 2016","Research Site, Alexander City, Alabama, United States|Research Site, Athens, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Alhambra, California, United States|Research Site, Anaheim, California, United States|Research Site, Bakersfield, California, United States|Research Site, Fountain Valley, California, United States|Research Site, La Mesa, California, United States|Research Site, Larkspur, California, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Modesto, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oakland, California, United States|Research Site, Oceanside, California, United States|Research Site, San Diego, California, United States|Research Site, San Marino, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Ventura, California, United States|Research Site, Westlake Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Loveland, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Davie, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona, Florida, United States|Research Site, Ft Lauderdale, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pannama City, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, The Villages, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Boise, Idaho, United States|Research Site, Aurora, Illinois, United States|Research Site, Bannockburn, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Melrose Park, Illinois, United States|Research Site, Normal, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Elkhart, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Minden, Louisiana, United States|Research Site, New Iberia, Louisiana, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, S Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Alpena, Michigan, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Lapeer, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Baxter, Minnesota, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, St Cloud, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Papillion, Nebraska, United States|Research Site, Reno, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Elizabeth, New Jersey, United States|Research Site, Elmer, New Jersey, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Linden, New Jersey, United States|Research Site, Mine Hill, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Mineola, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Southampton, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Sanford, North Carolina, United States|Research Site, Smithfield, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Fairfield, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Youngstown, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Johnstown, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Scranton, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, West Chester, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Florence, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Watertown, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Grapevine, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, MC Allen, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Provo, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Alexandria, Virginia, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Everett, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Bahia Blanca, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de BA, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Ciudadela, Argentina|Research Site, Cordoba, Argentina|Research Site, Coronel Suarez, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Haedo, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario Santa Fe, Argentina|Research Site, Rosario, Argentina|Research Site, San Luis, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolas, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Santa Fe, Argentina|Research Site, Santa Fé, Argentina|Research Site, Tucuman, Argentina|Research Site, Tucumán, Argentina|Research Site, Zarate, Argentina|Research Site, Adelaide, Australia|Research Site, Ashford, Australia|Research Site, Auchenflower, Australia|Research Site, Ballarat, Australia|Research Site, Bruce, Australia|Research Site, Chermside, Australia|Research Site, Clayton, Australia|Research Site, Concord, Australia|Research Site, East St Kilda, Australia|Research Site, Elizabeth Vale, Australia|Research Site, Epping, Australia|Research Site, Fremantle, Australia|Research Site, Geelong, Australia|Research Site, Gosford, Australia|Research Site, Greenslopes, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Kingswood, Australia|Research Site, Kogorah, Australia|Research Site, Launceston, Australia|Research Site, Melbourne, Australia|Research Site, Nedlands, Australia|Research Site, New Lambton Heights, Australia|Research Site, Richmond, Australia|Research Site, St Leonards, Australia|Research Site, Wollongong, Australia|Research Site, Woodville, Australia|Research Site, Woolloongabba, Australia|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Bouge, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brussels (Anderlecht), Belgium|Research Site, Brussels (Jette), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Brussels, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Huy, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Mechelen, Belgium|Research Site, Mol, Belgium|Research Site, Ottignies, Belgium|Research Site, Roeselare, Belgium|Research Site, Tienen, Belgium|Research Site, Turnhout, Belgium|Research Site, Yvoir, Belgium|Research Site, Zottegem, Belgium|Research Site, Aracaju, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Brasília, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campo Grande, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiânia, Brazil|Research Site, Maceio, Brazil|Research Site, Marilia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, S.J.Rio Preto, Brazil|Research Site, Salvador, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Uberlândia, Brazil|Research Site, Votuporanga, Brazil|Research Site, Dimitrovgrad, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, St-Lambert, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Thetford Mines, Quebec, Canada|Research Site, Val d'Or, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Osorno, Chile|Research Site, Rancagua, Chile|Research Site, Santiago Centro, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chongqing, China|Research Site, Guang Zhou, China|Research Site, Guangzhou, China|Research Site, Hang Zhou, China|Research Site, Lanzhou, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shengyang, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Armenia, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bogotá D.C., Colombia|Research Site, Bucaramanga, Colombia|Research Site, Cali, Colombia|Research Site, Cartagena, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Medillin, Colombia|Research Site, Brno, Czech Republic|Research Site, Caslav, Czech Republic|Research Site, Ceska Lipa, Czech Republic|Research Site, Cesky Krumlov, Czech Republic|Research Site, Chomutov, Czech Republic|Research Site, Havirov, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Kyjov, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Marianske Lazne, Czech Republic|Research Site, Ostrava-Poruba, Czech Republic|Research Site, Ostrava-Zabreh, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pelhrimov, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Pribram, Czech Republic|Research Site, Slany, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Usti nad Orlici, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, ABBEVILLE cedex, France|Research Site, Albi, France|Research Site, ANGERS Cedex 9, France|Research Site, Angers, France|Research Site, Avignon Cedex, France|Research Site, Bayonne, France|Research Site, Cannes, France|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, Jossigny, France|Research Site, La Rochelle Cedex, France|Research Site, Le Chesnay, France|Research Site, Le Coudray Cedex, France|Research Site, Limoges Cedex, France|Research Site, MARSEILLE Cedex 5, France|Research Site, Metz Cedex 1, France|Research Site, NICE Cedex 01, France|Research Site, NIMES Cedex 9, France|Research Site, Orléans Cedex 2, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Toulouse Cedex, France|Research Site, TOURCOING cedex, France|Research Site, Bad Krozingen, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Coburg, Germany|Research Site, Deggingen, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Esslingen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kassel, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Limburg, Germany|Research Site, Ludwigshafen, Germany|Research Site, Lübeck, Germany|Research Site, Mainz, Germany|Research Site, Mönchengladbach, Germany|Research Site, Ulm, Germany|Research Site, Warendorf, Germany|Research Site, Witten, Germany|Research Site, Ballasagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Békéscsaba, Hungary|Research Site, Cegléd, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kecskemét, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Albano Laziale, Italy|Research Site, Bari, Italy|Research Site, Benevento, Italy|Research Site, Brescia, Italy|Research Site, Carpi, Italy|Research Site, Catania, Italy|Research Site, Genova, Italy|Research Site, Legnano, Italy|Research Site, Lucca, Italy|Research Site, Massa, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Osio Sotto frazione di Zingoni, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pescara, Italy|Research Site, Pisa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, S Maria Capua Vetere, Italy|Research Site, San Remo, Italy|Research Site, Sassari, Italy|Research Site, Sessa Aurunca, Italy|Research Site, Siena, Italy|Research Site, Sorrento NA, Italy|Research Site, Vimercate, Italy|Research Site, Akishima-shi, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Imabari-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kamogawa-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kawachinagano-shi, Japan|Research Site, Kisarazu-shi, Japan|Research Site, Komatsushima-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kusatsu-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Matsue-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Miyazaki-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Saitama-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Shimada-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Takarazuka-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Tomakomai-shi, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wako-shi, Japan|Research Site, Yatsushiro-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Jeonju, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Almere, Netherlands|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Deventer, Netherlands|Research Site, Drachten, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Goes, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Heerenveen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, OSS, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Shertogenbosch, Netherlands|Research Site, Sittardgeleen, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bergen, Norway|Research Site, Bodo, Norway|Research Site, Bodø, Norway|Research Site, Flekkefjord, Norway|Research Site, Hamar, Norway|Research Site, Levanger, Norway|Research Site, Lillehammer, Norway|Research Site, Nesttun, Norway|Research Site, Oslo, Norway|Research Site, Skien, Norway|Research Site, Tromsø, Norway|Research Site, Tynset, Norway|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, San Borja, Peru|Research Site, Trujillo, Peru|Research Site, Cebu City, Philippines|Research Site, Fuente Osmena Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Las Pinas City, Philippines|Research Site, Lipa City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon, Philippines|Research Site, San Juan, Philippines|Research Site, Białystok, Poland|Research Site, Bielsko Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chorzow, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Kraków, Poland|Research Site, Legnica, Poland|Research Site, Lubin, Poland|Research Site, Nowa Sól, Poland|Research Site, Olsztyn, Poland|Research Site, Opole, Poland|Research Site, Ostrów Mazowiecka, Poland|Research Site, Oława, Poland|Research Site, Piotrkow, Poland|Research Site, Poznań, Poland|Research Site, Płock, Poland|Research Site, Skierniewice, Poland|Research Site, Sobótka, Poland|Research Site, Sokolka, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Włocławek, Poland|Research Site, Łańcut, Poland|Research Site, Łódź, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Buzau, Romania|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Deva, Romania|Research Site, Focsani, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Tg. Mures, Romania|Research Site, Timisoara, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St.-Petersburg,, Russian Federation|Research Site, St.-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Komarno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Liptovsky Hradok, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Partizanske, Slovakia|Research Site, Piestany, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Presov, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, Gatesville, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kempron Park, South Africa|Research Site, Panorama, South Africa|Research Site, Parow, South Africa|Research Site, Pretoria, South Africa|Research Site, Somerset West, South Africa|Research Site, Soweto, South Africa|Research Site, Worcester, South Africa|Research Site, Almeria, Spain|Research Site, Aviles, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Don Benito (Badajoz), Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Sabadell, Spain|Research Site, San Sebastian de los Reyes, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Eksjö, Sweden|Research Site, Göteborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Linkoping, Sweden|Research Site, Ljungby, Sweden|Research Site, Lund, Sweden|Research Site, Molndal, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umea, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Östersund, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Mersin, Turkey|Research Site, Dnepropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnitsa, Ukraine|Research Site, Zaporozye, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Antrim, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, East Kilbride, United Kingdom|Research Site, Ely, United Kingdom|Research Site, Hastings, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01225562"
190,"NCT01344447","Gadobutrol Enhanced MRA of the Supra-aortic Vessels","GEMSAV","Completed","Has Results","Carotid Stenosis","Drug: Gadobutrol (Gadovist, BAY86-4875)","Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA|Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%|Minimum Gadobutrol Performance for Specificity: Specificity > 50%|Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images|The Percentage of Segments With Artifacts Presence|Types of Artifacts on a Segment Basis by Blinded Reader 1|Types of Artifacts on a Segment Basis by Blinded Reader 2|Types of Artifacts on a Segment Basis by Blinded Reader 3|The Percentage of Location of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA|Length of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA|The Percentage of Presence of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease|Type of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease|Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA|The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 1|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 2|Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 3|Types of Additional Imaging Studies Recommended by the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","479","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14607|2010-023001-36","May 12, 2011","May 28, 2014","May 28, 2014","April 29, 2011","August 26, 2015","January 4, 2019","Tucson, Arizona, United States|Jacksonville, Florida, United States|Savannah, Georgia, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Jackson, Mississippi, United States|Bronx, New York, United States|Rochester, New York, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|Memphis, Tennessee, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Adrogué, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|New Lambton Heights, New South Wales, Australia|Clayton, Victoria, Australia|Parkville, Victoria, Australia|Innsbruck, Tirol, Austria|Wien, Austria|Shanghai, China|Shanghai, China|Brno, Czechia|Brest Cedex, France|BRON Cedex, France|Marseille, France|Paris Cedex 15, France|Paris, France|Karlsruhe, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Erlangen, Bayern, Germany|Münster, Nordrhein-Westfalen, Germany|Jena, Thüringen, Germany|Ferrara, Emilia-Romagna, Italy|Roma, Lazio, Italy|Catania, Sicilia, Italy|Massa-Carrara, Toscana, Italy|Aosta, Valle d'Aosta, Italy|Venezia, Veneto, Italy|Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Bydgoszcz, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Linköping, Sweden|Uppsala, Sweden|St. Gallen, Sankt Gallen, Switzerland|Antalya, Turkey|Erzurum, Turkey|Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT01344447"
191,"NCT03737214","A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease",,"Recruiting","No Results Available","Fabry Disease","Drug: Lucerastat","Treatment-emergent adverse events (AEs)","Idorsia Pharmaceuticals Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","108","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID-069A302|2018-002210-12","December 18, 2018","May 22, 2022","May 22, 2022","November 9, 2018",,"March 26, 2020","University of Alabama at Birmingham - Nephrology Research Clinic, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|University of Arizona Center for Applied Genetics & Genomics Medicine, Tucson, Arizona, United States|University of California Irvine, Irvine, California, United States|University of California - Los Angeles, Los Angeles, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation, Gainesville, Florida, United States|Emory University School of Medicine; Department of Human Genetics, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Stead Family Children's Hospital - Division of Medical Genetics, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Infusion Associates, Grand Rapids, Michigan, United States|University of Minnesota - Pediatric Gene Therapy, Minneapolis, Minnesota, United States|St. Peter's University Hospital Genetics & Genomic Medicine, New Brunswick, New Jersey, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center - Human Genetics Dept., Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh (UPMC), Pittsburgh, Pennsylvania, United States|Greenwood Genetic Center, Greenville, South Carolina, United States|Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States|University of Utah - Division of Medical Genetics, Salt Lake City, Utah, United States|Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States|Royal Melbourne Hospital, Department of Respiratory Medicine, Parkville, Australia|Royal Perth Hospital Unit - The University of Western Australia, Perth, Australia|Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse, Vienna, Austria|University Hospital Ghent, Ghent, Belgium|University Hospital Leuven, Leuven, Belgium|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|M.A.G.I.C Clinic Ltd, Calgary, Canada|Queen Elizabeth II Health Sciences Center - Halifax Infirmary - Division of Nephrology, Halifax, Canada|Research Center, Hôpital Du Sacré-Coeur de Montréal, Montréal, Canada|Vancouver Hospital & Health Sciences - Vancouver General Hospital, Vancouver, Canada|Health Sciences Center Winnipeg, Winnipeg, Canada|Charité-Virchow Klinikum - Nephrologie und Internistische Intensivmedizin, Berlin, Germany|SphinCS GmbH, Hochheim, Germany|Fachinternistische Gemeinschaftspraxis Markgräferland, Mühlheim, Germany|Medizinische Klinik und Poliklinik I der Universität - Schwerpunkt Nephrologie, Würzburg, Germany|Hosp Alma Mater Studiorum, Dublin, Ireland|AOU CAREGGI - NEPHROLOGY and CARDIOMIOPATIE, Florence, Italy|ASST Monza, Hospital San Gerardo, Nephrology, Monza, Italy|University of Naples Federico II (Nephrology), Naples, Italy|Hospital Academisch Medisch Centrum - Department of Internal Medicine Div. Endrocrinology and Metabolism, Amsterdam, Netherlands|Haukeland University Hospital Helse Bergen HF, Bergen, Norway|Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland|University Hospital in Cracow - Dep. of of Allergies and Immunology, Krakow, Poland|Cardinal Wyszynski Institute of Cardiology, Warsaw, Poland|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Universitari de Bellvitge; Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Ramon y Cajal. Servicio de Medicina Interna, Madrid, Spain|Hospital Quironsalud Zaragoza, Zaragoza, Spain|Universität Zürich Psychiatrische Universitätsklinik, Zurich, Switzerland|University Hospital Birmingham NHS Foundation Trust - Center for Rare Diseases, Birmingham, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|The Royal Free Hospital, Department of Haematology Royal Free London NHS Foundation Trust, London, United Kingdom|National Hospital for Neurology and Neurosurgery, London, United Kingdom|Salford Royal (Hope) Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03737214"
192,"NCT03600818","Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica",,"Suspended","No Results Available","Polymyalgia Rheumatica","Drug: Sarilumab SAR153191 (REGN88)|Drug: Sarilumab-matching placebo|Drug: Prednisone|Drug: Prednisone-matching placebo","Proportion of patients with sustained remission|Components of sustained remission (composite measure)|Cumulative corticosteroid dose|Time to first polymyalgia rheumatica (PMR) flare|Change in glucocorticoid toxicity index|Adverse events|Pharmacokinetic","Sanofi|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15160|2017-002989-42|U1111-1201-0777","October 9, 2018","December 2022","December 2022","July 26, 2018",,"April 15, 2020","Investigational Site Number 8400003, Upland, California, United States|Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400021, Bridgeport, Connecticut, United States|Investigational Site Number 8400009, Stamford, Connecticut, United States|Investigational Site Number 8400002, Boca Raton, Florida, United States|Investigational Site Number 8400007, Boise, Idaho, United States|Investigational Site Number 8400014, Iowa City, Iowa, United States|Investigational Site Number 8400012, Boston, Massachusetts, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 8400022, New York, New York, United States|Investigational Site Number 8400016, Duncansville, Pennsylvania, United States|Investigational Site Number 8400011, Dallas, Texas, United States|Investigational Site Number 8400025, Lufkin, Texas, United States|Investigational Site Number 8400010, Mesquite, Texas, United States|Investigational Site Number 8400015, Spokane, Washington, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320005, Buenos Aires, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320003, San Miguel de Tucuman, Argentina|Investigational Site Number 0360003, Camberwell, Australia|Investigational Site Number 0360001, Kogarah, Australia|Investigational Site Number 0360002, Maroochydore, Australia|Investigational Site Number 0360004, Woodville South, Australia|Investigational Site Number 0560004, Bruxelles, Belgium|Investigational Site Number 0560003, Gent, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560002, Liège, Belgium|Investigational Site Number 1240007, Hamilton, Canada|Investigational Site Number 1240010, Montreal, Canada|Investigational Site Number 1240001, Rimouski, Canada|Investigational Site Number 1240009, Saskatoon, Canada|Investigational Site Number 1240005, Sherbrooke, Canada|Investigational Site Number 1240003, Trois-Rivières, Canada|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500005, Brest Cedex, France|Investigational Site Number 2500011, Caen Cedex 9, France|Investigational Site Number 2500015, Le Kremlin Bicetre, France|Investigational Site Number 2500010, Lille Cedex, France|Investigational Site Number 2500002, Montivilliers, France|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500004, Paris, France|Investigational Site Number 2500016, Pierre Benite Cedex, France|Investigational Site Number 2500014, Toulouse Cedex 09, France|Investigational Site Number 2760008, Bad Abbach, Germany|Investigational Site Number 2760009, Berlin, Germany|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Dresden, Germany|Investigational Site Number 2760003, Kirchheim Unter Teck, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 2760007, Tübingen, Germany|Investigational Site Number 3480001, Debrecen, Hungary|Investigational Site Number 3760001, Haifa, Israel|Investigational Site Number 3760004, Haifa, Israel|Investigational Site Number 3760003, Kfar Saba, Israel|Investigational Site Number 3760002, Petah-Tikva, Israel|Investigational Site Number 3760005, Tel Hashomer, Israel|Investigational Site Number 3800006, Ferrara, Italy|Investigational Site Number 3800003, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800004, Pisa, Italy|Investigational Site Number 3800002, Reggio Emilia, Italy|Investigational Site Number 3800005, Rozzano, Italy|Investigational Site Number 3800008, Verona, Italy|Investigational Site Number 3920004, Chiba-Shi, Japan|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920006, Hachioji-Shi, Japan|Investigational Site Number 3920003, Kamakura-Shi, Japan|Investigational Site Number 3920005, Kawachinagano-Shi, Japan|Investigational Site Number 3920008, Okayama-Shi, Japan|Investigational Site Number 3920001, Takasaki-Shi, Japan|Investigational Site Number 3920007, Toshima-Ku, Japan|Investigational Site Number 5280003, Alkmaar, Netherlands|Investigational Site Number 5280002, Almelo, Netherlands|Investigational Site Number 5280007, Den Haag, Netherlands|Investigational Site Number 5280005, Leeuwarden, Netherlands|Investigational Site Number 5280004, Nijmegen, Netherlands|Investigational Site Number 5280008, Rotterdam, Netherlands|Investigational Site Number 6430005, Kemerovo, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430006, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430008, Saint-Petersburg, Russian Federation|Investigational Site Number 7240004, A Coruña / Santiago De Compostela, Spain|Investigational Site Number 7240005, Badalona, Spain|Investigational Site Number 7240001, Getafe, Spain|Investigational Site Number 7240008, Granada, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240006, Santander, Spain|Investigational Site Number 7240007, Valencia, Spain|Investigational Site Number 7560001, Bern, Switzerland|Investigational Site Number 7560002, St. Gallen, Switzerland|Investigational Site Number 8260004, Gateshead, United Kingdom|Investigational Site Number 8260003, Leeds, United Kingdom|Investigational Site Number 8260009, Manchester, United Kingdom|Investigational Site Number 8260007, Newport, United Kingdom|Investigational Site Number 8260002, Plymouth, United Kingdom|Investigational Site Number 8260001, Southend, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03600818"
193,"NCT02072226","A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke","PRISMS","Terminated","Has Results","Stroke","Drug: Alteplase|Drug: Alteplase Placebo|Drug: Aspirin|Drug: Aspirin Placebo","Percentage of Participants With a Modified Rankin Scale (mRS) Score of 0 or 1 at Day 90|Distribution of Participants Across the Ordinal mRS|Percentage of Participants With Global Favorable Recovery on mRS, NIHSS, BI, and GOS|Percentage of Participants With Symptomatic Intracranial Hemorrhage (ICH )|Percentage of Participants With Any ICH|Overall Mortality|Percentage of Participants Who Died Due to Stroke and Neurological Disorders|Percentage of Participants With Adverse Events|Percentage of Participants With Serious Adverse Events","Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","313","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ML29093","May 31, 2014","March 22, 2017","March 22, 2017","February 26, 2014","July 3, 2018","July 3, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|St. Jude Medical Center, Fullerton, California, United States|University of California San Diego, La Jolla, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|University of California Los Angeles, Santa Monica, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Medical Center of The Rockies, Loveland, Colorado, United States|Associated Neurologists PC, Danbury, Connecticut, United States|Associated Neurologists of Southern CT PC, Fairfield, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Christiana Care Health Services; Sponsor Programs Ammon Education Center, Newark, Delaware, United States|Nova Clinical Research, LLC, Bradenton, Florida, United States|Neurologic Consultants, P.A., Fort Lauderdale, Florida, United States|University of Miami Miller School of Medicine; Clinical Reseach Building, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|St. Elizabeth Edgewood; Cancer Care Center"" for Account St. Elizabeth Edgewood, Edgewood, Kentucky, United States|University of Louisville, Elizabethtown, Kentucky, United States|St. Elizabeth Florence, Florence, Kentucky, United States|St. Elizabeth Fort Thomas, Fort Thomas, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Sparrow Health System, Lansing, Michigan, United States|St Joesph Mercy Hospital Oakland, Pontiac, Michigan, United States|Beaumont Hospital, Royal Oak, Michigan, United States|The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri Health Care, Columbia, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Renown Health; Renown Institute for Neurosciences, Reno, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Shore Neurology, Toms River, New Jersey, United States|SUNY Downstate Medical Center., Brooklyn, New York, United States|Lutheran Medical Center, Brooklyn, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Guilford Neurologic Associates, Greensboro, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Akron General Medical Center, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|West Hospital, Cincinnati, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Jewish Hospital, Cincinnati, Ohio, United States|Anderson Hospital, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Wright State University, Dayton, Ohio, United States|Fairfield Hospital, Fairfield, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent's Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|York Hospital, York, Pennsylvania, United States|Medical University of South Carolina; MSC 300, Charleston, South Carolina, United States|University of South Carolina School of Medicine, Columbia, South Carolina, United States|The Neurology And Pain Clinic, Orangeburg, South Carolina, United States|Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Valley Baptist Medical Center, Harlingen, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|University Of Texas Health Science Center Houston, Houston, Texas, United States|Texas Tech Univ Health Sci Ctr, Lubbock, Texas, United States|University Hospital San Antonio, San Antonio, Texas, United States|University Of Utah, Salt Lake City, Utah, United States|Inova Fairfax Hospital, Fairfax, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Gunderson Health System, La Crosse, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02072226/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02072226/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02072226"
194,"NCT01678898","Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients",,"Completed","Has Results","Fabry Disease","Drug: PRX-102","Adverse Events","Protalix","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PB-102-F01 & PB-102-F02","October 2012","March 6, 2016","March 6, 2016","September 5, 2012","January 27, 2020","January 27, 2020","UC Davis Medical Center, MIND Institute Department of Pediatrics, Section of Genetics, Sacramento, California, United States|Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, United States|University of Iowa Health Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Research Baylor Institute of Metabolic Disease, Dallas, Texas, United States|O & O Alpan LLC, Fairfax, Virginia, United States|Royal Melbourne Hospital, Victoria Park, Australia|Hematology and Clinical Research Private Institute, Asuncion, Paraguay|Clinical Center of Serbia, Belgrade, Serbia|Hospital de Dia Quiron Zaragoza, Zaragoza, Spain|The Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01678898"
195,"NCT00940095","Clazosentan in Aneurysmal Subarachnoid Hemorrhage","CONSCIOUS-3","Terminated","No Results Available","Aneurysmal Subarachnoid Hemorrhage","Drug: Clazosentan 5 m/h|Drug: Clazosentan 15 mg/h|Drug: Placebo","Cerebral vasospasm-related morbidity and mortality of all-causes as defined by the protocol|Glasgow Outcome Scale Extended (GOSE) at Week 12 post-aSAH, dichotomized into good (score > 4) and poor (score ≤ 4) outcome.","Idorsia Pharmaceuticals Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","577","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-054-302","July 1, 2009","October 1, 2010","January 1, 2011","July 15, 2009",,"July 9, 2018","Glendale Adventist Medical Center, Glendale, California, United States|UCSF Medical Centre, San Francisco, California, United States|Stanford Hospital and Clinis, Stanford, California, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Yale Univerity School of Medicine, New Haven, Connecticut, United States|University of South Florida, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illnois, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Medical Centre, Boston, Massachusetts, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Barnes_Jewish Hospital, Saint Louis, Missouri, United States|Capital Health System Inc. d/b/a The Stroke and Cerebrovascular Center of New Jersey, Trenton, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|New York Presbyteruan Hospital - Weill Cornell Medical Centre, New York, New York, United States|State University of New York at Stony Brook, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Thomas Jefferson University School of Medicine, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Zale Lipshy Hospital, Dallas, Texas, United States|Univ. of VA Health System, Charlottesville, Virginia, United States|Virginia Commonwealth University Medical Centre, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Hospital Aleman, Buenos Aires, Argentina|Clinica De Sol, Buenos Aires, Argentina|ENERI, Buenos Aires, Argentina|Gold Coast Hospital, Southport, Queensland, Australia|Royal Brisbane & Women's Hosptal, Brisbane, Australia|Royal Prince Alfred Hosptial, Camperdown, Australia|Monash Medical Centre, Clayton, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Landeskrankenhaus und Medizinische Universitat, Graz, Austria|Medizinsche Universitat Innsbruck, Innsbruck, Austria|University Fur Neurochirurgie, SALK, Christian Doppler Hospital, Salzburg, Austria|AKH University of Vienna, Medical Univ. Of Neurosurgery, Vienna, Austria|UZ Antwerpen, Antwerp, Belgium|ULB Erasme, Brussels, Belgium|UZ Brussels, Brussels, Belgium|UCL Saint-Luc, Brussels, Belgium|UZ Brussels, Brussels, Belgium|UZ Gent, Gent, Belgium|UZ Gasthuisberg, Leuven, Belgium|Hospital das Clinicas da UFMG, Belo Horizonte, Brazil|Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil|Clinica de Neurologia de, Joinville, Brazil|Hospital de Clínicas de Niteroí, Niteroí, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Hospital Santa Marcelina, Sao Paulo, Brazil|Santa Case de Misericordia de Sobral, Sobral, Brazil|University of Calgary - Foothills Medical Center, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver Hospital & Health Sciences, Vancouver, British Columbia, Canada|QEII Heath Sciences Center - Halifax Infirmary, Halifax, Nova Scotia, Canada|Hamilton General Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada|CHUM Hospital - Notre Dame, Montreal, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Hopital de I'Enfant-Jesus, Quebec, Canada|Hospital Regional de Concepción, Concepcion, Chile|Institute de Neurocirugia, Santiago, Chile|Hospital Clinico Pontificia Universidad Católica de Chile, Santiago, Chile|Clinica Davila, Santiago, Chile|Hospital Carlos Van Buren, Valparaiso, Chile|Fakultni nemocnice Bmo, Brno, Czechia|Nemocnice Ceske Budejovice, Ceske Budejovice, Czechia|Fakultní nemocnice Ostrava, Ostrava, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Nemocnice Na Homolce, Praha, Czechia|ÚVN Praha, Praha, Czechia|Fakultni nemocnice Homoice, Praha, Czechia|Masarykova nemocnice Usti n. Labem, Usti nad Labem, Czechia|The Neuroscience Center, Copenhagen University Hospital, Copenhagen, Denmark|Glostrup Hospital, Glostrup, Denmark|Odense University Hospital, Odense, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Tampere University Central Hospital (TAYS), Tampere, Finland|CHU d'Angers, Angers Cedex 9, France|Hopital Pellegrin, Bordeaux cedex, France|Hopital neurologique et Neuro-Chirurgical Pierre Wertheimer, Bron, France|Hopital Henru Mondor, Creteil, France|Hopital General, Dijon, France|Hopital de la Timone - CHU de Marseille, Marseille cedex 5, France|Hopital Gui de Chauliac, Montpellier, France|Hopital central, Nancy, France|Universitatsklinikum Augsburg Clinic for Diagnostic Radiology and Neuroradiology, Augsburg, Germany|Charite Universitatsmedzin Berlin, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|University of Bonn Medical Center, Bonn, Germany|Klinik imd Poliklinik fur Neurochirurgie, Dresden, Germany|Universitaet Erlangen-Nuerberg Klinik fur Neurologie, Erlangen, Germany|University Hospital of Essen, Essen, Germany|Universitatsklinik Frankfurt, Klinik und Poliklinik f. Neurochirurgie, Frankfurt, Germany|Neuroradiologie der Universitatsklinik Freiburg, Freiburg, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Neurochirurggische Universitatsklinik des Heidelberg, Heidelberg, Germany|Klinik und Poliklinik fur Neurochirurgie, Leipzig, Germany|Thechnical University - Klinikum rechts der Isar, Munich, Germany|University Regensburg, Regensburg, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Prince od Wales Hospital, Shatin, Hong Kong|Borsod-Abauj-Zemplen County Hospital and University Teaching Hospital, Miskolc, Borsod Abauj-Zemplen, Hungary|Borsod-Abauj-Zemplen County Hospital and University Teaching Hospital, Miskolc, Borsod-Abauj-Zemplen, Hungary|University of Pecs, Faculty of Medicine Neurosurgery Clinic, Pecs, Hungary|University of Szeged, Faculty of Medicine, Pecs, Hungary|Post Graduate Institute of Medical Education and Research, Chandigarh, India|CARE Hospital, Hyderabad, India|King Edward Memorial Hospital, Pune, India|Rambam Medical Centre, Haifa, Israel|Hadassah Universtity Medical Center, Jerusalem, Israel|Sheba Medical Centre, Tel Hashomer, Israel|Osepedale Maggiore Bellaria, Bologna, Italy|Azienda Ospedaliera di Careggi, Firenze, Italy|Azienda Osepedaliera San Giovanni - Addolorata, Rome, Italy|Ospedale Maggiore, Verona, Italy|Instituto Nacional de Neurologia y Neurocirugia, Mexico City, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"" Universidad Autonoma de Nuevo Leon, Monterrey, Mexico|Elisabeth Ziekenhuis, Tilburg, Netherlands|Haukeland University Hospital, Helse Bergen HF, Bergen, Norway|Ulleval Univ Hosp, Oslo, Norway|Universitetssykehuset Nord-Norge, Tromso, Norway|Szpital Akademii Medycznej w Gdansku, Gdansk, Poland|Samodzielny Publiczny Centralny Szpital Kliniczy w Warszawie, Warszawa, Poland|National University Hospital, Singapore, Singapore|National Neuroscience Institute, Singapore, Singapore|University Clinical Centre Ljubljana, Ljubljana, Slovenia|General Hospital Maribor, Maribor, Slovenia|Hospital Vali d' Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Complejo Hospotalario Virgen de las Nieves-Hospital de Rehabilitacion y Traumatologia, Granada, Spain|Hospital Universitario 12 se Octubre, Madrid, Spain|Hospital de Son Dureta, Palma de Mallorca, Spain|Sahlgrenska University Hospital, Goteborg, Sweden|Linkoping University Hospital, Linkoping, Sweden|Lund University Hospital, Lund, Sweden|Kantonsspital Aarau, Aarau, Switzerland|Universitatsklinik Bern, Bern, Switzerland|Geneva University Hospital, Geneva, Switzerland|Universitatsspital Zurich, Zurich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00940095"
196,"NCT01458119","Open-Label Phase 3 Long-Term Safety Study of Migalastat","AT1001-041","Terminated","Has Results","Fabry Disease","Drug: migalastat hydrochloride","Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)|Annualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)","Amicus Therapeutics","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","85","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT1001-041|2011-004800-40","October 14, 2011","February 17, 2016","February 17, 2016","October 24, 2011","October 2, 2018","October 2, 2018","Atlanta, Georgia, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|New York, New York, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Dallas, Texas, United States|Fairfax, Virginia, United States|Seattle, Washington, United States|Pilar, Argentina|Adelaide, Australia|Parkville, Australia|Edegem, Belgium|Porto Alegre, Brazil|Montreal, Canada|Copenhagen, Denmark|Cairo, Egypt|Garches, France|Roma, Italy|Barcelona, Spain|Ankara, Turkey|London, United Kingdom|Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01458119"
197,"NCT02239120","Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)",,"Completed","Has Results","Stroke|Secondary Prevention","Drug: optional ASA as comedication|Drug: placebo to ASA|Drug: placebo to optional ASA as comedication|Drug: placebo to dabigatran etexilate|Drug: ASA 100 mg|Drug: dabigatran etexilate","Adjudicated Recurrent Stroke|First Major Bleed (Adjudicated)|Adjudicated Ischaemic Stroke|Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death|Disabling Stroke|All-cause Death|Adjudicated Intracranial Hemorrhage|Adjudicated Fatal Bleed|Adjudicated Life-threatening Bleed|Any Bleed (Investigator-reported)","Boehringer Ingelheim","All","18 Years to 150 Years   (Adult, Older Adult)","Phase 3","5390","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","1160.189|2013-003444-24","November 27, 2014","August 14, 2018","August 14, 2018","September 12, 2014","September 6, 2019","September 6, 2019","Bronislava Shafran, MD PC, Phoenix, Arizona, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|TriWest Research Associates, LLC, El Cajon, California, United States|University of California, Fresno, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|Collaborative Neuroscience Network, LLC (CNS), Long Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|Huntington Hospital, Pasadena, California, United States|University of California, San Diego, California, United States|University of California, San Francisco, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|University of Colorado Denver, Fort Collins, Colorado, United States|St. Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Tenet Florida Physician Services, Boynton Beach, Florida, United States|Nova Clinical Research, LLC, Bradenton, Florida, United States|Broward Health North, Deerfield Beach, Florida, United States|Center for Advanced Research Excellence, Hialeah, Florida, United States|Bruce W. Carter, Miami VA Healthcare System, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Bay Neurological Institute, Panama City, Florida, United States|Carol L Pappas, MD PhD PA, Saint Petersburg, Florida, United States|University of South Florida, Tampa, Florida, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, United States|Palm Beach Neuroscience Institute, West Palm Beach, Florida, United States|Augusta University, Augusta, Georgia, United States|WellStar Medical Group - Neurosurgery, Marietta, Georgia, United States|The Queen's Medical Center, Honolulu, Hawaii, United States|Saint Alphonsus Medical Center-Neurology, Boise, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Medicoricium, LLC, Fairview Heights, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Quincy Physicians and Surgeons Clinic, S.C., Quincy, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Culicchia Neurological Clinic, Marrero, Louisiana, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Flint, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health Medical Center, Grand Rapids, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|The Duluth Clinic dba Essentia Health Duluth Clinic, Duluth, Minnesota, United States|Abbott Northwestern Hospital, Radiology Department, Minneapolis, Minnesota, United States|HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States|Jackson Heart Clinic, P.A., Jackson, Mississippi, United States|Boone Hospital Center, Columbia, Missouri, United States|University of Missouri Health System, Columbia, Missouri, United States|SSM Health St. Clare Hospital, Fenton, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|St. Louis Heart and Vascular, P.C., Saint Louis, Missouri, United States|The Nebraska Medical Center, Omaha, Nebraska, United States|Renown Institute for Neurosciences, Reno, Nevada, United States|NYC Health + Hospitals/Coney Island, Brooklyn, New York, United States|New York Presbyterian Hudson Valley Hospital, Cortlandt Manor, New York, United States|UHS Wilson Medical Center,Office of Clin Trials, Johnson City, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Novant Health Neurology Specialists, Charlotte, North Carolina, United States|Duke Clinic 1L, Durham, North Carolina, United States|Cone Health System, Greensboro, North Carolina, United States|Novant Health Neurology Hickory, Hickory, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Altru Health System, Grand Forks, North Dakota, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Holzer Clinic LLC, Gallipolis, Ohio, United States|Advanced Neurology Associates, Youngstown, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Veterans Affairs Portland Health Care System, Portland, Oregon, United States|Sacred Heart Medical Center at RiverBend, Springfield, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Methodist University Hospital, Memphis, Tennessee, United States|Centennial Heart Cardiovascular Consultants, LLC, Nashville, Tennessee, United States|Saint Thomas Health, Nashville, Tennessee, United States|Seton Medical Center Austin, Austin, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Bhupesh Dihenia, M.D.,P.A., Lubbock, Texas, United States|University of Vermont, Burlington, Vermont, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Riverside, Roanoke, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Marshall University, Huntington, West Virginia, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|STAT Research, Caba, Argentina|Fundación Favaloro, Caba, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Instituto Médico DAMIC S.R.L., Cordoba, Argentina|Clinica Coronel Suarez SA, Coronel Suarez, Argentina|Hospital Privado de Comunidad, Mar del Plata, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Kanwal Medical Complex, Kanwal, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Calvary North Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Alfred Health, Victoria, Australia|LKH-Univ. Hospital Graz, Graz, Austria|Medical University of Innsbruck, Innsbruck, Austria|Kepler Univ. Klinikum Linz, Linz, Austria|Kepler Univ. Klinikum Linz, Linz, Austria|KH d. Barmherzigen Brüder Linz, Neurologie, Linz, Austria|Universitätsklinikum Tulln, Abteilung für Neurologie, Tulln, Austria|Hosp.Hietzing with Neuro.Centr Rosenhuegel,II Neuro.dep,Wien, Vienna, Austria|Wilhelminenspital, Wien, Austria|Aalst - HOSP Onze-Lieve-Vrouw, Aalst, Belgium|Arlon - HOSP Sud Luxembourg - Vivalia, Arlon, Belgium|AZ Sint-Jan Brugge, Brugge, Belgium|Brussels-UNIV Brugmann -Horta, Brussel, Belgium|Brussels - HOSP Europe (Ste-Elisabeth), Brussel, Belgium|Brussels - UNIV Saint-Luc, Bruxelles, Belgium|UNIV UZ Gent, Gent, Belgium|Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|Liège - HOSP St-Joseph, Liège, Belgium|Roeselare - HOSP AZ Delta, Roeselare, Belgium|Rumst - HOSP AZ Heilige Familie, Rumst, Belgium|Sint-Truiden - HOSP St-Trudo (St-Jozef), Sint-Truiden, Belgium|Wilrijk - HOSP GZA (St-Augustinus), Wilrijk, Belgium|Yvoir - UNIV UCL de Mont-Godinne, Yvoir, Belgium|Hospital Clinicas de Botucatu, Botucatu, Brazil|Instituto de Medicina Flumignano, Curitiba, Brazil|Clinica Neurologica e Neurocirurgica de Joinvile, Joinvile, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|H.C.da Fac. de Medicina de Ribeirao Preto, Ribeirao Preto, Brazil|Hospital Quinta D¿Or, Rio de Janeiro, Brazil|Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital (University of Alberta), Edmonton, Alberta, Canada|Grey Nuns Hospital, Edmonton, Alberta, Canada|Prairie Mountain Health, Brandon, Manitoba, Canada|Hopital Notre-Dame du CHUM, Montreal, Migration Data, Canada|Jewish General Hospital, Montreal, Migration Data, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Eastern Health (MUN), St. John's, Newfoundland and Labrador, Canada|Victoria Hospital (LHSC), London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|CSSS de Chicoutimi, Chicoutimi, Quebec, Canada|Hopital Charles - LeMoyne, Greenfield Park, Quebec, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|St Jerome Medical Research Inc., St-Jerome, Quebec, Canada|CHU de Quebec-Universite Laval Research Centre, Quebec, Canada|Clínica Alemana de Santiago S.A., Santiago, Chile|Clínica Dávila, Santiago, Chile|Clinica Alemana de Temuco, Temuco, Chile|Beijing Tiantan Hospital affiliated to Cap Med University, Beijing, China|Peking University Third Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, China|The First Affiliated Hospital of Jinan University, Guangzhou, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, China|2nd Affiliated Hosp Zhejiang University College of Medical, Hangzhou, China|Zhejiang Hospital, Hangzhou, China|The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China|Zhejiang University School of Medicine SIR RUN RUN SHAW Hospital, Hangzhou, China|Jinlin Central Hospital, Jilin, China|The Second Affiliated Hospital to Nanchang University, Nanchang, China|Nanjing Drum Tower Hospital, Nanjing, China|Zhongda Hospital Southeast University, Nanjing, China|QingDao Municipal Hospital, Qingdao, China|The affiliated hospital of medicalcollege qingdao university, Qingdao, China|Huashan Hospital, Fudan University, Shanghai, China|Tongji Hospital, Tongji University, Shanghai, China|General Hospital of Shenyang Military Region, Shenyang, China|First Affiliated Hospital of Xiamen University, Xiamen, China|Affiliated Hospital, Xuzhou Medical college, Xuzhou, China|Servicios Médicos Muñoz Solano, Bogotá, Colombia|Sociedad de Cirugia de Bogota Hospital de San José, Bogotá, Colombia|Fundación Valle del Lili, Cali, Colombia|Fundación Cardiovascular de Colombia, Floridablanca, Colombia|General Hospital Varazdin, Varazdin, Croatia|Clin.Hosp.Centre Zagreb,Cerebrovascul.disease w/ intens.care, Zagreb, Croatia|University hospital center Zagreb, Zagreb, Croatia|Univ. Hosp. Sisters of Mercy, Neurology Clinic, Zagreb, Zagreb, Croatia|Cerebrovascular site, private prac., Brno, Brno, Czechia|Hospital Jihlava, Jihlava, Czechia|University Hospital Olomouc, Olomouc, Czechia|Cerebrovascular site, Ostrava, Ostrava, Czechia|Cerebrovascular site, Ostrava, Ostrava, Czechia|Hospital Homolka, Prague, Prague 5, Czechia|University Hospital Motol, Praha 5, Czechia|East Estonia Central Hospital, Neurology Dept, Ahtme, Ahtme, Estonia|West Tallinn Central Hospital, Neurology Dept., Tallinn, Estonia|North Estonia Medical Centre Foundation, Tallin, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|HOP Pays d'Aix, Aix en Provence, France|HOP de Bayonne, Bayonne, France|HOP Jean Minjoz, Besançon, France|HOP Pellegrin, Bordeaux, France|HOP de la Cavale Blanche, Brest, France|HOP Pierre Wertheimer, Bron, France|HOP Côte de Nacre, Caen, France|HOP Grenoble, Neuro, Grenoble, Grenoble, France|HOP Roger Salengro, Lille, France|HOP Mercy, Metz, France|HOP Paris Saint-Joseph, Paris, France|GHU Paris Psychiatrie et Neurosciences, Paris, France|HOP Purpan, Toulouse, France|Klinikum Altenburger Land GmbH, Altenburg, Germany|Neurologische Klinik GmbH, Bad Neustadt, Bad Neustadt, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Evangelisches Klinikum Bethel gGmbH, Bielefeld, Germany|Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Bochum, Germany|St. Josef- und St. Elisabeth-Hospital gGmbH, Bochum, Germany|Gesundheit Nord gGmbH   Klinikverbund Bremen, Bremen, Germany|Klinikum Bremerhaven, Bremen, Germany|Krankenhäuser Buchholz und Winsen gGmbH, Buchholz, Germany|Allgemeines Krankenhaus, Celle, Celle, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Klinikum Coburg gGmbH, Coburg, Germany|Klinikzentrum Mitte, Dortmund, Dortmund, Germany|Städtisches Klinikum Dresden, Dresden, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Marien-Hospital, Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Alfried Krupp Krankenhaus Essen, Essen, Germany|Universitätsklinikum Essen AöR, Essen, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Klinikum Frankfurt Höchst GmbH, Frankfurt, Germany|Klinikum Friedrichshafen, Friedrichshafen, Germany|Klinikum Fulda gAG, Fulda, Germany|Evangelische Klinik Gelsenkirchen, Gelsenkirchen, Germany|SRH Wald-Klinikum Gera GmbH, Gera, Germany|Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Bezirkskrankenhaus, Günzburg, Günzburg, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Asklepios Klinik Harburg, Hamburg, Germany|Asklepios Klinik Wandsbek, Hamburg, Germany|Asklepios Klinik Barmbek, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Klinikum Hanau GmbH, Hanau, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Klinikum Idar-Oberstein, Idar-Oberstein, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|Universitätsklinikum Magdeburg AöR, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Gießen und Marburg GmbH, Marburg, Germany|Elblandklinikum Meißen, Meißen, Germany|Johannes Wesling Klinikum, Minden, Germany|Kliniken Maria Hilf GmbH, Moenchengladbach, Germany|Ökumenisches Hainich Klinikum gGmbH, Mühlhausen, Germany|Klinikum der Universität München - Campus Großhadern, München, Germany|Klinikum rechts der Isar der Technischen Universität München, München, Germany|Universitätsklinikum Münster, Münster, Germany|Klinikum Nürnberg, Nürnberg, Germany|Sana Klinikum Offenbach GmbH, Offenbach, Germany|Klinikum Osnabrück GmbH, Osnabrück, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Nordwest-Krankenhaus Sanderbusch gGmbH, Sande, Germany|Kreisklinikum Siegen GmbH, Siegen, Germany|Bürgerhospital, Stuttgart, Stuttgart, Germany|Nervenklinik Teupitz, Teupitz, Teupitz, Germany|Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|RKU - Universitäts- und Rehabilitationskliniken Ulm gGmbH, Ulm, Germany|Sophien- und Hufeland-Klinikum gGmbH, Weimar, Germany|Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Univ.Hosp. of Alexandroupolis, Alexandroupolis, Greece|Gen.Hosp.of Ath.Evangelismos, Athens, Greece|Attikon University Hospital, Athens, Greece|Gen.Univ. Hosp. of Herakleion, Herakleion, Greece|General University Hospital of Larissa, Larissa, Greece|Univ. Gen. Hosp. of Patras, Patras, Greece|Univ.Gen.Hosp. of Thessaloniki, Thessaloniki, Greece|Prince of Wales Hospital, Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Semmelweis University, Budapest, Hungary|National Instit.of Neurosciences,Neurology Dept,Budapest, Budapest, Hungary|Univ. Debrecen Medical Health Science Center, Neurology Dept, Debrecen, Hungary|Pest Megyei Flor Ferenc Hospital, Kistarcsa, Hungary|CRU Hungary Ltd, Private Practice, Miskolc, Miskolc, Hungary|Univ. of Pecs Clinic for Neurology, Pecs, Hungary|St. Johns medical College and Hospital, Bangalore, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India|Lalitha Super Specialities Hospital, Guntur, India|Nizam's Institute of Medical Sciences, Hyderabad, India|Shree Krishna Hospital and Research Centre, Karamsad, India|Caritas Hospital, Kottayam, India|Mangala Hospital and Mangala Kidney Foundation, Mangalore, India|LTMMC & GH Medical College,, Mumbai, India|Magnum Heart Institute, Nashik, India|All India Institute of Medical Sciences, New Delhi, India|Sahyadri Speciality Hospital, Pune, India|Hillel Yaffe Medical Center, Hadera, Hadera, Israel|Wolfson Medical Center, Holon, Israel|The Chaim Sheba Medical Center Tel Hashomer, Tel Hashomer, Ramat Gan, Israel|Sourasky Medical Center, Telaviv, Israel|Osp. SS Filippo Nicola, Avezzano, Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|A.O. Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliero Universitaria di Ferrara, Cona (FE), Italy|Policlinico San Martino, Genova, Italy|A.O.U.Policlinico G.Martino, Messina, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Istituto Auxologico Italiano, Milano, Italy|Nuovo Ospedale Civile S. Agostino-Estense, Modena, Italy|Azienda Ospedaliera Universitaria di Padova, Padova, Italy|Ospedale S.Maria della Misericordia, AO di Perugia, Perugia, Italy|Osp. Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|Ospedale Santa Corona Azienda Sanitaria Locale n.2 Savonese, Pietra Ligure, Italy|Università degli Studi Campus Bio-Medico, Roma, Italy|A.O. San Camillo Forlanini, Roma, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|Ospedale Maria Vittoria, Torino, Italy|Ospedale S. Maria di Ca' Foncello Azienda ULSS9 TREVISO, Treviso, Italy|A. O. Ospedale Circolo Fond. Macchi, Varese, Italy|Ospedale Policlinico G.B. Rossi (Borgo Roma) di Verona, Verona, Italy|Chubu Rosai Hospital, Aichi, Nagoya, Japan|National Hospital Organization Toyohashi Medical Center, Aichi, Toyohashi, Japan|Toyota Memorial Hospital, Aichi, Toyota, Japan|Reserch Institute for Brain and Blood Vessels Akita, Akita, Akita, Japan|Juntendo University Urayasu Hospital, Chiba, Urayasu, Japan|Go Neurosurgical Clinic, Fukuoka, Chikushi-gun, Japan|Fukuoka University Chikushi Hospital, Fukuoka, Chikushino, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka, Japan|Fukuoka Wajiro Hospital, Fukuoka, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Fukuoka, Japan|Fukuoka Tokushukai Medical Center, Fukuoka, Kasuga, Japan|Steel Memorial Yawata Hospital, Fukuoka, Kitakyushu, Japan|Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Kitakyushu, Japan|St. Mary's Hospital, Fukuoka, Kurume, Japan|Shin Koga Hospital, Fukuoka, Kurume, Japan|Fukuoka Shin Mizumaki Hospital, Fukuoka, Onga, Japan|Social Insurance Tagawa Hospital, Fukuoka, Tagawa, Japan|Shin Yukuhashi Hospital, Fukuoka, Yukuhashi, Japan|Fujita General Hospital, Fukushima, Date-Gun, Japan|Shinseikai Masu Memorial Hospital, Fukushima, Nihonmatsu, Japan|Asahi University Hospital, Gifu, Gifu, Japan|Japanese Red Cross Takayama Hospital, Gifu, Takayama, Japan|Mihara Memorial Hospital, Gunma, Isesaki, Japan|Maebashi Red Cross Hospital, Gunma, Maebashi, Japan|Medical corporation Suiseikai Suiseikai Kajikawa Hospital, Hiroshima, Hiroshima, Japan|Araki Neurosurgical Hospital, Hiroshima, Hiroshima, Japan|Hiroshima Prefectural Hospital, Hiroshima, Hiroshima, Japan|Sapporo Shiroishi Memorial Hospital, Hokkaido, Sapporo, Japan|Nakamura Memorial Hospital, Hokkaido, Sapporo, Japan|Kobe City Medical Center General Hospital, Hyogo, Kobe, Japan|JA Toride Medical Center, Ibaraki, Toride, Japan|Tsukuba Medical Center Hospital, Ibaraki, Tsukuba, Japan|Iwate Medical University Hospital, Iwate, Morioka, Japan|Kagoshima City Hospital, Kagoshima, Kagoshima, Japan|National Hospital Organization Kagoshima Medical Center, Kagoshima, Kagoshima, Japan|Shonan Kamakura General Hospital, Kanagawa, Kamakura, Japan|Saiseikai Kumamoto Hospital, Kumamoto, Kumamoto, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Kumamoto, Japan|Kumamoto City Hospital, Kumamoto, Kumamoto, Japan|Uji-Tokushukai Medical Center, Kyoto, Uji, Japan|National Hospital Organization Sendai Medical Center, Miyagi, Sendai, Japan|South Miyagi Medical Center, Miyagi, Shibata-gun, Japan|Ina Central Hospital, Nagano, Ina, Japan|Nagano Municipal Hospital, Nagano, Naganoi, Japan|Nagasaki University Hospital, Nagasaki, Nagasaki, Japan|Nozaki Tokushukai Hospital, Osaka, Daito, Japan|Higashiosaka City Medical Center, Osaka, Higashiosaka, Japan|Wakakusa Daiichi Hospital, Osaka, Higashiosaka, Japan|Rinku General Medical Center, Osaka, Izumisano, Japan|Kishiwada Tokushukai Hospital, Osaka, Kishiwada, Japan|Yagi Neurosurgical Hospital, Osaka, Osaka, Japan|Tominaga Hospital, Osaka, Osaka, Japan|Osaka University Hospital, Osaka, Suita, Japan|TMG Asaka Medical Center, Saitama, Asaka, Japan|Saitama Medical University International Medical Center, Saitama, Hidaka, Japan|Sainokuni Higashiomiya Medical Center, Saitama, Saitama, Japan|Saitama Municipal Hospital, Saitama, Saitama, Japan|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Tokyo Metropolitan Geriatric Hospital, Tokyo, Itabashi-ku, Japan|Kyorin University Hospital, Tokyo, Mitaka, Japan|Tokyo Women's Medical University Hospital, Tokyo, Shinjuku-ku, Japan|Saiseikai Wakayama Hospital, Wakayama, Wakayama, Japan|Yamagata City Hospital SAISEIKAN, Yamagata, Yamagata, Japan|Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Kyungpook National Univ. Hosp, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejoen, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Chosun University Hospital, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Sarawak General Hospital, Kuching, Malaysia|Hospital Seberang Jaya, Pulau Pinang, Malaysia|Hospital Sultanah Nur Zahirah, Terengganu, Malaysia|Hospital General de Culiacán ""Dr. Bernardo J. Gastellum"", Culiacán, Mexico|Hospital General ""Dr. Miguel Silva"", Morelia, Mexico|Hospital Angeles del Pedregal, México, D.F., Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez, Nuevo Leon, Mexico|H. Central Dr Ignacio M. P., San Luis Potosi, Mexico|Auckland City Hospital, Grafton / Auckland, New Zealand|North Shore Hospital, Takapuna, Takpuna Auckland, New Zealand|Wellington Hospital, Wellington, New Zealand|Instituto Nacional de Ciencias Neurológicas, Barrios Altos, Peru|Hospital Nacional Guillermo Almenara Irigoyen, La Victoria, Peru|PI HOUSE Sp. z o.o., Gdansk, Gdansk, Poland|Spec.Hosp.of Dr. Wladyslaw Bieganski in Grudziadz, Grudziadz, Poland|Univ.Clin.Centr Gibinski of Silesian Med,Neurol.dep,Katowice, Katowice, Poland|University Hospital in Krakow, Krakow, Poland|Center of Clinical Neurology, private prac, Krakow, Krakow, Poland|Clin.Research Center,Leszek Szczepanski,Private Prac.,Lublin, Lublin, Poland|Medicome Sp. z o.o., Oswiecim, Poland|Specialist Holy Spirit Hospital, Neurology Dept,Sandomierz, Sandomierz, Poland|Public Central Clinical Hosp,Neurology Clinic,Warsaw, Warsaw, Poland|Military Institute of Medicine Neurology Clinic, Warsaw, Warsaw, Poland|Hospital Garcia de Orta, EPE, Almada, Portugal|Hospital Fernando Fonseca, EPE, Amadora, Portugal|Hospital de Braga - Centro Clínico Académico (2CA), Braga, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|CHLC, EPE - Hospital de São José, Lisboa, Portugal|CHLO, EPE - Hospital Egas Moniz, Lisboa, Portugal|CHULN, EPE - Hospital de Santa Maria, Lisboa, Portugal|Hospital Beatriz Ângelo, Loures, Portugal|USLM, EPE - Hospital Pedro Hispano, Matosinhos, Portugal|H. Santo António - Centro Hospitalar do Porto, Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião, Santa Maria da Feira, Portugal|Interreg. Clinical & Diagnostic Center, Neurol. Dept., Kazan, Kazan, Russian Federation|Reg.Clin.Hosp#1 na S.V.Ochapovskiy,Neurology#1 Dep,Krasnodar, Krasnodar, Russian Federation|City Clin.Emergency Hosp of Kursk, Neurology Department No.2, Kursk, Russian Federation|Clin.Hosp#2,na.Semashko,Russ.Railways,Restorative Med&Rehab., Moscow, Russian Federation|CityClin.Hosp na I.V.Davydovsky of Dept of Healthcare Moscow, Moscow, Russian Federation|Research&Clini Cent Neuropsychiatry Dep. Healthcare,Moscow, Moscow, Russian Federation|City Clin.Hosp#1na N.I.Pirogov,Dept of Healthcare of Moscow, Moscow, Russian Federation|Ltd liabilityCom.CityNeurologic Cntr Sibneiromed,Novosibirsk, Novosibirsk, Russian Federation|Saratov State Med.Univ na V.I.Razumovsky,FacultyTherapy Clin, Saratov, Russian Federation|Reg.State Instit.of Healthc.Smolensk Reg.Clin.Hosp,Neurology, Smolensk, Russian Federation|Research Inst. of Emerg. Med., Vascul. Center,St. Petersburg, St. Petersburg, Russian Federation|Military Medical Academy n.a. C. M. Kirov, St. Petersburg, St. Petersburg, Russian Federation|Sverdlovsk Reg.Clin.Hosp.No.1, Yekaterinburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Special Hosp.for Cerebrovascul.Disease,'Sveti Sava,Belgrade, Belgrade, Serbia|Clinical Centre Nis, Nis, Serbia|Clinical Center of Vojvodina, Novi Sad, Serbia|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Neuroscience Institute, Singapore, Singapore|Faculty Hospital L. Pasteura, Kosice, Kosice, Slovakia|Faculty Hospital Nitra, Nitra, Slovakia|Instit.f.applicative Research in med.rehab.Dobrna, Dobrna, Slovenia|Cardial d.o.o., Specialist out-patient unit, Ljubljana, Ljubljana, Slovenia|Univ. Medical Center Maribor, Maribor, Slovenia|University of Pretoria, Pretoria, South Africa|Dr. Moodley and Dr. Sarvan, Tongaat, South Africa|Hospital General Universitario de Albacete, Albacete, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Son Espases, Palma de Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Universitari Joan XXIII, Tarragona, Spain|Hospital Mútua Terrassa, Tarrasa (Barcelona), Spain|Hospital Clínico de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Sahlgrenska US, Göteborg, Göteborg, Sweden|Sahlgrenska Universitetssjukhuset, Östra, Göteborg, Sweden|Skaraborgs Sjukhus, Skövde, Sweden|Karolinska Univ. sjukhuset, Stockholm, Sweden|Karolinska Univ. sjukhuset, Stockholm, Sweden|Danderyds Sjukhus, Stockholm, Sweden|Canton Hospital Aarau, Neurology Dept., Stroke Center, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Univ. Hospital Bern, Neurology Dept, Stroke Center, Bern, Switzerland|CHUV - Centre hospitalier universitaire vaudois, Lausanne, Switzerland|Regional Hospital Lugano,Neurocenter of Southern Switzerland, Lugano, Switzerland|Kantonsspital St.Gallen, St. Gallen, Switzerland|University Hosp. Zürich, Dept. of Neurology, Stroke Center, Zürich, Switzerland|Chang-Hua Christian Hospital, Changhua, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan,, Taiwan|NCKUH, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Cheng Hsin General Hospital, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan, Taiwan|Chulalongkorn University, Bangkok, Thailand|Ramathibodi Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Lampang Hospital, Lampang, Thailand|Ankara Universitesi Tip Fakultesi, Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi Noroloji A.B.D., Ankara, Turkey|Gazi Universitesi Tip Fakultesi, Ankara, Turkey|Eskisehir Osmangazi Universitesi Tip Fakultesi, Eskisehir, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Noroloji A.B.D., Istanbul, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Bakırkoy Dr. Sadi Konuk Egitim Ve Arastirma Hastanesi, Istanbul, Turkey|Bakirkoy Prof. Dr. Mazhar Osman Ruh Sagligi ve Sinir Hastaliklari, Istanbul, Turkey|Sisli Hamidiye Etfal Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Dokuz Eylul Universitesi Tip Fakultesi Noroloji A.B.D., Izmir, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Turkey|Namik Kemal Universitesi Tip Fakultesi, Tekirdag, Turkey|Bukovinian Med.Univ.Chernivtsi Reg.Psychiatric Hosp,Neurolog, Chernivtsi, Ukraine|City Clinical Hospital No. 7, Kharkov, Kharkiv, Ukraine|Instit.of Neurol,Psychiatry&Narcol,Vascul. Malformations Dep, Kharkiv, Ukraine|Instit.of Gerontology na D.F.Chebotarev,Brain Vascular Path., Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Lviv, Ukraine|Ternopil State Med.Univ.na Gorbachevskiy,Neurology Dept N3, Ternopil, Ukraine|Vinnitsia Reg.Psychoneurol.Hosp.na Yushchenko,Dept.N3,Neurol, Vinnitsia, Ukraine|Zhytomyr Reg.ClinHosp na Gerbachevskiy RegCouncil,Neurol.Dep, Zhytomyr, Ukraine","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02239120/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02239120/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02239120"
198,"NCT01831934","Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)",,"Completed","Has Results","MELAS Syndrome","Biological: Fluzone®","Clinical Safety of TIV Vaccine","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","22","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SU-18615|R21HD061709-01A1","September 2010","December 2011","March 2012","April 15, 2013","April 21, 2017","May 30, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01831934"
199,"NCT04020055","A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variants and Severe Renal Impairment",,"Not yet recruiting","No Results Available","Fabry Disease","Drug: migalastat HCl 150 mg","Maximum observed concentration (Cmax)|Concentration at the end of a dosing interval at steady state (Ctrough)|Average plasma migalastat concentration over the dosing interval (Cavg)|Time to maximum concentration (tmax)|Apparent terminal elimination half-life (t½)|Area under the concentration time curve at steady state during the dosing interval (AUC0-τ)|Plasma clearance (CL/F)|peak and trough plasma migalastat concentrations|Change in Amount excreted urine|Change in Fraction of the dose recovered in urine|adverse events (AEs)|Number of subjects with abnormal clinical chemistry laboratory test results|Number of subjects with abnormal hematology laboratory test results|Number of subjects with abnormal urinalysis laboratory test results|Number of subjects with abnormal electrocardiogram (ECG) findings as a measure of safety and tolerability|change from baseline in estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation (eGFR MDRD)|change from baseline eGFR based on the Chronic Kidney Disease Epidemiology Collaboration equation (eGFRCKD-EPI)|change from baseline in plasma globotriaosylsphingosine (lyso-Gb3)|Number of subjects with abnormal echocardiogram (ECHO) results","Amicus Therapeutics","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT1001-025","March 30, 2021","December 31, 2021","December 31, 2021","July 15, 2019",,"December 5, 2019","Emory SOM, Atlanta, Georgia, United States|NYU School of Medicine, New York, New York, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Antwerp University Hospital, Edegem, Belgium|Internal Medicine Unit Croix Saint Simon Hospital, Paris, France|Azienda Ospedalira Universitaria CAREGGI S.O.D.c. Nefrologia Dialisi Trapianto, Florence, Italy|S.C. Nefrologia - Clinica Nefrologica, Monza, Italy|Hospital Universitario Virgen del Rocio, Sevilla, C.p., Spain|Hospital General Universitario de Elda, Elda, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Royal Free London NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04020055"
200,"NCT04065113","Middle Meningeal Artery Embolization for Chronic Subdural Hematoma",,"Recruiting","No Results Available","Chronic Subdural Hematoma","Procedure: Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Procedure: Drainage of Subdural Hematoma","Number of patients with recurrent or refractory hematoma (Radiographic resolution)|Number of patients requiring secondary evacuation surgery (Treatment Efficacy)|Procedure-related complication rate (Safety)|Change in NIH Stroke Scale Score (Functional outcome)|Change in modified Rankin Scale (Functional outcome)|Change in size of subdural hematoma","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201905146","September 19, 2019","August 18, 2021","January 1, 2022","August 22, 2019",,"September 24, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04065113"
201,"NCT01697267","Rituximab Vasculitis Maintenance Study","RITAZAREM","Completed","No Results Available","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis|Microscopic Polyangiitis|Wegener Granulomatosis","Biological: Rituximab|Drug: Azathioprine","Time to relapse|Remission at 24 and 48 months|Combined damage assessment score|Health-related quality of life|Cumulative GC exposure|Severe adverse event rate|Infection rates","Cambridge University Hospitals NHS Foundation Trust|Arthritis Research UK|Roche Pharma AG|Genentech, Inc.|University of Pennsylvania","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","188","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RITAZAREM|2012-001102-14","April 2013","November 22, 2018","November 21, 2019","October 2, 2012",,"February 28, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Hospital for Special Surgery, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|St. Joseph's Healthcare, Hamilton, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|General Faculty Hospital, Prague, Czechia|Cork University Hospital, Cork, Ireland|University Hospital of Parma, Parma, Italy|Okayama University, Kita-ku, Okayama, Japan|Chiba University, Chiba-shi, Japan|Kitano Hospital, Kyoto, Japan|University of Miyazaki, Miyazaki, Japan|Teikyo University, Tokyo, Japan|Tokyo Metropolitan Geriatric, Tokyo, Japan|Kyorin University school of medicine, Tokyo, Japan|Auckland City Hospital, Grafton, Auckland, New Zealand|North Shore Hospital, Westlake, Auckland, New Zealand|Karolinska University Hospital, Stockholm, Sweden|Leicester General Hospital, Leicester, Leicestershire, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Brighton and Sussex University Hospitals, Brighton, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Russells Hall Hospital, Dudley, United Kingdom|Ipswich Hospital, Ipswich, United Kingdom|Chapel Allerton Hospital, Leeds, United Kingdom|Imperial College, London, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Queen's Medical Centre Campus, Nottingham University Hosp, Nottingham, United Kingdom|University of Oxford, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01697267"
202,"NCT01663623","Belimumab in Remission of VASculitis","BREVAS","Completed","Has Results","Vasculitis","Biological: Placebo|Biological: Belimumab 10 mg/kg|Drug: Azathioprine","Time to First Relapse|Number of Participants With Major Relapse During the Double-blind Phase of the Study","Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","115466","March 20, 2013","February 6, 2017","February 6, 2017","August 13, 2012","April 18, 2018","April 18, 2018","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Covina, California, United States|GSK Investigational Site, Palo Alto, California, United States|GSK Investigational Site, San Leandro, California, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Kansas City, Kansas, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, West Springfield, Massachusetts, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Camden, New Jersey, United States|GSK Investigational Site, Great Neck, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Wyomissing, Pennsylvania, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Garran, Australian Capital Territory, Australia|GSK Investigational Site, New Lambton, New South Wales, Australia|GSK Investigational Site, Malvern, Victoria, Australia|GSK Investigational Site, Liverpool, Australia|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Praha 4, Czechia|GSK Investigational Site, Lille cedex, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pessac, France|GSK Investigational Site, Rennes, France|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Kirchheim unter Teck, Germany|GSK Investigational Site, Muenchen, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Torrette Di Ancona, Marche, Italy|GSK Investigational Site, Bari, Italy|GSK Investigational Site, Bologna, Italy|GSK Investigational Site, Milano, Italy|GSK Investigational Site, Reggio Emilia, Italy|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Kristiansand, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Callao, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Katowice, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Cluj-Napoca, Romania|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Stavropol, Russian Federation|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, St. Gallen, Switzerland|GSK Investigational Site, Zuerich, Switzerland|GSK Investigational Site, Reading, Berkshire, United Kingdom|GSK Investigational Site, Aberdeen, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT01663623/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT01663623/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01663623"
203,"NCT01218659","Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease",,"Completed","Has Results","Fabry Disease","Drug: migalastat hydrochloride|Biological: agalsidase","Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate|Annualized Rate Of Change From Baseline To Month 18 In eGFR|Annualized Rate Of Change From Baseline To Month 18 In eGFR By The Modification Of Diet In Renal Disease Equation","Amicus Therapeutics","All","16 Years to 74 Years   (Child, Adult, Older Adult)","Phase 3","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT1001-012|ATTRACT|2010-022636-37","September 8, 2011","May 27, 2014","May 28, 2015","October 11, 2010","November 1, 2018","November 1, 2018","Los Angeles, California, United States|Aurora, Colorado, United States|Decatur, Georgia, United States|Grand Rapids, Michigan, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Fairfax, Virginia, United States|Milwaukee, Wisconsin, United States|Parkville, Victoria, Australia|Perth, West Australia, Australia|Vienna, Austria|Edegem, Belgium|Sao Paulo, Brazil|Copenhagen, Denmark|Garches, France|Lille, France|Firenze, Italy|Niigata, Japan|Osaka, Japan|Osaka, Japan|Tokyo, Japan|Cambridge, United Kingdom|London, United Kingdom|London, United Kingdom|Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01218659"
204,"NCT01791153","An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)",,"Completed","Has Results","Giant Cell Arteritis","Drug: Tocilizumab|Drug: Prednisone|Drug: Tocilizumab Placebo|Drug: Prednisone Placebo|Drug: Corticosteroids|Drug: Methotrexate","Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper)|Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 52 Weeks Prednisone Taper)|Time to First GCA Disease Flare|Total Cumulative Prednisone Dose|Change From Baseline in Short Form (SF)-36 Questionnaire Score at Week 52|Change From Baseline in Patient Global Assessment (PGA) of Disease Activity Assessed Using Visual Analogue Scale (VAS) at Week 52|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Steady State of Tocilizumab|Maximum Serum Concentration at Steady State (Cmax,ss) of Tocilizumab|Minimum Serum Concentration at Steady State (Cmin,ss) of Tocilizumab|Minimum Observed Serum Concentration (Ctrough) of Tocilizumab|Serum Interleukin-6 (IL-6) Level|Serum Soluble IL-6 Receptor (sIL-6R) Level|Erythrocyte Sedimentation Rate (ESR)|C-Reactive Protein (CRP) Level|Percentage of Participants With Anti-Tocilizumab Antibodies","Hoffmann-La Roche","All","50 Years and older   (Adult, Older Adult)","Phase 3","251","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA28119|2011-006022-25","July 22, 2013","April 11, 2016","June 4, 2018","February 13, 2013","May 18, 2017","February 6, 2020","Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Rheumatology Assoc. of S. Florida - Clinical Research Center, Boca Raton, Florida, United States|Sarasota Arthritis Res Center, Sarasota, Florida, United States|Four Rivers Clinical Research Inc., Paducah, Kentucky, United States|Rheumatology Associates, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Hospital For Special Surgery; Dept of Medicine - Rheumatology, New York, New York, United States|Asheville Arthritis & Osteoporosis Center, PA, Asheville, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Utah; Division of Rheumatology, Salt Lake City, Utah, United States|Marshfield Clinic Wausau Ctr, Wausau, Wisconsin, United States|Hospital Erasme, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Clin. de Rhumatologie, Trois-rivieres, Quebec, Canada|Nordsjællands Hospital - Hillerød;Department of Rheumatology 0731, Hillerod, Denmark|Hopital Avicenne; Medecine Interne H5, Bobigny, France|Hopital La Cavale Blanche; Rhumatologie, Brest, France|Hopital Claude Huriez; Internal Medicine, Lille, France|Hôpital de la Conception, Marseille, France|Hopital Emile Muller; Medecine Interne, Mulhouse, France|Hopital Cochin; Medecine Interne, Paris, France|Asklepios Kllinikum Bad Abbach; Klinik für Rheumatologie und Klinische Immunologie, Bad Abbach, Germany|Rheuma-Klinikum Bad Bramstedt Klinik fuer Rheumatologie und Immunologie, Bad Bramstedt, Germany|Charité Campus Mitte, Med.Klinik, Rheumatologie und Klinische Immunologie, Berlin, Germany|Schlosspark Klinik; Abt. Rheumatologie, Berlin, Germany|Universitätsklinikum ""Carl Gustav Carus""; Medizinische Klinik III, Dresden, Germany|Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie, Erlangen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Medizinische Hochschule Zentrum Innere Medizin Abt.Klinische Immunologie und Rheumatologie, Hannover, Germany|Rheumazentrum-Ruhrgebiet, St. Josefs-Krankenhaus; Rheumatologie, Herne, Germany|Universitätsklinikum Jena; Klinik für Innere Medizin III, Jena, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Medizinische Klinik, Pneumologie, Mainz, Germany|Klinikum der Universitat Munchen; Bereich Pettenkoferstr; Rheumaeinheit der medizinischen Klinik IV, München, Germany|Kreiskliniken Esslingen gGmbH Klinik Plochingen Medizinische Klinik, Plochingen, Germany|Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II, Tübingen, Germany|Arcispedale Santa Maria Nuova; Reumatologia, Reggio Emilia, Emilia-Romagna, Italy|Policlinico Univ. Uni Degli Sudi Di Udine; Clinica Di Reumatologia, Udine, Friuli-Venezia Giulia, Italy|Università Degli Studi Di Genova - Dimi; Reumatologia, Genova, Liguria, Italy|Irccs San Raffele; Div Med Gen Immunologia Clinica, Milano, Lombardia, Italy|A.O. Universitaria Pisana; Psichiatria, Pisa, Toscana, Italy|Azienda Ospedaliera di Padova; Cattedra e Divisione di Reumatologia, Padova, Veneto, Italy|Azienda Ospedaliera di Verona-Ospedale Civile Maggiore, Verona, Veneto, Italy|VU Medisch Centrum; Reumatologie 4-A-A2, Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Ziekenhuisgroep Twente, Hengelo, Hengelo, Netherlands|Akademisch Ziekenhuis St. Radboud; Rheumatology, Nijmegen, Netherlands|Sørlandet Sykehus Kristiansand, Kristiansand, Norway|Rikshospitalet; Revmatologisk Avd Seksjon Barnerevmatologi, Oslo, Norway|Ålesund sjukehus, Ålesund, Norway|Szpital Uniwersytecki; nr 2 im. Dr J. Biziela, Bydgoszcz, Poland|Klinika Reumatologii I Chorób Wewn. Pum W Szczecinie; Samodzielny Publiczny Szpital Kliniczny Nr 1, Szczecin, Poland|Hospital Geral de Santo Antonio; Servico de Imunologia Clinica, Porto, Portugal|Hospital Univ A Coruna; Rheumatology, A Coruna, LA Coruña, Spain|Hospital Universitario de Canarias;servicio de Reumatologia, La Laguna, Tenerife, Spain|Hospital de Basurto; Servicio de Reumatologia, Bilbao, Vizcaya, Spain|Hospital Universitari de Bellvitge; Servicio de Reumatologia, Barcelona, Spain|University of Barcelona; Dept. of Internal Medicine,, Barcelona, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Skånes Universitetssjukhus, Lund, Sweden|Skånes Universitetssjukhus Malmö; Reumatologkliniken, Malmo, Sweden|Karolinska Sjukhuset; Reumatologkliniken D2-1, Stockholm, Sweden|Akademiska Sjukhuset; Lungmedicinska Kliniken, Uppsala, Sweden|Aberdeen Royal Infirmary; Medical Oncology Dept, Aberdeen, United Kingdom|Barnsley General Hospital; Rheumatology, Barnsley, United Kingdom|Old Queen Elizabeth Hospital; Pharmacy Building;Clinical Research offices, Birmingham, United Kingdom|Colchester General Hospital; Aseptic Dept, Pharmacy Support Unit, Colchester, Essex, United Kingdom|University of Edinburgh; The Queens Medical Research Institute, Edinburgh, United Kingdom|CHAPEL ALLERTON HOSPITAL; Unit of Musculoskeletal Disease, Leeds, United Kingdom|Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom|Freeman Hospital; Dept of Rheumatology, Newcastle Upon Tyne, United Kingdom|Queen's Hospital, Romford, United Kingdom|Haywood Hospital; Staffordshire Rheumatology Centre, Stoke-on-trent, United Kingdom|Royal Cornwall Hospital; Rhuematololgy Dept, Truro, United Kingdom|Southend Hospital; Rheumatology Department, Westcliffe-on-sea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01791153"
